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SUMMARY
The functional significance of neuropeptide Y in the rat spinal cord is unclear
and there have been no reports of the stimuli needed to produce release of this peptide
in vivo. When a peripheral nerve is injured a de novo synthesis of neuropeptide Y
occurs in many large and some medium sized dorsal root ganglion neurones. The
experiments in this thesis employed the antibody microprobe technique to study both in
normal rats and in those with a peripheral mononeuropathy the spinal release of
extracellular immunoreactive neuropeptide Y and to determine the origin of such
release.
In the initial experiments, microprobes bearing immobilised antibodies to
neuropeptide Y were inserted into the lumbar spinal cord of urethane anaesthetised
normal rats. In the absence of peripheral stimuli microprobes detected a high basal
presence of immunoreactive NPY throughout the entire dorsal and ventral hom.
Electrical stimulation of large diameter afferents of the ipsilateral sciatic nerve and
unmyelinated primary afferents did not significantly alter the spinal release of
immunoreactive neuropeptide Y in the spinal cord. Transection of the spinal cord at
a low thoracic level resulted in increased levels of immunoreactive neuropeptide Y
only in the lower ventral horn. The predominant failure of electrical stimulation and
of spinalisation to significantly alter the basal levels of immunoreactive neuropeptide
Y suggests that the latter results from spontaneous activity in intrinsic neurones.
For studies of rats with a peripheral mononeuropathy, the model of Bennett
& Xie was used. Postoperatively the development of mechanical allodynia and
hyperalgesia were assessed and animals used at 10-14 days only if they displayed the
characteristic behavioural signs associated with this model. Sham experiments were
carried out in separate animals as controls for the effect of surgery per se. In sham
animals both sides of the lumbar spinal cord showed a significant spinal release of
immunoreactive neuropeptide Y throughout the entire dorsal horn. The site of
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greatest extracellular levels was the superficial dorsal horn. A similar distribution
was also found in the neuropathic animal on the side contralateral to the nerve
ligation. On the ipsilateral side of the neuropathic rat however there was a further
zone of spontaneous release of immunoreactive neuropeptide Y in the mid and lower
dorsal horn (approximating to laminae III, IV and V). Additionally, electrical
stimulation of large diameter afferents of the ipsilateral sciatic nerve resulted in an
increase in the spinal release over the entire dorsal and upper ventral horn.
Stimulating both large diameter myelinated afferents and small unmyelinated
afferents did not increase release of immunoreactive neuropeptide Y above that
observed by stimulating large myelinated fibres alone. Thus, the additional zone of
spontaneous release found on the ipsilateral side of the neuropathic rat probably
represents spontaneous activity in damaged and/or regenerating primary afferents.
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CHAPTER 1: Introduction to Neuropeptide Y
1. NEUROPEPTIDE Y
The ultimate aim of this work is to contribute to the understanding of
neuropathic pain which arises in the absence of an adequate stimulus and occurs in
both man and animals. Animal models have been developed which may help our
understanding of this clinical syndrome. However, before considering these models
and the changes which follow peripherally and centrally, it is first necessary to
describe the literature of the neuropeptide of interest in this study, neuropeptide Y.
1.1. SYNTHESIS AND STRUCTURE OF NEUROPEPTIDE Y
1.1.2. THE ORIGINS OF THE PANCREATIC FAMILY
In 1968 during the purification of insulin isolated from the chicken pancreas,
avian pancreatic peptide (aPP, a 36 amino acid peptide) was discovered as a by¬
product (Kimmel et al, 1968; Kimmel et al, 1975). Avian PP was detected in
pancreatic extracts of a number of birds and reptiles by radioimmunoassay (Langslow
et al, 1973). Cells containing aPP were found to share many features with other
known peptide hormone producing cells such as the presence of cytoplasmic granules
and the ability to take up and decarboxylate administered amine precursors (Larsson
et al, 1974). This peptide was found to be present in the pancreas of a number of
avian and reptilian species by a later study (Larsson et al, 1976). Subsequently, a 36
amino acid was isolated from bovine pancreas and was found to be homologous to
avian pancreatic peptide for 15 of the 36 amino acids (Lin & Chance, 1974). A
peptide with structural similarities to avian pancreatic peptide was isolated from
porcine duodenum by Tatemoto & Mutt (1978). They described a method for
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detecting the presence of peptide amides using a chemical technique based on the
fragmentation of peptides in tissue extracts and subsequent chromatographic
identification of the resulting C-terminal alpha amide fragments. This sequence was
called peptide YY (PYY) by Tatemoto & Mutt, (1980) because of its N and C-
terminal tyrosines (Y being the abbreviation for tyrosine in the single amino acid
code). Sequence similarities to pancreatic peptide are observed in the entire PYY
molecule, 18 identical positions to porcine and bovine PP and 19 identical positions to
avian PP. Tatemoto (1982a) therefore proposed that PYY and PP together formed a
new peptide family. At first, PYY was also thought to be the PP-like peptide of the
brain. The isolation from brain extracts of a peptide amide showed however that the
peptide present in the brain was different from PYY. This peptide while having
structural and biological similarities to both PYY and PP was previously
uncharacterised. It was found to have a tyrosine at both N and C terminals of the
molecule and was named neuropeptide Y (Tatemoto et al, 1982; Tatemoto, 1982b).
In addition, to having identical N and C terminals as PYY, NPY has an equal number
of Ala, Arg, Gly, His, Lys, Pro, Thr and Tyr residues (Tatemoto, 1982b). It was
suggested that NPY was only present in nerve cells and PYY only in endocrine cells
(Tatemoto et al, 1982). Early experiments investigating the coexistence of NPY with
catecholamines in the central nervous system employed antibodies to avian PP (Hunt
et al, 1981a; Lundberg et al, 1980), bovine pancreatic polypeptide (bPP) (Olschowka
et al, 1981) and later to NPY (Hokfelt et al, 1983).
It became apparent that the endogenous peptide present in catecholamine
neurones was neither aPP nor bPP but was more likely to be NPY (Everitt et al,
1984). DiMaggio and co-workers demonstrated that the PP like immunoreactivity
previously observed in the brain was in fact due to the cross-reactivity of the antibody
used with NPY (DiMaggio et al, 1985). Immunoreactive PYY was also found to be
present in the CNS especially in the brainstem, various hypothalamic areas and in the
autonomic ganglia (Bromme et al, 1985; Ekman et al, 1986; Happola et al, 1990).
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Table 1. Amino acid sequence of members of the pancreatic polypeptide family
This shows the amino acid sequence of members of the pancreatic polypeptide family
and has been adapted from Tatemoto (1982a & b). Amino acids have been
highlighted in the sequences of avian (aPP), bovine (bPP), porcine (pPP) & porcine
peptide YY (PYY) where similar to the sequence of porcine neuropeptide Y (NPY).
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Aminoacidsequenceofmembersthpancreaticpolyp ptidefa ily PeptideSequence pNPYTyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-GIu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-IIe-Asn- Leu-IleThr-Arg-Gly-Arg-Tyr-NH2 bPPAla-Pro-Leu-Glu-Pro-Glu-Tyr-Pro-Gly-Asn-Asp-Ala-Thr-Pro-GIu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Glu-Leu-Arg-Arg-Tyr-Ile- Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 aPPGly-Pro-Ser-Gln-Pro-Thr-Tyr-Pro-Gly-Asp-Asp-Ala-Pro-Val-Glu-Asp-Leu-Ile-Arg-Phe-Tyr-Asp-Asn-Leu-Gln-Gln-Tyr-Leu- Asn-Val-ValThr-Arg-His-Arg-Tyr-NH2 pPPAla-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asp-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Glu-Leu-Arg-Arg-Tyr-Ile- Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 pPYYTyr-Pro-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu- Asn-Leu-Val-Thr-Arg-Gly-Arg-Tyr-NH2
The distribution of ir-NPY has also been found to be present in the peripheral and
central nervous system where it has many physiological roles (see section 1.2.).
1.1.3. THE TERTIARY STRUCTURE OF NEUROPEPTIDE Y
X-ray crystallography has been used to determine the tertiary structure of
pancreatic polypeptide (PP; Blundell et al, 1981: Glover et al, 1983). The peptide has
a globular structure, with NFb terminal residues 1-8 assuming a left handed
polyproline II-like helix that is closely packed through hydrophobic interactions
against an alpha-helix consisting of residues 13-32 to form a hydrophobic core.
Studies of the structure of NPY are based on the sequence homology of this peptide
with pancreatic peptide (PP). Comparison of the possible structure of NPY with that
of avian pancreatic peptide has shown that structural elements in PP are maintained in
porcine NPY and porcine PYY (Allen et al, 1987; MacKereii et al, 1989). This model
suggests that NPY preserves a similar compact tertiary structure characterised by
hydrophobic interactions between a COOH-terminal amphiphilic alpha-helix formed
by residues 13-32 and an NH2-terminal polyproline II-Iike helix that also has
amphiphilic character and that these two structures are connected by a beta-turn
(Allen et al, 1987; MacKereii, 1988; MacKereii et al, 1989; Minakata et al, 1989).
The tyrosine residue in position 1 and amino acid residues at position 20-36 are
located in close proximity to each other thus the structure has been described as a
hair-pin.
Another model has been proposed on the basis of the data obtained using
circular dichroism and nuclear magnetic resonance spectroscopy (Saudek & Pelton,
1990). This study proposed that the N and C terminals are not in close proximity as
the C-terminal segment folds into an amphiphilic alpha-helix between 11-36.
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Furthermore, the tyrosine at position 36 in association with residues 32 and 34
stabilised the folded structure and contributed to the formation of the alpha helix
(Saudek & Pelton, 1990) whereas the tyrosine at position 1 did not interact with the
rest of the structure. This study suggested that the 3 proline residues located in the
N-terminal segment of the molecule may exist in either the cis or trans confirmation
conferring no regular structure to this segment of the molecule.
The majority of structure activity models favour the hair-pin like model. It
has been found that deletion of tyrosine at position 1 markedly decreased the affinity
of NPY for its receptor sites (MacKerrell, 1988; Quirion et al, 1990) and has
consequently been suggested to interact with NPY receptors. In addition, it has been
suggested that the tyrosine at this position stabilises the hair-pin like structure of NPY
(McLean et al, 1990). It has also been shown that modifications which are believed to
increase interactions between the N- and C-terminal alpha helix and stabilise the hair¬
pin like structure, increase the affinity of these analogues for NPY receptor binding
sites (Minakata & Iwashita, 1990).
1.1.4. OVERVIEW OF PEPTIDE SYNTHESIS AND METABOLISM
Unlike classical neurotransmitters which are synthesised in nerve terminals
by a variety of enzymatic reactions, neuropeptides are synthesised in the neuronal cell
body. They are derived by the enzymatic cleavage of large and generally inactive
precursors or polypeptide molecules. In the cell nucleus, the gene encoding is
transcribed into messenger ribonucleic acid which is translated on the surface of the
rough endoplasmic reticulum into the pre-propeptide sequence. This pre-propeptide
contains a signal peptide (a hydrophobic NH2 terminal sequence) which directs the
nascent protein chain into the lumen of the rough endoplasmic reticulum where
protein folding and the formation of disulphide bonds occurs (Gething & Sambrook,
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1992; Helenius et al, 1992). Proteolytic cleavage occurs removing the signal
sequence which is then rapidly degraded. The propeptide is transported from the
endoplasmic reticulum to the cis-Golgi compartment (Pfeffer & Rothman, 1987). The
Golgi complex consists of three functionally distinct compartments termed cis, medial
and trans which correspond to sequential cisternae in its track. The pro-peptide then
moves from cis to rran.v-Golgi network by a series of residue fusion and budding
steps. Within this network, the peptides are sorted and packaged into secretory large
dense-core vesicles (LDCV) before transport to the nerve terminal. Post-translational
processing occurs during this stage as enzymes present in the vesicles release the
peptide from the propeptide and further modify it (as reviewed by Bean et al, 1994;
Sossin et al, 1989; Lynch & Snyder, 1986). Multiple combinations of peptides
derived from distinct gene products may be released separately or together from a
single nerve terminal. This packaging process may relate to differences in the
transcription and/or translation rates coupled with random protein aggregation in the
Golgi or fusion of mature vesicles (Hekimi et al, 1991). Three models have been
proposed to explain the mechanism of vesicle formation (reviewed by Pryer &
Wuestechube, 1992). Neuropeptides require assistance to cross biological
membranes due to their size and lipophilic nature. Thus, their release from the nerve
ending occurs via exocytosis.
Rat prepro-NPY has been shown to be similar to human prepro-NPY except
it is a 97 amino acid long whereas human prepro-NPY has been shown to be 98
amino acids long (Higuchi et al, 1988; Minth et al, 1984; Minth et al, 1986). The
structure of rat prepro-NPY was confirmed by Allen et al, 1987 and Larhammar et al,
1987. It has been suggested from the processing of human prepro-NPY that the
signal peptide is cleaved after 28 residues resulting in pro-NPY (Minth et al, 1984).
The active peptide (the 36 residue NPY sequence) has been found to be followed by
an amidation site where glycine is followed by 2 basic amino acids. This enables
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Figure 1. General stages involved in the neuronal synthesis of neuropeptides
The DNA encoding the precursor is transcribed into mRNA in the nucleus of the
synthesising neurone (1). This mRNA is then translated by ribosomes on the surface
of the rough endoplasmic reticulum to form a pre-propeptide (2). The Nth-terminal
signal peptide directs the passage into the lumen of the endoplasmic reticulum, where
it is subsequently removed. The propeptide is then transported to the Golgi apparatus
(3) where is is packaged into secretory granules (large dense core vesicles) (4). These
are transported along the axon to the nerve terminal (5). During stages (4) and (5)
the propeptide is subjected to various proteolytic steps and post-translational
modifications to yield one or more biologically active peptides. These peptides are




amidation to occur by oxidative removal of glyoxylate from glycine to form a
carboxyl terminal amide (Bradbury et al, 1982). The amidation site has been shown
to be followed by a 30 residue C-terminal sequence. (Higuchi et al, 1988).
Once peptides are released and bound to their receptors, they need to
become inactivated to avoid a constant stimulus. Classical transmitter systems often
have enzymic degrading or reuptake systems to remove the active molecule from the
synaptic cleft, terminating its physiological action. There is very limited evidence for
the uptake of neuropeptide ligands by cells following release in vivo (Morel et al,
1994; Beudet et al, 1994). This is consistent with the finding that peptide messengers
have more prolonged actions and can function at a distance from release sites. In
vitro studies have led to the belief that neuropeptide inactivation is carried out by
peptidases in the extracellular space (as reviewed by Csuhai et al, 1995). Peptidases
may be either located on the outside of the cytoplasmic membrane or secreted into the
extracellular space. Post-translational modifications such as amidation and disulphide
linkages are thought to assist in the longlevity of some peptide messengers, protecting
them from peptidases present in the extracellular space.
NPY, PYY and pancreatic peptide all have an initial proline rich sequence
which is inert to the attack of common proteinases but not specific aminopeptidases.
Only a few peripheral peptidases are capable of cleaving NPY. In endothelial cells,
dipeptidylpeptidase IV, a serine peptidase which is proline specific has been shown to
metabolise NPY and peptide YY (Mentlein et al, 1993). Processing of NPY by this
enzyme generates NPY(3-36) by removing the N-terminal dipeptide Tyr-Pro. The
former fragment is a selective agonist at Y2 receptor subtype and demonstrates that
post-secretory processing can modify receptor selectivity. NPY has also been found
to be metabolised by endopeptidase-24.18 in rat kidney membranes (Price et al,
1991). Aminopeptidase P has been found in the kidney, lung, intestine and brain
(Hooper et al, 1990). It has been found to remove the N-terminal tyrosine of NPY
producing NPY(2-36) (Mediros & Turner, 1996).
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Neuropeptides have been shown to be degraded by some specialised central
neuropeptidases. These include aminopeptidase M, pyroglutamylaminopeptidase II,
angiotensin-converting enzyme, endopeptidase 3.4.24.11, endopeptidase 3.4.24.15
and endopeptidase 3.4.24.16. (Bauer et al, 1990; Checler, 1993; Dahms & Mentlein,
1992) which are present in the brain. The latter 2 endopeptidases have been found
only to cleave 8-30 amino acid residue peptides (Dahms & Mentlein 1992) and
therefore do not cleave NPY. Metabolism of NPY by endopeptidase 3.4.24.11
produces NPY(l-20) and NPY(31-36) (Mediros & Turner, 1996). In addition, NPY
has been shown to be stable against degradation by angiotensin-converting enzyme
(Ludwig et al, 1995) which is present in the spinal cord of the dog (Santos et al,
1988) and aminopeptidases N and W (Mediros & Turner, 1996).
1.2. GENERAL OBSERVATIONS ON THE FUNCTIONS OF
NEUROPEPTIDE Y
Although the experiments in this thesis focus on NPY and the spinal cord an
overview of the wide distribution of NPY in the peripheral and central nervous system
will be described briefly. This peptide exerts a wide range of effects. In the central
nervous system there is evidence that NPY is involved in the regulation of food
intake, the control of blood pressure, may function as an endogenous anxiolytic and is
involved in nociception. Peripherally NPY may play an important role in sympathetic
vascular control.
1.2.1 NEUROPEPTIDE Y IN THE CENTRAL NERVOUS SYSTEM
Immunohistochemistry and radioimmunoassay techniques have
demonstrated that NPY-like material is present in relatively large quantities in the
brain of various mammalian species (Adrian et al, 1983; Hendry et al, 1984;
Chronwall et al, 1985; Smith et al, 1985; Kohler et al, 1986; Covenas et al, 1990).
NPY-like immunoreactivity (ir) has been observed in the rat brain in various
hypothalamic nuclei as well as in the striatum, nucleus accumbens, amygdala, septum
and throughout the cerebral cortex and hippocampus (Allen et al, 1983; Sawchenko et
al, 1985; Pelletier et al, 1984; Ceccatelli et al, 1989; Aoki & Pickel, 1990). The
presence of high amounts of NPY-like ir in the cortex, septum, amygdaloid body and
hippocampus may suggest a role for this peptide in the limbic system (Albers & Feris,
1984; Chronwall et al, 1985; Kohler et al, 1986). In situ-hybridisation has revealed
that the localisation of NPY mRNA correlates well with the distribution of ir-NPY,
thus providing evidence that ir-NPY is synthesised, processed and stored in these
neurones (Terenghi et al, 1987; Chan-Paley et al, 1988). This peptide has been found
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co-localised with noradrenaline (NA) in a proportion of neurones in the brainstem and
hypothalamic nuclei (Lundberg et al, 1980; Huntetal, 1981a; Everitt et al, 1984;
Chronwall et al, 1985; Holets et al, 1988). NPY has also been found to be co-
localised with somatostatin in the cortex, hippocampus and striatum (Vincent et al,
1982; Beal et al, 1986; Chronwall et al, 1984; Kohler et al, 1987, Smith & Parent,
1986). It has been suggested that NPY has a role in the modulation of the activity of
NA in certain central pathways due to their colocalisation.
Functional implications that can be derived from anatomical studies is
obviously limited as these results provide no evidence of whether a co-localised
peptide will be co-released. Such studies however, do highlight the areas of potential
interest.
1.2.2 THE ROLE OF NPY IN FEEDING
Although the precise physiological role for NPY in the CNS is uncertain,
various pharmacological and behavioural effects of centrally administered NPY have
been demonstrated. Central administration of NPY has been found to stimulate food
and water intake (Clarke et al, 1984; Stanley & Leibowitz, 1984; Levine & Morley,
1984).
Endogenous concentrations of NPY have been found to be highest in the
paraventricular nucleus (PVN. Allen et al, 1983) and are modulated by fasting and
feeding (Fuxe et al, 1983) suggesting that exogenously applied peptide engages
receptors in or near the PVN to activate ingestive pathways. Injections of NPY and
PYY into the paraventricular nucleus of the hypothalamus produced the most robust
increase in feeding and drinking behaviours (Stanley & Leibowitz 1984, Stanley et al,
1985a & b; 1990) revealing the critical role of this hypothalamic nucleus. Morley and
collegues reported that the most marked effect of microinjection was in the anterior
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ventromedial nucleus (VMN), whereas Stanley and co-workers found the PVN to be
the major site (Stanley et al, 1985b). As cell bodies from the arcuate nucleus send
projections to the PVN (Gray & Morley, 1986) it is possible that the enhanced effect
of anterior VMN micro-injections is due to an excitatory effect of NPY both on the
arcuate and PVN nucleus, secondary to local diffusion. Although the drinking
response observed with NPY has been reported as considerably smaller than the
feeding response, it appears to be a direct consequence of this neuropeptide (Stanley
& Leibowitz, 1984). The feeding effect of NPY has been shown to be highly selective
for carbohydrate-rich foods (Levine et al, 1985; Stanley et al, 1986; Morley et al,
1987) and has been attenuated by intravenous infusions of glucose but not fructose
(Rowland 1988). By contrast, injection of NPY into the fourth ventricle elicited a
feeding response without affecting water intake (Corp et al, 1990). Other areas may
also be involved in the stimulatory effects of NPY and related peptides on food and
water intake but to a lesser extent (Stanley et al, 1985a & b; 1990; Morley et al,
1987). The secretion of NPY from hypothalamic neurones has been reported to be
increased in food-deprived rats and reduced during the course of eating (Stanley et al
1993; Kalraet al, 1991). In agreement with this, injection of antisera to NPY
(Stanley et al, 1993) or antisense oligonucleotides directed against mRNA for NPY
has been found to suppress food intake in rats (Akabayshi et al, 1994).
Clinical studies have suggested that NPY & PYY are pathogenetic factors in
anorexia and bulimia (Kaye et al, 1990). The concentration of NPY has been
reported to be elevated in the cerebrospinal fluid of under weight anorexic patients
and the concentration normalised when the patients gained weight and returned to
normal menstrual cycles. Obesity in experimental animals has been found to be
associated with high levels of this peptide in the hypothalamus (Kalraet al 1990;
1991; Stanley et al, 1993). A functional interaction between the neurones that contain
5-hydroxytryptamine (5-HT) and NPY has been suggested as fenfuramine, which
depletes 5-HT, lowered the concentration of NPY in the hypothalamus (Rogers et al.
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1991). No synergistic or additive effects of NPY and noradrenaline on food intake
have been demonstrated (Levine et al, 1985). However, the effect of NPY on feeding
has been reported to be attenuated by the opioid feeding pathway (Morley et al, 1983,
Morley & Levine, 1985) but NPY has been shown to produce a greater and more
prolonged effect than the opioid peptides.
1.2.3. NPY AS AN ENDOGENOUS ANXIOLYTIC
Central administration of NPY has been found to produce anxiolysis and
sedation depending on the dose. Low doses of NPY have induced anxiolysis whereas
high doses evoked sedation (Grundemar & Hakanson, 1994). Treatment for patients
with anxiety disorders (such as lithium, electroconvulsive therapy and 5-HT reuptake
inhibitors) have been shown to raise hypothalamic, hippocampal and frontal cortical
concentrations of NPY and mRNA for NPY in rats (Weiner et al, 1992). Thus,
endogenous NPY may play a role in controlling mood (Heilig, 1992; 1993;
Wahlestedt et al, 1993a). Low levels of NPY in the cerebrospinal fluid are associated
with loss of appetite and anxiety, and it appears that the synthesis and/or processing
of NPY is altered in patients with depression (Heilig & Widerlov 1990; Widdowson et
al, 1992).
1.2.4. THE ROLE OF NEUROPEPTIDE Y IN CARDIOVASCULAR
CONTROL
Since NPY immunoreactivity has been found in nerves innervating
peripheral and cerebral arteries and veins, in cardiac autonomic ganglia and in various
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brainstem areas known to affect cardiovascular functions many studies have examined
a role for NPY both centrally and peripherally.
Certain nuclei in the brainstem are important for cardiovascular reflexes, and
central injection of NPY in such areas has evoked hypotension and bradycardia in the
rat (Fuxe et al, 1983). Injection into the nucleus tractus solitarius of intact rats has
produced significant dose-dependent, reductions of mean arterial pressure, heart and
respiratory rates and tidal volume (Tseng et al, 1988; Barraco et al, 1990; Kubo &
Kihara, 1990; Grundemar et al, 1991a & b).
It has also been proposed that NPY can modulate aortic baroreceptor
reflexes and abolish the responsiveness to glutamate, the proposed endogenous
transmitter in baroreceptor pathways (Grundemar et al, 1991 a & b; Shih et al, 1992).
Other possible targets for NPY in central cardiovascular regulation include the caudal
ventrolateral medulla, the area postrema and the posterior hypothalamus (McAuley &
Westfall, 1993).
As well as centrally, peripheral roles for NPY have been proposed. NPY is
a potent vasoconstrictor agent in many arteries in vitro and in vivo and several
mechanisms of action have been suggested (Fredholm et al, 1985; Lobaugh &
Blackshear, 1990; Xiong et al, 1993; Xiong & Cheung, 1994). Indirect
vasoconstriction via potentiation of other vasoconstrictor stimuli has been suggested
as the activity of NPY on many arteries (Edvinsson et al, 1984; Lundberg et al,
1985b). Additionally, this peptide has been found to enhance NA-induced
vasoconstriction (Edvinson et al, 1984; Wahlestedt et al, 1985; Pernow & Lundberg,
1988) but to inhibit the NA release evoked by nerve stimulation (Lundberg & Stjarne
1984). It has therefore been suggested that NPY could play an important role in
sympathetic vascular control together with NA.
Functional studies have suggested that NPY exerts an indirect effect on the
heart by modulating the release of transmitter from the autonomic nervous system. In
support of this, NPY has been found to inhibit NA release in the perfused guinea-pig
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heart (Wahlestedt et al, 1987) and in the isolated mouse atria (Foucart et al, 1989).
Activation of presynaptic neuropeptide Y receptors has suppressed the release of both
NA and NPY from sympathetic nerve terminals. Furthermore, activation of
presynaptic alpha 2 adrenoreceptors by NA has been found to inhibit the release of
NPY (Haass et al, 1989). In addition, NPY has been found to exert a prejunctional
inhibitory effect on capsaicin-sensitive neurones in the guinea-pig left atria and inhibit
the release of acetylcholine from the vagal nerve (Guiliani et al, 1989). NPY's
distribution in association with the atrioventricular node and especially around
coronary vessels suggests that it may play a role in coronary vasospasm (Gu et al,
1983; Potter, 1989).
High concentrations of NPY have been found in the sympathetic ganglia and
in tissues such as the vas deferens, heart, atria, blood vessels and spleen all of which
receive a dense sympathetic innervation (Lundberg et al, 1982; 1985 a; Hassall &
Burnstock ,1984). These findings have been reported in a number of species
including humans (Lundeberg et al, 1985b).
Support for a presynaptic action of NPY at sympathetic terminals has come
from studies on the vas deferens. NPY has been found to be co-stored with NA and
adenosine triphosphate (ATP) in noradrenergic sympathetic terminals of the mouse
and human vas deferens (Adrian et al, 1984; Stjarne et al, 1986). In the whole
isolated vas deferens of the rat a NPY-mediated depression of [3H]-NA secretion
evoked by trains of pulses has been demonstrated (Lundberg & Stjarne, 1984).
However, this peptide was ineffective in inhibiting the contractile response to single
stimuli in the epidydmal portion of the rat vas deferens (presumably mediated by NA
release) but potently suppressed the same response evoked in the prostatic portion
(Donso et al, 1988) suggesting that NPY may differentially affect NA and ATP
release in epidydimal and prostatic portions of the rat vas deferens.
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1.2.5. DISTRIBUTION OF NPY IN THE SPINAL CORD
NPY-like immunoreactive (ir) cell bodies & fibre terminations have been
shown by immunohistochemical studies to be present within the spinal cord of many
species including cat, dog, horse, marmoset, rabbit, fish and rat (Gibson et al, 1984;
Marti et al, 1987; Cameron et al, 1990; Merighi et al, 1990; Roddy et al, 1990;
Lewellyn-Smith et al. 1990). Although early immunohistochemical studies were
performed with antisera raised against avian pancreatic peptide, these antisera
probably detected mainly NPY (Hokfelt et al, 1981; Hunt et al, 1981 a & b).
Immunoreactive-NPY has been found in every region of the spinal grey matter
(Gibson et al, 1984; Doyle & Maxwell 1994) with an especially dense concentration in
laminae I-II (Gibson et al, 1981; Suburo et al, 1992; Merighi et al, 1990; DeQuidt &
Emson, 1986; Sasek & Elde, 1985) with the deeper layers of dorsal horn containing
lower levels. Two groups have reported that the highest concentration in the rat is in
lamina I and the outer part of lamina II (Hunt et al, 1981b; Sasek & Elde, 1985),
while Hokfelt's group found that immunoreactive fibres are less dense in lamina I than
in lamina II (Hokfelt et al, 1981).
Immunoreactive -NPY has also been found present in intermediolateral cell
columns of the thoracic and sacral segments and around the area of the central canal
(Gibson et al, 1984; Krukoff, 1987; Dequidt & Emson, 1986; Llewellyn-Smith et al,
1990, Merighi et al, 1990) and to a lesser extent in the ventral horn (Allen et al, 1984;
Gibson et al, 1984; Sasek & Elde, 1985; Dequidt & Emson, 1986; Krukoff, 1987;
Llewellyn-Smith et al, 1990; Merighi et al, 1990; Roddy et al, 1990).
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1.2.5.(a). The sources of NPY in the spinal cord
(ai) Primary afferents
Until recently, immunohistochemical studies have provided no evidence for
NPY in rat dorsal root ganglion cells of primary afferents despite the fact that other
peptides are readily detected. Substance P, CGRP. somatostatin and galanin are
produced by many small and medium sized dorsal root ganglion neurones whose
axons terminate mainly in laminae I & II of dorsal horn (Hokfelt et al, 1981;
Rosenfeld et al, 1983; Skotfitsch & Jacobwitz, 1985). Immunoreactive-NPY has
been found in a few dorsal root ganglion cells in cat (Gibson et al, 1984, Lindh et al,
1989) in chicken and in horse (Gibson et al, 1984). However, no cell bodies
immunoreactive for NPY have been found in the rat. It was suggested that these
results perhaps reflect that the levels present were below the detection limit of the
immunohistochemical methods used.
(aii) Intrinsic neurones
No changes were reported in the density & distribution of NPY
immunostaining after procedures known to destroy primary afferent input to the
dorsal horn of rats (Hokfelt et al, 1981; Hunt et al, 1981 a & b; Gibson et al, 1984).
Dorsal rhizotomy did not alter the NPY like immunoreactive fibres in the lumbar
dorsal horn (Hunt et al, 1981 a& b) or the cervical cord (Gibson et al, 1984). This
was in agreement with the lack of effect of cord section and neonatal capsaicin
treatment (Hokfelt et al, 1981; Hunt et al, 1981b).
The use of colchicine in some of these studies (Hunt et al, 198 la; Sasek &
Elde, 1985; DeQuidt & Emson, 1986; Krukoff, 1987) blocked axonal transport and
accentuated the accumulation of neuropeptides in the cell bodies and hence assisted
localisation of the latter (Norstrom et al, 1971). NPY containing cell bodies have
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been detected in the superficial laminae throughout the cord and are most numerous in
lamina II (Hunt et al, 1981a; Sasek & Elde, 1985; DeQuidt & Emson, 1986). In
addition, NPY-containing cell bodies have been found present in the deeper layers, the
region of the dorsal horn commisure and sacral parasympathetic nucleus (Hunt et al,
1981 a; Sasek & Elde, 1985; Krukoff, 1987). In the pig, a few of these were found in
laminae II-III without colchicine treatment (Merighi, 1990). The presence of NPY-
containing cell bodies in the superficial laminae of the rat has been confirmed by a
technique which detected a low concentration of peptide present in perikaryal
cytoplasm without the use of colchicine (Rowan et al, 1993). Cell bodies have only
been found caudal to T2 in the cat in laminae VI, IX with the highest concentration
found in lamina VII (Krukoff, 1987).
(aiii) Fibres of supraspinal origin
A potential source of NPY terminals in the dorsal horn are neurones with cell
bodies located in the brainstem. In accordance, radioimmunoassay and
immunocytochemical studies have demonstrated a widespread distribution of NPY
immunoreactivity throughout the brain. In the rat, many catecholamine neurones in
the lower medulla oblongata belonging to noradrenergic A1/A2 cell group and
adrenergic C1/C2 cell groups contain NPY like immunoreactivity (Hokfelt et al, 1983;
Everitt et al, 1984). It was suggested that on the basis of the extensive co-localisation
with catecholamines in the periphery, projecting brainstem nuclei may also contain
both NPY and catecholamines. They are extensively co-stored in axon terminals
within the thoracic intermediolateral cell column (Blessing et al, 1987; Tseng et al,
1993). These axons are derived mainly from the rostral ventrolateral medulla (CI
catecholamine nucleus; Tseng et al, 1993) and degenerate following cervical cord
transection (Hokfelt et al, 198 1). However, results from retrograde tracing studies
suggest that only the CI cell group of the medulla and locus coeruleus contain
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spinally projecting neurones with as few as 2% of neurones of the locus coeruleus
projecting to the spinal cord containing ir-NPY (Blessing et al, 1987; Holets et al,
1988). As the locus coeruleus is a major source of noradrenergic neurones
innervating the dorsal spinal cord, this would suggest that coexistence of
noradrenaline and NPY in fibres in the dorsal spinal cord is limited. Double labelling
studies have provided no evidence for NPY terminals that contain catecholamine in
dorsal horn (Blessing, 1987) with limited co-localisation being reported in the cat
(Doyle & Maxwell, 1994).
1.2.5.(b) NPY terminals-ultrastructural studies
Doyle & Maxwell reported that in the cat, the majority of structures
containing NPY were axon terminals which contained mainly clear and round vesicles
(Doyle & Maxwell, 1993). Occasionally large dense -core vesicles were found that
were intensely immunoreactive. Almost all ir-NPY axon terminals formed synaptic
specialisations such as synaptic junctions on dendrites and somata of dorsal horn
neurones. Axodendritic synapses were most frequently found on medium sized
dendrites. Immunoreactive terminals also formed axo-axonic synapses onto other
axons in the cat substantia gelatinosa of the dorsal horn (Doyle & Maxwell, 1993).
These included central axons of glomeruli which were thought to be of primary
afferent origin. Such synapses have not been found in the rat (Zhang et al, 1995b).
In the lamprey, all ir-NPY material appears to originate from spinal cord
cells and not from descending axons (Van Dongen et al, 1985). Immunoreactive-NPY
varicose fibers have been shown to have close appositions on axons of dorsal root
ganglion neurones. These fibres presumably all originate in small interneurones
containing NPY localised just below the dorsal columns, since they are the only cell
bodies known to provide ir-NPY fibres in the spinal cord of the lamprey (Bongianni et
al, 1990).
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Recently, a study in the rat using a post-embedding immunoelectron
microscopy technique found low levels of ir-NPY & very low levels of ir-VIP in some
primary afferent terminals in laminae I & II of rat lumbar spinal cord (Zhang et al,
1995b). This study indicated co-localisation with CGRP which is assumed to
represent a marker for some sensory afferents in dorsal horn (Chung et al, 1988;
Traub et al, 1989) and less frequently also with ir-galanin. They suggested that these
represent unmyelinated afferents arising from small and some medium sized dorsal
root ganglion neurones. Zhang & co-workers found several NPY positive nerve
endings containing many synaptic vesicles, a few large dense core vesicles (LDCV)
and some ir-NPY dendrites in lamina I and the outer third of lamina II. The terminals
often formed synapses on NPY-negative dendrites and occasionally an NPY-positive
terminal formed a glomerulus. In the inner two thirds of lamina II, ir-NPY structures
were more frequent and numerous ir-NPY dendrites and dendritic-like neuronal
processes with LDCV's were found. The latter frequently formed dendrodendritic
synapses with NPY-negative dendrites. It has therefore been suggested that NPY
transmission in the inner 2/3rds of lamina 2 appears mainly to go from ir-NPY-
dendrite like processes to dendrites of unidentified neurones (Zhang et al, 1995b).
1.2.6. ELECTROPHYSIOLOGICAL STUDIES OF NEUROPEPTIDE Y
The involvement of NPY in differing functional systems may still result from
a common electrophysiological mechanism. Electrophysiological studies in the
periphery suggest that NPY may have an inhibitory role (Cheung & Dukkipati, 1991;
Klapstein & Colmers, 1993; Cunningham et al, 1994). NPY has been shown to inhibit
neurotransmitter release in enteric neurones and sympathetic neurones by inhibiting
the intracellular calcium influx (Walker et al, 1988; Hirning et al, 1990; Schofield &
Ikeda, 1988). In these neurones, NPY appears to inhibit selectively the N-type Ca2+
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channel (Hirning et al, 1990; Wiley et al, 1990; Plummer et al, 1991) which has been
associated with providing Ca2+ influx associated with neurotransmitter release
(Miller, 1990).
Many effects of NPY in the CNS can also be attributed to inhibition of
transmitter release. NPY reversibly inhibits excitatory synaptic transmission from
stratum radiatum to CA1 pyramidal cells as measured by a reduction in amplitude of
the extracellular population spike and inhibits the excitatory postsynaptic potentials
(EPSPs) evoked in these pyramidal neurones (Colmers et al, 1985; 1987; 1988; Hass
et al, 1987). Thus, NPY abolishes neurotransmission in cultured hippocampal
neurones by preventing glutamate release from presynaptic nerve terminals. In
addition, it has been proposed that NPY has inhibitory postsynaptic actions acting at a
distal dendritic site to reduce postsynaptic excitability. NPY reduces the spontaneous
firing rate and hyperpolarisation in the locus coeruleus (Illes & Regenhold, 1990) and
has been found to inhibit the excitatory and inhibitory synaptic potentials in 5-HT
containing cells of the dorsal raphe nucleus (Kombian & Colmers, 1992). In contrast,
the NMDA-induced neuronal activation by an atypical NPY receptor in C3 cells of
the dorsal hippocampus has been found to be potentiated by NPY (Monnet et al, 1992
a; b).
NPY has been shown to inhibit voltage sensitive calcium currents in dorsal
root ganglion neurones and this was shown to be associated with an inhibition of the
depolarisation-induced (high potassium concentration) release of substance P (Walker
et al, 1988). A subsequent study by Bleakman and co-workers demonstrated that the
action of NPY was via the Y2 dorsal root ganglion receptor (Bleakman et al, 1991).
Supporting these in vitro studies, microinjection of NPY was reported to reduce the
peripheral nerve stimulus-evoked release of substance P in the superficial dorsal horn
of the cat (Duggan et al, 1991). Substance P release over the dorsal horn was
reduced initially with subsequent inhibition becoming restricted to lamina I and II.
The presence of ir-NPY in axons presynaptic to central boutons may be a
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physiological correlate to this effect (Maxwell & Doyle, 1994). As substance P is
released by noxious peripheral stimuli (Duggan et al, 1987), NPY may be involved in
normal control of pain and possibly other sensory modalities. .
1.2.7. NPY AND NOCICEPTION
NPY has been shown to modulate the processing of nociceptive information
centrally. Intracerebroventricular (i.e.v.) administration of very low doses of NPY
had antinociceptive effects in a mouse formalin procedure but induced hyperalgesia in
the hot plate test (Melleado et al, 1993). Intracerebroventricular as well as
intrathalamic administration of NPY to spontaneously hypertensive rats, which are
hypoalgesic when compared to genetic control Wistar-Kyoto rats, induced a further
elevation in nociceptive threshold in the hot plate paradigm (Merlo et al, 1990).
Administered i.e.v. NPY, PYY, NPY(2-36) and the Y[ agonist [Leu31, Pro34]NPY
but not the Y2 agonist NPY( 13-36) produced dose-dependent inhibition of acetic
acid-induced writhing in mice. The antinociceptive action of NPY was reversible over
time and obtained at doses that did not produce detectable decreases in motor activity
(Broquaet al, 1996). In contrast, lateral ventricular injection of NPY in rats did not
alter the nociceptive threshold in 55°C warm-water tail flick (Heilig et al, 1992) or 54
°C hot plate procedures (Jolicoeur et al, 1991). The antinociceptive effects of i.e.v.
administered NPY may be dependent on both the intensity and the modality of the
painful stimulus.
Functional studies on the role of NPY in the dorsal horn have suggested that
NPY has an inhibitory effect on spinal nociception. Intrathecal administration of NPY
in rats has been shown to inhibit spinal nociceptive reflexes (Hua et al, 1991).
Intrathecal NPY produced a dose dependent elevation in nociceptive threshold but
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was not active in paw pressure test. C-terminal fragments of NPY, NPY( 14-36),
NPY(16-36), NPY(18-36) NPY(19-36) produced antinociceptive effects on the paw
pressure tests in the rat (Hua et al, 1991). NPY was found to have mixed effects on
nociceptive spinal reflexes when measured electrophysiologically (Xu et al, 1994). It
had a biphasic effect in flexor reflex: excitability with facilitation at low doses and
depression at high doses. Hua and co-workers did not report a hyperalgesic effect of
NPY in rat nociceptive tests which may be due to a lower sensitivity of behavioural
experiments. Although NPY is likely to have a modulatory role centrally, there
appears to be no reports on the effects of NPY on the responses of spinal neurones to
peripheral noxious stimuli following ionophoretic administration of this peptide.
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1.3. NEUROPEPTIDE Y RECEPTOR TYPES
Evidence for the classification of NPY receptors by agonists will be
considered along with their possible antagonists and cellular mechanisms. The initial
classification will be described as well as the other subtypes which have since been
cloned.
NPY receptors have been pharmacologically differentiated into several
subtypes (see table 2). The distinction between Y| & Y2 receptors has been based on
the binding and functional potencies of a range of agonists, which are truncated or
residue-substituted versions of the parent peptide (Wahlestedt et al, 1986; 1989;
Fuhlendorff et al, 1990a; Michel, 1991). Based on the differential potencies of NPY
and its C-terminal fragments such as NPY( 13-36) or PYY( 13-36) in various
bioassays, Wahlestedt and co-workers first proposed this classification of receptors in
1986 & 1987. Due to the co-existence of NPY with noradrenaline within sympathetic
fibres innervating blood vessels much of the original studies investigated transmission
between sympathetic nerves and vascular smooth muscle. It was suggested that the
Y| receptor was postjunctional to adrenergic nerves and that the Y2 receptor was
exclusively prejunctional at this synapse and sensitive to both NPY, PYY and the (13-
36) fragment whereas the Y \ receptor type was not sensitive to fragments
(Wahlestedt et al, 1986). The Yj receptor has been reported to mediate an
enhancement of noradrenaline-evoked vasoconstriction at the vascular sympathetic
neuroeffector junction (Wahlestedt et al, 1986). Indeed, Yj receptors mediate most
of the vascular effects although the involvement of other receptors has been proposed
(Tessel et al, 1993). In contrast, a prejunctional Y j receptor was proposed to be
present in rabbit isolated vas deferens due to the rank order of potency exhibited by
NPY and some truncated analogues (Doods & Krause, 1991).
NPY Y2 receptors in the periphery are generally considered to be localised
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at prejunctional sites on sympathetic neurones, parasympathetic neurones and sensory
C-fibres (Wahlestedt et al, 1986; Grundemar et al, 1990; Stjernquist & Owman, 1990;
Westfall et al, 1990). These receptor types have been found to be involved in the
suppression of the electrically stimulated twitch contractile response of the isolated
vas deferens and inhibit acetylcholine release from the vagus nerve (Potter, 1985;
Wahlestedt et al, 1986; Potter, 1989). A third type was originally proposed which did
not bind peptide YY and tentatively named Y3 (Wahlestedt et al, 1991; 1992). Y3
receptors occur in the adrenal medulla, brainstem and heart but their effects have not
been fully characterised (Balasubramaniam & Sherriff, 1990). An additional subtype
has been suggested which in contrast to Y3 binds peptide YY with high affinity
(Larburthe et al, 1986). It was found to be located in the rat intestinal epithelial cells.
Other results have suggested more subtypes. Radioligand binding and
receptor solubilization studies, indicated that NPY was found to bind to peptides of
varying molecular weight ranging from 38 to lOOkDa which suggested that NPY had
more than 3 receptor subtypes (Michel, 1991). The order of binding affinity of an
array of analogues in different tumour lines also suggested that more subtypes may be
identified (Inui et al, 1992).
Based on the observation that NPY and C-terminal fragments were potent
inhibitors of nicotine-induced catecholamine release from chromaffin cells, but PYY
was ineffective, another receptor subtype has been proposed (Hexum et al, 1994). A
receptor that binds all 3 peptides and called the PP-fold receptor has been found (Nata
et al, 1990).
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Table 2. The proposed rank order of potency of NPY agonists and related
peptides at receptors Yj-Yj.
Studies using NPY, NPY analogues and related peptides in various model systems and
cell types have demonstrated different orders of potency for the receptors Y|,Y2 &
Y3. Some examples of the model systems for each receptor type have been included.
This table has been adapted from tables in the reviews of Michel 1991; Dumount et al,
1992; Wahlestedt & Reis 1993; Colmers & Bleakman 1994; Grundemar & Hakanson
1994; Wan & Lau 1995; Larhammar 1996.
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Theproposedrankorderft ncyNPYagonistsdrelatpepti esc ptorsY1- 3 Y,Y,Y, PYY>NP[Pro34]NPY =[Leu31Pro34]NPY »NPY2-36P >NPY13-36NPY8Y2PYY>NPP -36 >NPY13-36 »[Pro34]NPY=PNPY>[Pro34]NPY >NPY13-36»PYY>a P HELcelllin (Fethetal,1992) SKNMCcelllin (Fuhlendorftal,1990) bloodvesselsvasoconstriction (Wahlestedtel,1986; McAuley&Westfa l1992) ratcerebralortex (Micheletal,1990)SKNBE2celllin (Wahlestedtetl,1990,2) hippocampus (Flood&M rley1989) ratv sdeferens (Wahlestedtel,1986, Doods&Krua1991) dorsalrootganglion neurones (Bleakmantl,1991)bovineadrenalchromaffin cells (Wahlestedtel,1990) ratcolon (Cadieuxetl,1990) ratcardiacventricular
membrane (Balasubramaniam&Sheriff 1990)
1.3.1. NPY RECEPTOR
Y| receptor requires an intact N-terminus of NPY to become fully activated.
Loss of agonist potency occurs when only 1 or 2 N-terminal amino acids are
eliminated or substituted (Grundemar et al, 1993a & b). Systematic d-substitutions in
any of the first five amino acid residues in the N-terminal end of NPY result in a
marked loss of potency at the Y| receptor (Boublik et al, 1990). By contrast
substitutions in C-terminus, have been introduced without loss of potency. [Pro
34]NPY or similar variants have been shown to be effective agonists at Y[ receptors
(Schwartz et al, 1990: Grundemar et al, 1993b). C terminus substitutions at position
31 and at position 34 results in analogues ([Pro 34JNPY and [Leu 31, Pro 34]NPY)
which have full activity at Y( receptors while being virtually inactive at Y2 receptors
(Grundemar et al, 1993a & b). From the results obtained using analogues, it has been
suggested that the hairpin loop is not essential for binding the N and C termini of
NPY molecule in close apposition (Schwartz et al, 1989:1990). However, the
importance of the close steric arrangement of the N and C termini has been illustrated
by the substitution from Tyr to Pro in position 20. [Pro 20]NPY has been found to
break the hairpin like loop, resulting in a loss of affinity for the Y j receptor.
Molecular cloning of receptors has enabled characterisation of the receptor
structure to be studied as well as the receptors pharmacology and tissue distribution.
Using a rat forebrain cDNA library, a clone has been isolated and was subsequently
identified as a Y| receptor (Eva et al, 1990). In addition, cDNA for human Y|
receptor has been isolated and expressed in transfected cells. It has been confirmed
that the isolated Y | receptor from humans is stringent in its demand on N-terminal
part of the ligand (Herzog et al, 1992; Larhammar et al, 1992). Developmentally Y |
mRNA has been detected at day 14 in the rat diencephalon and spinal cord (Jazin et
al, 1993b). In the adult rat a subset of dorsal root ganglion cells express Yi mRNA
(Zhang et al, 1994a). The distribution of the mRNA for this receptor is widespread in
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the brain including the thalamus, hippocampus and cerebral cortex and hypothalamus
(Eva et al, 1990; Mikkelsen & Larsen, 1992; Larsen et al, 1995).
An a-typical Y| receptor located prejunctionally has recently been
characterised in the rabbit isolated vas deferens (Palea et al, 1995). It has also been
suggested that NPY is an important mediator of feeding behaviour through a variant
of Yi receptor (Kalra & Crowley, 1992; Stanley et al, 1992).
1.3.2. NPY Y2 RECEPTOR
N-terminally truncated forms of NPY and peptide YY can activate Y2
receptors (Han & Abel, 1987; Grundemar & Hakanson, 1994; Grundemar et al,
1993b). Hence, NPY (2-36) is about equipotent with NPY or PYY whereas
NPY( 13-36) is less potent than NPY(Wahlestedt & Reis, 1993). It has been shown
that substitutions made to the centre part of the molecule did not affect the ability to
bind to this receptor, suggesting that the hairpin loop of the molecule is not involved
in the recognition at the Y2 receptor per se (Grundemar et al, 1993b). The hairpin
loop is not essential for binding, but it may help to create a steric conformation of the
C-terminal hexapeptide amide that is favourable for Y2 receptor recognition
(Schwartz et al, 1990; Grundemar & Hakanson, 1994; Grundemar et al, 1993a). An
intact C-terminal end of NPY/PYY is required for activation of the Y2 receptor.
Substitution from Gly to Pro at position 34 in [Pro 34]NPY results in a loss of affinity
for the Y2 receptor. It is well established that N-terminal fragments of NPY are
inactive (Wahlestedt et al, 1986; Danger et al, 1987; Wahlestedt et al, 1987;Danhoet
al, 1988; MacKerrell et al, 1989; Wahlestedt et al, 1990). From studies in which
amino acid residues have been substituted, it has been suggested that His 26 is
important for the recognition of Y2 receptor (Minakata et al, 1989). Not only is the
amino acid sequence of the C-terminal of NPY essential but also the C-terminal amide
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group since desamido-NPY and the C-terminally extended form NPY-Gly-Lys-Arg
failed to activate the Y2 receptor (Wahlestedt et al, 1986).
The Y2 clone has only more recently been established compared to the Yj
subtype clone which was identified in 1992. Low sequence identity has been shown
between Yj and Y2 clones. Y2 mRNA has been detected in several brain areas
(Gerald et al, 1995; Rose et al, 1995; Gehlert et al, 1996).
1.3.3. NPY Y3 RECEPTOR
The Y3 receptor recognises NPY but not peptide YY and displays a rank
order of potency for NPY-related peptides that differs markedly from those of the
known Yi & Y2 receptors (Grundemar et al, 199lb; 1993). The main differences
between NPY and PYY are found in the 13-23 segment, where PYY differs from
NPY in 7 of 1 1 positions. The N-terminus of NPY appears to have some importance
for the activation of this receptor, since NPY( 13-36) has less affinity than the intact
molecule. Moreover, like Y| and Y2 receptors, Y3 receptors require an amidated C-
terminal in order to become activated. As of the NPY receptor, a change to Leu at
position 31 and to Pro at position 34 of NPY has virtually no effect on the binding
affinity of the Y3 receptor. It has been suggested that NPY( 18-36) acts as a specific
antagonist to a newly discovered class of NPY receptors which may be present in the
cardiac ventricular system (Balasubramaniam & Sherriff 1990).
A bovine receptor isolated from a locus coeruleus cDNA library was
proposed as the Y3 receptor (Rimland et al, 1991). The human clone from foetal
brain (hFB22) which had 92% sequence homology with the bovine receptor have
been shown not to bind NPY or PYY specifically (Jazin et al, 1993a).
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1.3.4. NPY4/PP! RECEPTOR
This receptor has been found to bind preferentially to PP and was called PPj
and because of its similarity to the Yj receptor it was also named Y4 (Nata et al,
1990; Ballantyne et al, 1993). PYY, NPY & PP all bind with high affinity. In
addition, [Leu 3 1, Pro 34]NPY binds with high affinity and thus is not entirely
selective for Y | receptors (Gregor et al, 1996; Lundell et al, 1996). Furthermore, the
selectivity of this receptor seems to differ between species. PP has been reported to
have a distinct receptor in dog intestinal mucosa (Gilbert et al, 1986; 1990), in rat
phaeochromocytoma PC 12 cells (Schwartz et al, 1987) as well as in the rat vas
deferens (Jorgensen et al, 1990), rat adrenal cortex, and medulla (Whitcomb et al,
1990; 1996). The rat receptor expressed in PC 12 cells has high affinity for bovine PP
and exhibits very low affinity for NPY. In contrast the human receptor binds NPY
with high affinity (Schwartz et al, 1987; Lundell et al, 1995).
This receptor has the highest sequence homology to the Y] receptor type. It
has been isolated from rat (Lundell et al, 1996), mouse (Gregor et al, 1996) and
human (Bard et al, 1995; Lundell et al, 1995) DNA libraries using oligonucleotide
probes based upon the Y | sequence and polymerase chain reaction (PCR) primers.
Northern hybridisation has detected mRNA for this receptor in the colon, small
intestine, pancreas and prostate (Lundell et al, 1995). In addition, mRNA has been
found at low levels in the brain including the hypothalamus and coronary arteries
(Bard et al, 1995). Thus, the distribution of this receptor is more restricted than that
of the Y ] receptor.
1.3.5. NPY Y5 RECEPTOR
A receptor has been isolated in the mouse with 50% sequence homology to
the murine Y| has been named the Y5 receptor (Weinberg et al, 1996). Although, the
Y5 receptor had equal affinity for both NPY & PYY this affinity was reduced
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compared to the human Y j receptor. The high affinity of this receptor for PYY
suggests that this receptor is different from the Y3 receptor In situ hybridisation of
mouse brain sections reveals expression of this receptor within discrete regions of the
hypothalamus (Weinberg et al, 1996).
A rat hypothalamic cDNA encoding an NPY receptor has recently been
discovered (Gerald et al, 1996). It has been suggested that this receptor is the
postulated feeding receptor, its mRNA being found primarily in the CNS including the
paraventricular nucleus of the hypothalamus. It has also been called Y5 although it is
not related to the mouse Ys; receptor. This receptor has been found to be activated
with equal potency by human NPY, PYY and PP. It is also activated by porcine
NPY, NPY2-36 and [Leu31, Pro34] but poorly stimulated by rat PP.
1.3.6. THE SIGMA RECEPTOR
NPY and PYY have been reported to bind with strong affinities to the rat
brain sigma binding sites (Roman et al, 1989; 1990). In the mouse hippocampal
formation, NPY, PYY and [Leu31 ,Pro34] have been reported to displace
approximately 35% of the specific binding of [3H](+)-SKF-10047 to sigma receptors
(Bouchard et al, 1993). However, others failed to reproduce these results using the
same technique (Tarn & Mitchell. 1991).
Other in vivo studies provide evidence for the interaction of NPY with
sigma receptors. In hippocampal pyramidal neurones the potentiation by NPY of
NMDA-induced activation of CA3 has been suggested to occur via sigma type
receptors (Monnet et al, 1992a & b). It is unlikely that NPY interacts with all of the
sigma receptor subtypes, as it appears to discriminate between alpha sites labelled
preferentially with ( + )-[3H]SKF-10,047 and those labelled with [3H]DTG (Bouchard
et al, 1993; Roman et al, 1991).
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1.4. NPY ANTAGONISTS
Benextramine, a tetramine disulphide, was first synthesised by Melchiorre et
al, 1979 as an irreversible adrenergic receptor antagonist. Comparison of
benextramine's chemical composition to the presumed pharmacophore region of the
NPY receptor has suggested that it is an antagonist of this receptor (Allen et al,
1987). Benextramine analogues have demonstrated that the benextramine binding site
on NPY receptors is distinctly different from that on adrenergic receptors (Doughty et
al, 1993). This nonpeptide antagonist has both in vitro and in vivo activity (Doughty
et al, 1990, Tessel et al, 1993, Melchiorre et al, 1994). In the rat brain, benextramine
has been shown to competitively displace a maximum of only 61% of specifically
bound [3H]-NPY (Doughty et al, 1990; 1992). Doughty and collegues have
demonstrated that benextramine-sensitive binding sites in the rat brain were of Yt
subtype while benextramine-insensitive sites were of the Y2 subtype (Doughty et al,
1992). Benextramine has not been shown to discriminate between the peripheral,
postsynaptic Y) & Y2 receptors as it blocks the vasoconstrictive activity of both
[Leu31, Pro34]NPY & NPY( 13-36), in isolated rat femoral artery, with near equal
potency (Tessel et al, 1993). As the constriction produced by NPY appears to be at
least partially mediated by the influx of extracellular calcium, it has been suggested
that benextramine blocked the NPY-induced contractions in vascular tissue by this
mechanism and not through interaction with NPY receptors. In support of the
suggestion that there are distinct differences between the rat brain Y2 receptor which
has low affinity for benextramine and the peripheral postsynaptic Y2 receptor in the
rat, it has been shown that benextramine almost completely abolished contractions
induced by NPY, [Leu 31,Pro34]NPY and NPY 13-36, in the rat isolated femoral
artery (Doughty et al, 1992). Benextramines use is limited as it's effects are
irreversible and it is of low potency (Doughty et al, 1993). Chaurasia and collegues
synthesised new benextramine analogues as NPY functional group mimetics
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(Chaurasia et al, 1994). The retramine carbon analogue N,N'-bis[6-[N-(2-
napthylmethyl)amino]hexyl]-l,6-hexanediamine was equipotent with benextramine in
a rat brain [3H]NPY displacement assay (Chaurasia et al, 1994). The analogues of
benextramine have been reported to be selective, competitive antagonists of
postsynaptic NPY receptors in the femoral artery of the rat (Chaurasia et al, 1994).
Tatemoto introduced 2 C-terminally based benzyl analogues of NPY with
antagonistic properties for the Yj receptor subtype found in human erythroleukaemia
cells (HEL). They are Ac-[3-(2,6-dichlorobenzyl)Tyr27,D-Thr32]NPY-(27-36)amide
and Ac-[3-(2,6-dichlorobenzyl)Tyr27,36, D-thr32]NPY27-36 PYX1 & PYX2
respectively. Both bind to the NPY receptors in rat brain membranes which are
predominantly of Y2 type (Schwartz et al, 1989). Although, PYX2 is more potent
than PYX1 the peptide nature of PYX2 and its unknown stability both in vitro and in
vivo it is likely that its use is limited (Wahlestedt & Reis, 1993). There have been
inconsistent reports in the literature of PYX2 as a Y[ antagonist. It has been reported
to reduce the magnitude of contractions induced by NPY in both isolated uterine
artery and vena cava of guinea-pig (Morris & Sasbesan, 1994). In addition, PYX2
has been reported to inhibit NPY-induced carbohydrate intake in Sprague-Dawley rats
(Leibowitz et al, 1992) yet failed to inhibit food intake in obese Zucker rats via the
putative Y) receptor (Beck et al, 1994). There is evidence that NPY is an important
mediator of feeding behaviour through a variant of the Y j receptor (Stanley et al,
1992). Thus, it is not clear if PYX2 is an antagonist of the Y | receptor or if it is able
to discriminate between 2 different subtypes of this receptor.
1229U91 effects has been assayed in the mesenteric arteries of the mouse
and rat and in the rat vas deferens (Lew et al, 1996). This study reported that it is a
competitive antagonist of smooth muscle Y| receptors of the mesenteric arteries. In
contrast, it has some apparent agonist activity, but no detectable antagonist activity in
the rat deferens assay which has previously been shown to contain prejunctional
receptors of Y2 subtype (Doods & Krause, 1991). The effect of 1229U91 is
36
relatively rapid in onset taking just one minute to peak and declines slightly over 5
minutes. The effect of NPY has a slower onset of at least 5 minutes and does not
exhibit any significant decline. Yet, unlike a partial agonist of Yj it caused no
rightward shift of the concentration-response curve. However, it has been suggested
that the difference in time course from NPY is due to different sites of action. The
difference between its reported potency in the brain (Daniels et al, 1995) and in rat
vas deferens assay (Lew et al, 1996) suggests that nominally Y2 receptors may be a
heterogeneous class.
The C-terminal octapeptide NPY( 18-36) has been shown to be a
competitive NPY antagonist in rat cardiac ventricular membrane (Balasubramaniam &
Sherriff, 1990). NPY( 18-36) however, has been known to exhibit NPY agonist
activity in reducing cardiac output (Boublik et al, 1990). At Y2 like NPY receptors in
various tissues, NPY( 18-36) acts as a full agonist compared to NPY with a potency
very similar to that of NPY and PYY (Michel et al, 1990). Therefore NPY( 18-36)
may be an antagonist at Y3 like receptors, a partial agonist at Y[ like and a full
agonist at Y2 like NPY receptors. This fragment thus serves as little use as an
antagonist (Wahlestedt & Reis, 1993).
HE90481 is a potent H2 histamine receptor agonist that also binds to alpha
2-adrenoceptors (Michel & Motulsky, 1990). It blocked NPY evoked Ca2+
mobilisation and NPY binding to cells but with low potency (Michel & Motulsky,
1990). Its lack of specificity and low potency invalidates its use in physiological
assays (Michel, 1991).
BIBP3226, SRRO107A and SR120819A, non-peptide antagonists, have
been found to act at Yi receptors (Rudolf et al, 1994; Serradiel-Le Gal et al, 1995)
but not on Y2 or Y2 receptors (Doods et al, 1995; Jacques et al, 1995; Lundberg &
Modin, 1995). BIBP3226 has been found to reduce the duration of the
vasoconstrictor response to sympathetic nerve stimulation in vascular beds of the pig
(Lundberg & Modin 1995). The corresponding S-enantiomer BIBP3435 was not
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active at Yj receptors (Rudolf et al, 1994). Transient effects of BIBP3226 on blood
pressure and basal vascular conductance in spleen and mesenteric circulation have
been found without major changes in heart rate. However, these changes also
occurred with the S-enantiomer suggesting that this effect is unlikely to involve Y t
receptor mechanisms. Instead it has been suggested that these effects are mediated
indirectly via the charged arginine like groups (Lundberg et al, 1996).
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1.5. MECHANISM OF ACTION OF NPY RECEPTORS AT A
CELLULAR LEVEL
Ideally second messenger activation should be considered in relation to
defined receptors. In some of the studies below however, the effects of second
messengers have been linked to NPY without consideration of the receptors involved.
Most of the action of NPY seem to involve a Gi/Go type guanine nucleotide binding
proteins as these actions are pertussis toxin (PTX) sensitive (nodose neurones: Wiley
et al, 1993, cardiac cells: Keung & Karliner, 1990, dorsal root ganglion cells: Holz et
al, 1989). Biochemical analysis has revealed that dorsal root neurones contain the
alpha subunits of at least two types of pertussis toxin substrates Gi2 and Go. The
latter subunit was found in the highest concentration (Ewald et al, 1989). NPY
receptors in dorsal root ganglion neurones can be modulated by GTP and its stable
analogues (Walker et al, 1988). The ability of NPY to inhibit calcium currents can be
abolished by pertussis toxin and reconstituted by the 39-kDa alpha subunit of Go but
not by 2 closely related G-proteins, Gij and Gi2 (Ewald 1988 a & b). In contrast,
NPY-mediated presynaptic inhibition in the hippocampus was PTX insensitive,
suggesting that tissue specific differences exist in the signal transduction pathways
that couple NPY receptors to intracellular second messenger systems (Colmers &
Pitman 1989). Furthermore, Y2 receptors have been shown to be coupled to multiple
signal transduction pathways in the same cell type, all of which are pertussis toxin
sensitive (Shigeri & Fujimoto, 1994). Whether this coupling is to activation of
phospholipase C or generation of inositol triphosphates is uncertain. It has been
demonstrated that NPY can stimulate the synthesis of inositol triphosphate (IP3) and
diacylglycerol in dorsal root ganglion neurones (Perney & Miller, 1989). Both NPY
and bradykinin can activate IP3 in the same cell but seem to utilise different G-
proteins. Some evidence suggests a role for the enzyme protein kinase C as the ability
of NPY to inhibit neuronal Ca2+ channels is reduced following down-regulation of
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protein kinase C due to prolonged exposure to phorbol esters (Rane & Dunlap, 1986;
Ewald et al, 1988a). Since mobilisation of Ca2+ from intracellular stores by many
receptors occurs secondary to the generation of IP3, it has been debated whether or
not Ca2+ mobilisation of NPY receptors depends on the activation of a phospholipase
C. Generation of IP3 at early time points (before or during the Ca2+ rise) has been
convincingly demonstrated in two studies (Daniels et al, 1989; Perney & Miller,
1989). Other investigators, however, were unable to demonstrate inositol phosphate
generation by NPY at early time points, even though other hormones (which were
equally effective at raising intracellular Ca2+) significantly stimulated inositol
phosphate generation (Motulsky & Michel, 1988; Mihara et al, 1989; Lobaugh &
Blackshear, 1990).
Inhibition of adenylate cyclase by NPY has been demonstrated in every
tissue studied and in several cell lines, including model systems with pharmacological
characteristics of Y [ like (Michel et al, 1990), Y2 like (Wahlestedt et al, 1990), and
Y3 like (Balasubramaniam & Sheriff, 1990) NPY receptors. Inhibition of adenylate
cyclase has been demonstrated in many studies including pig spleen (Lundberg et al,
1988), neuroblastoma SK-N-MC cell line (Olasmaa et al, 1987), human
erythroleukemia cells (Motulsky & Michel, 1988), rat atrial cells (Kassis et al, 1987),
and the human frontal & temporal cortex (Westlind-Danielsson et al, 1987). A
catalytic substitution for cAMP-dependent protein kinase A increased calcium
currents in nodose neurones (Gross et al, 1990). Thus NPY receptors can couple to
mobilisation of Ca2+ from intracellular stores via inositol phosphate dependent and
independent pathways. Although the inositol phosphate-independent pathway of
Ca2+ mobilisation is still obscure, it is clear that it does not involve lipoxygenase or
cycloxygenase products of arachidonic acid or a sodium/hydrogen antiporter but
instead uses a thatpsigargin sensitive store (Motulsky & Michel 1988; Aakerlund et al,
1990). NPY receptors may also stimulate inositol phosphate generation indirectly-in
some cell types NPY enhances the generation induced by other hormones (Haggbald
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& Fredholm, 1987; Lobaugh & Blackshear, 1990). Since some isoforms of
phospholipase C are Ca2+ sensitive it is possible that this potentiation of inositol
phosphate generation is a result of NPY-induced increases in intracellular Ca2+.
(a) NPY receptors and Ca2+ channels
Studies investigating the mechanisms by which NPY might inhibit calcium
channel activity has been complicated by lack of suitable antagonists. In addition,
preparations of isolated sympathetic neurones respond in heterogeneous manner to
applications of NPY (Schofield & Ikeda, 1988; Foucart et al, 1993) with modulation
of Ca2+ channel activity being restricted to sub populations of cells. In isolated rat
sensory nodose neurones opposing effects of NPY have been observed: where NPY
inhibits currents via Y2 receptors and enhances currents via Y| receptor activation
(Wiley et al, 1993).
The mechanisms by which NPY receptors are coupled to Ca2+ channels has
not been resolved. Bath applied NPY has been shown to be ineffective on Ca2+
channels recorded in cell attached patches (Hirning et al, 1990) a finding which argues
in favour of a closely coupled membrane-delimited mechanism. The effects of NPY
on Ca2+ influx through voltage-dependent Ca2+ channels have been examined in
cultured dorsal root ganglion neurones. The inhibition of the channel has been
accompanied by a slowing of the activation kinetics (McDonald et al, 1995). This
effect has been described for the action of numerous other G-protein receptors on
voltage gated channels (Bean, 1989). Luebke & Dunlap suggested that 2 distinct
pathways for inhibition of N-type current exist: one associated with kinetic slowing
which is voltage dependent, the other simply reducing current amplitude without any
voltage dependence or change in current kinetics and that noradrenaline & GABA are
capable of using either pathway (Luebke & Dunlap, 1994). Mobilisation of Ca2+
from intracellular stores was first demonstrated in HEL cells (Motulsky & Michel,
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1988) and has now been found in various other cell types (Perney & Miller, 1989;
Aakerlund et al, 1990; Mihara et al, 1989). Bleakman et al (1991) found that NPY
inhibited the calcium influx through voltage gated Ca2+ channels NPY has also been
effective in reducing Ca2+ influxes when trains of action potentials have also been
used to elicit increases in intracellular Ca2+ (Bleakman et al, 1991). The receptor
subtype mediating this inhibition of voltage dependent calcium channels appears to be
of the Y2 type by virtue of its response to C terminal fragments (Bleakman et al,
1991). In acutely isolated vagal afferent neurones dissociated from rat nodose
ganglion, NPY at maximal concentration blocked about 30% of the peak current
ganglion via Y2 receptors. In approximately 5% of these neurones, application of
NPY increased the influx of Ca2+ through voltage dependent Ca2+ channels by about
20%. This facilitation has been reported to result from the activation of Y| receptors
(Wiley etal, 1993).
NPY has been shown to inhibit Ca2+ currents in sympathetic cells (Plummer
et al, 1991). Although the Y2 receptor has been shown to mediate inhibition of
noradrenaline release from sympathetic terminals in intact preparations (Whalestedt &
Reis 1993), it appears that inhibition of voltage sensitive calcium channels in acutely
isolated superior ganglion cells is mediated by a different receptor (Foucart et al,
1993). The agonist profile resembles that of the Y3 receptor (Balasubramaniam &
Sherriff, 1990; Grundemar et al, 1991b).
In the neurones of the bullfrog paravertebral sympathetic ganglia, NPY, like
noradrenaline activates, an inwardly rectifying potassium current (Zidichouski et al,
1990). However, NPY has been found to potentiate but not activate the inwardly
rectifying potassium current produced by activation of the alpha 2 adrenoreceptors in
locus coeruleus neurones (McEnery et al, 1994).
In SH-SY5Y cells the effects of NPY were additive with nifedipine
suggesting that NPY predominantly inhibits N-type Ca2+ channels. This finding is in
agreement with the results obtained with NPY's presynaptic action in sympathetic
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neurones which were co-cultured with atrial myocytes (Toth et al, 1993). Similarly,
NPY has been shown to inhibit somatic N type channels in isolated sympathetic and
sensory neurones via Y2 receptor activation (Foucart et al, 1993; Wiley et al, 1993).
Inhibition of N-type Ca2+ channels by NPY has been studied electrophysiologically in
various neuronal preparations including dorsal root ganglion neurones (Walker et al,
1988; Perney et al, 1989), rat vagal afferent neurones (Wiley et al, 1990) and cultured
rat myenteric neurones (Hirning et al, 1990). These studies have also demonstrated
that inhibition is mediated via Go and is not accompanied by inhibition of L or T-type
Ca2+channels (Wiley et al, 1990; Hirning et al, 1990). Inhibition of N-type Ca2+
channels in neuronal preparations may be the mechanism for presynaptic inhibition of
transmitter release.
Evidence that L type Ca2+ channels are activated by NPY is indirect and
comes mainly from functional studies on vascular smooth muscle. Such studies
demonstrate that NPY-stimulated direct and indirect (i.e. potentiation of
noradrenaline response) vasoconstriction in vitro and in vivo is sensitive to
dihydropyridine-type Ca2+ entry blockers (Lundberg et al, 1985b & 1988).
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CHAPTER 2: Introduction to Neuropathic Pain
2. NEUROPATHIC PAIN
This second part of the introduction focuses on neuropathic pain. It begins
with a brief historical description of neuropathic pain in humans followed by a
description of the associated animal models developed. The role of the sympathetic
system after nerve injury is discussed as well as the changes which occur peripherally
and centrally in rats with a partial nerve injury produced using the Bennett & Xie
method.
2.1. COMPLEX REGIONAL PAIN SYNDROMES-CAUSALGIA
After the American civil war, causalgia was first described by Mitchell as a
painful syndrome which sometimes develops after peripheral nerve injury associated
with penetrating wounds but not involving a complete transection. Causalgia is
characterised by a rapid onset (usually within hours of insult) of spontaneous constant
burning pain in addition to hyperalgesia (increased sensitivity to noxious stimuli) and
allodynia, pain response to low threshold stimuli which is normally innocuous,
(Mitchell, 1872; Livingston, 1943, Sunderland & Kelly, 1948). The constant burning
pain has been found to be exacerbated by several factors such as temperature change,
movement of the involved limb, visual and auditory stimuli and emotional
disturbances (Bonica et al, 1970; Loh & Nathan, 1978; Merskey, 1986). The pain has
been reported to sometimes spread beyond the cutaneous distribution of the damaged
nerve (Merskey, 1986; Proccacci & Maresca, 1987; Rabin & Anderson, 1985). In
addition, the pain may appear in mirror image sites on the contralateral intact limb
(Rabin & Anderson, 1985; Mitchell, 1872). This syndrome has been well documented
especially in military populations (Mitchell 1864; Livingston 1943, Sunderland &
Kelly, 1948; Richards, 1967; Sunderland, 1976; Bonica, 1979). In addition to the
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above syndrome others have used different criteria in identifying cases of causalgia
(for review see Schott, 1986). Patients with a similar pain syndrome without evidence
of nerve injury have been reported as mimocausalgia (Patman et al, 1973; Thompson
& Patman, 1975) and minor causalgia (Hardy et al, 1958; Wirth & Rutherford, 1970).
In 1953 Bonica reserved the term causalgia for persistent burning pain that
follows traumatic injury of a major peripheral nerve and later reported that this pain
may be exacerbated by sympathetic arousal or tactile stimulation (Bonica, 1953;
1970). In 1979 the syndrome was redefined by the International Association for the
Study of Pain (IASP) as a syndrome of sustained burning pain after a traumatic nerve
lesion combined with vasomotor and sudomotor dysfunction and later trophic
changes. This pain was often accompanied by hyperpathia (delay, over reaction and
after sensation to stimulus, especially repetitive stimuli) and allodynia (IASP 1979,
Merskey, 1982). Tahmoush reported that this syndrome occurred after a wide
spectrum of injuries in both civilian and military populations, either with or without
clinical evidence of nerve damage of vasomotor and sudomotor dysfunction and
trophic skin changes (Tahmoush, 1981). He suggested that the autonomic
disturbances had been overemphasised in the IASP definition and thus suggested an
alternative set of criteria that were necessary to define causalgia. Tahmoush
suggested that within weeks prior to the onset of pain a traumatic event occurs
proximal to the painful area. The presence of hyperalgesia, allodynia and continuous
burning pain distal to the site of injury were required to define the syndrome as
causalgia.
In some patients with trauma-related continuous pain syndromes, dystrophic
changes in a limb are prominent. Evans (1946) described the global term reflex
sympathetic dystrophy (RSD) to describe clinical conditions in which pain was likely
to be maintained by the ongoing activity of the sympathetic nervous system. The term
algodystrophy has also sometimes been used to describe this syndrome. Minor tissue
trauma and fractures and non-traumatic nerve lesions were among the precipitating
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events. The term RSD has generally been used when the condition was not associated
with obvious peripheral nerve trauma. The changes associated with this syndrome
have been found to occur distally in the affected extremity showing a triad of
autonomic, motor and sensory symptoms with a glove- or sock-like distribution being
reported (Blumberg, 1991: Blumberg & Janig, 1993; Kurvers et al. 1995). Patients
have some or all of the following symptoms: spontaneous burning pain, hyperalgesia ,
hyperpathia (delayed and exaggerated painful response to stimuli), dystrophic changes
in skin and deep somatic tissues and a conspicuous abnormal neural regulation of
sympathetic reflexes supplying blood vessels and sweat glands (Rizzi et al, 1984).
Similarities between causalgia and RSD have frequently been described (Evans, 1946;
Bonica 1953).
The use of sympathetic blocks also led to the idea that some patients have
sympathetically maintained pain (SMP) and others sympathetically independent pain
(SIP) (Roberts & Elardo, 1985). The term sympathetically maintained pain was
introduced by Roberts (1986) and subsequently used by others (Campbell et al, 1992;
Frost et al, 1988; Meyer et al, 1992). SMP may be a feature of several types of
painful disorders thus it may accompany a wide spectaim of disorders. The principal
symptoms are spontaneous pain and mechanical and cold allodynia within the zone of
the lesioned nerve (Blumberg & Janig, 1993; Frost et al, 1988; Meyer et al, 1992;
Tredde et al, 1992; Torebjork et al, 1995). The definition of SMP is entirely
pragmatic, depending on the outcome of regional blocks. It has been reported that
sympathetically maintained pain is a phenomenon that appears to be inconsistent and
variable over time, such that at one observation, a given patient may have pain that is
partially or wholly sympathetically maintained but at another (usually later) time, the
pain may be entirely sympathetically independent. In addition some authors have
reported that a series of blocks may be necessary to produce pain relief (Wynn Parry
& Withrington, 1984) which creates a practical problem in the diagnosis of SIP.
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In 1995 the IASP redefined causalgia, RSD and SMP. The classification
was based upon the signs and symptoms as the underlying mechanisms for these
disorders remain unclear (Stanton-Hicks et al, 1995). Causalgia and RSD were
termed as complex-regional pain syndromes (CRPS) with specific criteria determining
the type of syndrome. The overall term, CRPS, infers that regional pain and sensory
changes following a noxious event must be present. The name is intended to be self
explanatory. Complex was used to denote the varied clinical phenomena found in
addition to pain. It is usually the distal part of a limb that is affected although the
symptoms have also been reported on the torso or face and may spread to other areas
(Bentley &Hammeroff, 1980) thus the term regional has been used. Pain is the
cardinal symptom for this syndrome.
Type I corresponds to the most common disorder previously known as RSD
and attempts to describe the symptoms of the typical patient without a definable nerve
lesion whereas type II, formerly called causalgia, refers to cases where a definable
nerve lesion is present. The frequent accompaniments of altered vasomotor,
sudomotor and trophic states were not included as diagnostic prerequisites since no
constant relationship between these states and the pain has been established. CRPS
type 1 (RSD) develops after an initiating event. It typically has deep, diffuse pain
which may respond to sympathetic block. Variable etiological factors can include
repetitive minor trauma, stoke, immobilisation, myocardial infarction and over-strain
(Askey, 1941; Steinbrocker et al, 1948; Moskowitz et al, 1958; Patman et al, 1973;
Low & Nathan, 1978). Both syndromes report pain that is disproportionate to the
inciting event either in the form of spontaneous pain and/or allodynia and hyperalgesia
which may extend beyond the territory of a single peripheral nerve. There is evidence
at some time (not necessarily at the time of diagnosis) of edema, changes in skin blood
flow or abnormal sudomotor activity in the region of pain. CRPS type II (causalgia)
develops after nerve injury and is intended to include patients fitting the classical
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description of causalgia (Richards, 1967;Bonica, 1970; 1990). These patients have a
partial lesion which is acutely followed by pain within the zone of the lesioned nerve.
This report emphasised that SMP may be a feature of several types of
painful conditions and is not as essential requirement of any one condition. It is pain
that is maintained by sympathetic efferent innervation or by circulating catecholamine.
It was suggested that a patient may have a portion of the pain which was
sympathetically maintained and a portion sympathetically independent. It can be
associated with a number of diseases and a positive response to a sympathetic block
should neither be a factor in the nomenclature of the disease nor define the disease.
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2.2. DIFFERENT MODELS OF NEUROPATHIC PAIN
Peripheral nerve transection has been extensively studied experimentally but
it does not produce the signs and symptoms associated with clinical nerve damage
since there is complete deafferentation. Therefore models have been developed which
more closely resembled the human syndromes associated with nerve injury. The
Bennett & Xie model was the first animal model of this type and will be described in
the greatest detail in the following sections as this was used in the present studies.
The initial study for each of these these partial nerve injury models is desribed below.
2.2.1. THE BENNETT & XIE MODEL
Bennett & Xie described this procedure in 1988. The following description
is taken from this publication. Adult male Sprague Dawley rats were anaesthetised
with sodium pentobarbital and the common sciatic nerve exposed at the middle of the
thigh by blunt dissection through the biceps femoris. Proximal to the sciatic nerve's
trifurcation, the nerve was freed of adhering tissue and 4 ligatures (4.0 chromic
catgut) were tied loosely around the nerve with approximately 1mm spacing. The
ligatures were tied so that the diameter of the nerve was found to be just barely
constricted when viewed with 40x magnification. Sham operations were performed
on the opposite side of each animal.
Pain-related behaviours ipsilateral to the sciatic ligation were found to occur
in most of the rats by 6-8 days after surgery and became maximal during the second
postoperative week (12-15 days). The results obtained by this initial study are
described in more detail below.
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2.2.1.(a) Posture and gait
The gait of the rat was most variable during the initial week postoperatively.
The affected paw was everted with only the medial edge of the foot touching the
floor. Toes were held together and were ventroflexed. Rats were often seen to
suddenly raise the affected hind paw quickly from the floor and hold it in a protected
position next to the flank while standing or sitting. Bennet & Xie (1988) suggested
that this sudden action was due to sudden pain. In addition, the rats walked with a
limp which was most prominent during the first few postoperative days and became
much less noticeable after 4-6 weeks. About 70% of the rats exhibited autotomy
(self-mutilation) which began on the first postoperative day and was most common
during the first 10 days postoperatively. Extensive autotomy was rare. In most cases
autotomy began with gnawing of the claw tips and proceeded until the root claw was
bloodied. Autotomy was not evident on the hind paw on the sham-operated side.
2.2.1.(b) Mechanical allodynia
Mechanical thresholds were determined using a Randall-Selitto
analgesymeter. Calibrated pressure of gradually increasing intensity was applied to
the middle of the hind paw dorsum between the second and third or third and fourth
metatarsals until the rat withdrew the hindpaw. Placement was varied slightly
between trials and the stimulus intensity was recorded as grams of force. Hind paws
were tested alternatively at 3-4 min intervals until 3 measurements were obtained for
each side. A difference score was calculated by subtracting the average of the control
side from the average of the ligated side. Difference scores between the right and left
hind paws were determined before surgery and on postoperative day 19. The
preoperative withdrawal threshold and the preoperative mean difference scores for the
control group did not differ significantly from those obtained for the ligated animals.
Postoperative mean difference scores for ligated animals and separate sham operated
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animals were not significantly different from each other. Thus evidence of mechanical
allodynia was not obtained in this initial study.
Evidence of mechanical allodynia and hyperalgesia however was found in
the study of Attal et al (1990). They used a modified version of the analgesymeter to
determine the vocalisation threshold to paw pressure. Until day five the lesioned paw
was hypoalgesic as indicated by a significant increase in thresholds for vocalisation.
By two weeks after surgery the mean vocalisation threshold of the ligated paw was
approximately 66% of the preoperative control reflecting a significant allodynia. The
threshold for vocalisation was also significantly reduced in the opposite paw, the sham
operated paw, compared to the preoperative control values at this time. The
mechanical allodynia of the ipsilateral hind paw was thus maximal during the second
week postinjury after which time it began to decrease until recovery by week 8.
Attal and co-workers used a pair of graduated smooth serrated forceps to
pinch the middle of the plantar hind paw. The onset of hyperalgesia in the ligated hind
paw appeared to be variable during the first five days postoperatively when some rats
were hypoalgesic. Two weeks after surgery, the majority of rats had a maximal
reaction to pinch. This hyperalgesia declined gradually until complete recovery at
week 12. In contrast, no changes occurred in the sham operated paw after surgery.
2.2.1.(c) Thermal allodynia
Normally innocuous thermal stimuli were applied to the hind paw after
surgery to detect whether allodynia was present after surgery. Rats were exposed for
20 minutes to a floor that was warmed by a 30°C bath or chilled by a cold water bath
at 4°C. The behaviour of the animal was noted and an event recorder was used to
measure the time that either hind paw was held above the floor while the animal was
sitting or standing. Occasionally the rats stood with the affected hind paw elevated
above the floor for I -5 seconds. Thirty days after surgery, the cumulative duration of
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such events averaged 30 seconds for the 20 minute observation period Paw
withdrawals were more frequent and often occurred in a series of 3-4. The average
frequency of hind paw withdrawals on the nerve-damaged side increased 5-fold and
the average cumulative duration of the hind paw withdrawals increased 2-fold. The
cold stimulus frequently did not elicit a response in the hindpaws of control animals.
2.2.1.(d) Thermal hyperalgesia
To behaviourally test the response to noxious heat, rats were placed beneath
an inverted clear plastic cage upon a glass floor. A heat source placed at 90° to the
hind paw was positioned such that the proximal 1/2 of the plantar surface was
irradiated. Stimulus onset activated a timer that was controlled by a photocell
positioned to receive light reflected from the hind paw. By interrupting the
photocell's light the hind paw withdrawal reflex automatically stopped the timer. The
hind paws were tested alternately with 5 minute measurements taken for each hind
paw in each test session. The 5 latencies per side were averaged and a difference
score computed by subtracting the average latency of the control side from the
average latency of the ligated side. The results were expressed as difference scores
and result from the ligated and sham operated animals were compared.
A single heat test session during the first 5 postoperative days evoked severe
edema in the hindpaw on the ligated side in the majority of rats but not in the sham
operated side. Although the onset of hyperalgesia was earlier than day 5 for some
animals, tests were performed after postoperative day 5 to avoid this edema. Eighty
five percent of the rats were hyperalgesic (as defined by a negative mean difference
score that was more than one standard deviation below the mean of the normal
population). The remaining 15% of animals were hyperalgesic by days 8-10.
Hyperalgesic responses to noxious radiant heat were evident on the second post
operative day and lasted for over 2 months.
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2.2.1.(e) Temperature changes in the hind paws
The temperature of the plantar surface of the hind paw was measured by
placing it on a small plate made of thin copper which had a thermistor attached at the
site where the paw was placed. The hind paw was held against the plate such that the
plate was covered completely by the part of the sole that lies proximal to the plantar
pads. Stable temperature readings were obtained in 30-60 seconds and measured to
the nearest 0.1°C. Only I out of 30 normal rats had a temperature difference greater
than ±1.0°C when the temperature of the right paw was subtracted from the
temperature of the left paw. In contrast, temperature differences greater than 1°C
were found more frequently when the hind paws in the nerve injured animals were
compared. The hind paw on the injured side was found to be either abnormally cool
or warm relative to normal control values. Therefore, the mean temperature
difference of the nerve damaged group was approximately zero and thus not
significantly different from the mean of the normal group.
2.2.1.(f) Chemical hyperalgesia
Mustard oil was applied to the distal 2/3rds of the dorsal hind paw to
demonstrate hyperalgesia to a noxious chemical stimulus. Notes were made of the
animals behaviour and a stopwatch was used to measure the latency of the initial
reaction and the duration of time that the hind paw was held above the floor during a
5 minute observation period. Prior to nerve injury mustard oil evoked a stereotyped
series of responses. After an average latency of 1 1 seconds, the rats rapidly shook the
treated hindpaw rapidly during the next 15-20 seconds. The shakes were too rapid to
count and usually occurred as the rat walked. This was followed by grooming the
paw which only lasted a few seconds probably because the mustard oil tasted
unpleasant. Postoperative responses from the hind paw on the sham-operated side
were identical to the preoperative responses but the responses of the ligated side were
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clearly abnormal. The rapid shaking and grooming was similar but the hindpaw was
elevated above the floor for over 30 seconds at a time. When the paw returned to the
floor another prolonged withdrawal was often evoked immediately.
2.2.2. THE MODEL OF KIM AND CHUNG
In this procedure the lumbar ( L ) spinal nerves L5 and L6 or the L5 spinal
nerve alone of one side of the rat were tightly ligated with 3.0 silk thread. The same
procedure was carried out on the opposite side of the animal without nerve ligation.
The results obtained by the initial study by Kim and Chung (1992) are described
below.
2.2.2.(a) Posture and gait
Postoperatively, the paw of the rat was everted on the injured side and the
toes held together. Sixteen weeks later (at the end of the study) this deformity was
still present. The hind paw on the operated side was held elevated in the air in a
protected position for 6 weeks. Observations of the general behaviour of the rat
suggested that spontaneous pain had developed in the hind paw after the surgical
procedure. The rat sometimes suddenly licked the operated hind paw which was
followed by immobility in the absence of external stimuli. In addition, licking of toes
and pulling the nails with the mouth occurred although signs of autotomy were
absent. The licking behaviour may be correlated with that of the human neuropathic
patient who attempts to relieve pain by wetting the painful extremity with water
(Richards, 1967; Tahmoush, 1983).
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2.2.2.(b) Mechanical allodynia
The rats were placed on a metal mesh floor and mechanical stimuli were
applied from underneath the animal with 6 different Von Frey hairs to the plantar
surface of the foot. The occurrence of foot withdrawal was expressed as a frequency
of response. From twelve to twenty hours after surgery the rats began to respond to
mechanical stimulation by the weakest Von Frey hair (8.4mN) which produced no
response prior to injury. The strongest force (186.7mN) produced no response in
shams but a response in both the ipsilateral hind paw from day one and contralateral
hind paw from postoperative day 21. This sensitivity on both paws was still present at
16 weeks which was the end of the study period.
2.2.2.(c) Thermal hyperalgesia
The latency of foot withdrawal to noxious heat stimuli was measured using
the method described by Bennett & Xie (1988). On the side ipsilateral to the nerve
injury, the withdrawal latency to heat was shorter and the behavioural response to
noxious heat stimuli became exaggerated. Licking the paw after stimulation was
frequently observed. This model produced a long-lasting hyperalgesia to noxious heat
which was significant from day 3 until postoperative week 5. After this time, the
difference scores were not significantly different from that of the unoperated control
group. These results suggested that the peripheral nerve injury induced thermal
hyperalgesia in these rats.
2.2.3. THE MODEL OF SELTZER AND SHIR
This model was described in 1990 by Seltzer et al, 1990. Under ether
anaesthesia the sciatic nerve was exposed at high thigh level. Silicon-treated suture
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(8-0) was inserted into the nerve and tightly ligated around 1 /3rd to 1/2 of the sciatic
nerve thickness leaving the remainder unaltered. Sham operations were performed in
separate animals.
2.2.3.(a) Posture and gait
After surgery, the paw was guarded by holding elevated in the air and when
placed on the floor the two lateral toes were flexed. This deformity was found to last
for several weeks and when the rats were encouraged to walk no limping was noticed.
2.2.3.(b) Mechanical allodynia
Mechanical allodynia was determined using Von Frey hairs in ascending
order of force. A quick flick of the paw indicated that threshold had been reached.
One hour after injury the average thresholds in the injured paw and in contralateral
intact paw decreased. This decrease was more marked in the injured side. These
bilateral changes remained during the follow up period which extended to 54 days
postoperatively.
2.2.3.(c) Mechanical hyperalgesia
A single prick was given at the midplantar area using a sharply pointed
plastic rod and the behavioural response noted. Pin-prick elicited exaggerated
responses in the paw ipsilateral to the nerve injury. Fifty four percent of the responses
to pin-prick were exaggerated by the second postoperative day. The proportion then
decreased to 30% at which it remained for the next 5 weeks. Exaggerated responses
to this stimulus were also obtained for the contralateral intact paw, but were less
frequent than those obtained for the operated side.
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2.2.3.(d) Thermal allodynia
The withdrawal threshold to heat was determined by beaming short pulses of
infra-red radiation from a C02 laser at the mid-plantar area of each paw and
averaging the values obtained at 3 different locations. Thresholds were measured by
gradually increasing the duration of the pulses until the rat responded with a paw
flick. The threshold for a paw was calculated as the average of the threshold
determined at 3 locations per paw. In sham operated animals, the withdrawal
threshold to noxious heat pulses did not change postoperatively. However, a bilateral
decrease in threshold was obtained in animals with a partial nerve injury. This was a
rapid (present 1 hour after surgery) and long-lasting decrease in the withdrawal
threshold to heat stimuli. A suprathreshold heat stimulus produced a quick flick and
brief licking of the hindpaw in sham animals. In addition to a more robust flick when
the injured paw was stimulated the behavioural response was exaggerated with the
animal attempting to escape. As the actions of the animal were variable the duration
of the response was quantified. The peak ipsilateral increase occurred during the first
week postoperatively, thereafter it declined to a plateau which was still more than
double the preoperative value, or that of the contralateral intact hindpaw. When
studied 7 months postoperatively, the response duration at the right hind paw was still
twice that of the left side.
2.2.3.(e) Thermal hyperalgesia
Three C02 laser heat pulses of noxious but non-tissue damaging intensity
were aimed at the mid-plantar area of each foot, alternating between the two hind
paws. The time that lapsed between lifting the paw until replacing it on the floor was
recorded.
Decreased withdrawal thresholds to C02 laser pulses appeared in 97% of
partially injured rats, both in the right and left paws. Increased response duration of a
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suprathreshold heat pulse was detected in the right hind paw in 78% and in the left
hind paw in 11% of the partially injured rats.
2.2.3.(f) Cold allodynia
To test the behavioural response to a cold stimulus a metal plate with a
surface temperature of 5 ±0.2 C was used and the time the paw was in the air
measured. When the rats were placed on a 5°C cold plate for 5 minutes, at day 14
postoperatively, unoperated paws were withdrawn significantly more than operated
paws.
2.2.4. DELEO'S MODEL
Cryoanalgesia, the technique of freezing nerves, was first used clinically for
the treatment of postoperative and chronic pain. Paradoxically, this same technique
has been found to produce characteristics in a rat model suggestive of neuropathic
pain (DeLeo et al, 1994). Freeze lesions temporarily disrupt normal functioning but
do not induce endoneurial structural damage. This peripheral nerve lesion has been
produced in the rat by applying a cryoprobe cooled to -60°C in a 30-5-30 second
freeze-thaw-freeze cycle proximal to the sciatic nerve trifurcation. In addition, the
contralateral nerve was exposed for the same time period but not cryolesioned serving
as a sham-surgery control.
2.2.4.(a) Posture and gait
Immediately following recovery from anaesthesia the rats were found to
hold the injured paw above the floor. The toes were closed and ventroflexed and the
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sole of the foot was turned up medially. This postural sign was evident until
approximately 14-16 days postoperatively. The spontaneous nociceptive behaviour of
the rat was assessed as previously described by Hayes et al (1992). Rats were
observed for 5 minutes and the time course of these behaviours recorded. The
animals were studied for signs of elevation of the hind paw, licking or scratching of
the hind paw or placement of only the medial edge of the heel on the surface.
Autotomy was present in this model from the first day after surgery. The
average onset occurred by 4 days postoperatively and significantly increased in
severity between 10-14 days. By 3 weeks the presence of autotomy had disappeared
and substantial healing of the affected paw was present.
2.2.4.(b) Mechanical allodynia
To determine mechanical allodynia Von Frey hairs were used. The gauge of
probe that elicited foot withdrawal was recorded as the sensitivity threshold for the
paw on that day. After injury until day 15 the tactile sensitivity in the operated paw
was significantly suppressed but there was no change in the sensitivity of the control
paw. At 15 days postoperatively tactile sensitivity in the operated paw returned to
normal, however mechanical allodynia was evident in contralateral paw at this time.
By 26 days postoperatively mechanical allodynia was present in both paws and
persisted until 42 days.
2.2.4.(c) Thermal allodynia
Hindpaw withdrawal reflexes were measured as previously described.
Immediately after the nerve lesion, paw withdrawal to radiant heat was reduced
indicating that the affected paws were hypoesthetic. Rats did not withdraw the
affected limb from a radiant heat until postoperative day 7. By the beginning of the
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3rd postoperative week, 80% of the rats had returned to their baseline latency in
response to the noxious heat stimulus.
Summary
Although these models differ in duration and onset times they produce
comparable behavioural changes including allodynia and hyperalgesia to both
mechanical and thermal stimuli. The model of DeLeo et al (1994) has been included
as it demonstrated that freezing the nerve produces some behavioural changes
(mechanical and thermal allodynia) similar to different types of ligation of the
peripheral or spinal nerve. This model also results in severe autotomy which was also
present in the model of Bennett and Xie but was not extensive. These models may be
analogous to the clinical conditions associated with peripheral nerve injury now
termed the complex regional pain syndromes type I & II (Stanton-Hicks et al, 1995).
The ligation models have also been found to respond to sympathectomy. Although,
this was not described when these models were initially presented, the sympathetic
role is worth further discussion as it may help explain why these behavioural changes
occur (see section 2.5).
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2.3. NERVE HISTOLOGY OF THE SCIATIC NERVE-CHANGES
AFTER NERVE IN JURY
Bennett and Xie found constrictions beneath each of the 4 ligatures and that
the diameter of the nerve had reduced by 25-75% at the sites of constriction by the
first postoperative day (Bennett & Xie, 1988). Adjacent constrictions have been
shown to merge 2-3 days postoperatively. At this time, almost 70% of the nerves
examined had a distinct swelling just proximal to the most proximal constriction but a
caudal swelling was rare (Bennett & Xie, 1988). By 3 days a neuroma had formed as
well as a dense mass of connective tissue at the ligated region that had adhered to
adjacent muscle (Bennett & Xie, 1988; Coggeshall et al, 1993). This neuroma has
been characterised by a disrupted perineurium and numerous growth cones
(Sunderland, 1988). Nerves examined 1-3 weeks after surgery had either 2
constrictions or a region with a broad reduction in diameter which resulted from the
merging of adjacent constrictions. The majority of nerves had a pronounced swelling
just proximal to the constricted region and most had a distinct, but smaller, swelling
distally at 1-3 weeks. Although the ligatures had appeared to lose their continuity at
10-14 days postoperatively, suture debris has been found in the connective tissue
during the third postoperative week (Bennett & Xie, 1988; Guilbaud et al, 1993).
Two to four months after surgery, the connective tissue capsule had been resorbed
and the proximal and distal swellings had gone although the ligated region remained
thinner than normal (Bennett & Xie, 1988; Coggeshall et al, 1993).
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2.3.1. THE NATURE OF THE NERVE INJURY
It has been suggested from recent results that several local factors may be
critical for the development of the behaviours characteristic of the Bennett & Xie
model (Maves et al, 1993; Myers et al, 1993; Clatworthy et al, 1995). These factors
include peri-axonal inflammation, an acidic milieu around the nerve, ischemia and
endoneurial fluid pressure. The evidence supporting these factors is described below.
2.3.1.(a) Peri-axonal inflammation
The role of peri-axonal inflammation in the development of guarding
behaviour and thermal hyperalgesia in the Bennett & Xie model of neuropathic pain
has been investigated (Clatworthy et al, 1995). The sciatic nerve was ligated with
silk, plain or chromic gut and all nerves were found encapsulated by scar tissue by day
20 or 30 postoperatively although nerves ligated with silk had less encapsulation. In
agreement with this result, the use of both plain and chromic gut sutures in human
surgery has been shown to incite a local tissue inflammatory response (Stewart et al,
1990). The failure of silk to produce hyperalgesia in this loose ligation model
provides indirect evidence in support of the hypothesis that the development of
hyperalgesia associated with loose ligation depends upon a local inflammatory
response as silk has been found only to produce a small inflammatory response
(Maves et al, 1993).
The presence of a foreign material (the ligature) will initiate a localised
inflammatory reaction resulting in a granuloma close to the ligated peripheral nerve.
Cytokines released from inflammatory cells form part of the cascade of chemical
changes in the microenvironment. It has been suggested that these changes may lead
to excitation or sensitisation of afferent endings (Cunha et al, 1991; Maves et al,
1993; Sommeret al, 1993). Clatworthy and co-workers investigated the role of peri-
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axonal inflammation in the development of thermal hyperalgesia and guarding
behaviour by using cotton sutures soaked in Freunds complete adjuvant prior to
ligation (Clatworthy et al, 1995). This study suggested that the presence of
inflammation close to the peripheral nerves is critical for the development of
hyperalgesia in this model.
It has been shown that daily intraperitoneal injections of dexamethasone
prior to and after ligation reduced the inflammatory response induced by the sutures
and prevented the development of guarding behaviour and thermal hyperalgesia
(Clatworthy et al, 1995). The numerous inflammatory cells (macrophages,
neutrophils, multi-nucleated giant cells) which have been found surrounding the
normal nerve were found to be absent from the nerve of dexamethasone-treated
animals.
2.3.1.(b) Acidic milieu and the chemicals in chromic gut
The possibility that a chemical component of chromic gut sutures interacts
with the sciatic or sympathetic nerves to produce pain has been investigated (Maves et
al, 1993). Alterations in the rats posture associated with the Bennett & Xie model
have been demonstrated when chromic gut is placed alongside but not around the
nerve (Maves et al, 1993). The chemicals associated with chromic gut may act
indirectly by inducing or enhancing an inflammatory response around the nerve
(Clatworthy et al, 1995). Plain gut sutures appear to produce a similar inflammatory
reaction to that produced by chromic gut sutures, but only chromic gut ligatures
produce behavioural changes associated with neuropathy. It has been suggested that
the chromic gut results in a change in the chemical milieu around the nerve or the
closely associated sympathetic nerves. Chromic gut sutures are plain gut sutures to
which chromic salts and pyrogallol have been added.
Pyrogallol is an inhibitor of catechol-o-methyltransferase (COMT) and
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endothelium-derived relaxing factor (EDRF)/nitric oxide production. Inhibition of
EDRF/NO may result in a number of vascular and neuronal changes. Altered
sympathetic function may result from inhibition of COMT because catecholamines are
rapidly inactivated by this enzyme even though the principle pathway for
noradrenaline termination is reuptake into nerve terminals. Inhibition of EDRF/NO
may result in a number of vascular and neuronal changes. Preliminary results from
Maves and co-workers revealed that a continuous infusion of pyrogallol directly on
the sciatic nerve for 7 days produced a marked thermal hyperalgesia and postural
change identical to the loose ligation model from day 2 until day 20.
As an alternative mechanism of the effects of chromic catgut, it has been
suggested that chemicals released from chromic ligatures causes a reduction in local
pH producing activation of capsaicin sensitive afferents in the sciatic nerve (Geppetti
etal, 1990; 1991).
2.3.1.(c) Ischemia
The role of focal nerve ischemia in this model of peripheral nerve injury has
been investigated. Nerve blood flow has been shown to be significantly decreased in
the ligated segment during the development of thermal hyperalgesia (Myers et al,
1993). This suggested that the changes in blood flow caused by the ligature
compression contributed to the fibre injury. In addition, this study investigated
different injuries to the sciatic nerve. The sciatic nerve had either been crushed, made
ischemic by ligating the femoral artery or had the surrounding epineurium removed.
The pathological changes in the ligature model were less severe than the crush model
but greater than those from the femoral artery ligation and epineurial
devascularisation. This order also correlated with the average behavioural scores
obtained in response to applying heat to the ipsilateral paw. Removal of the
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epineurium did not result in a significant hyperalgesia to thermal stimuli. Nerve
ischemia has been found sufficient to initiate the development of behavioural
hyperalgesia in the ipsilateral paw, when Wallerian degeneration has been produced.
It was suggested by Myers & co-workers that the pathological events iniated by nerve
ischemia may be more directly related to the development of hyperalgesia than the
initial ischaemic insult.
2.3.1.(d) Endoneurial fluid pressure
Bennett and Xie (1988) suggested that partial occlusion of the nerve's
vasculature resulted in an intraneural edema the force of which opposes the unyielding
ligatures and results in strangulation of the nerve. Endoneurial edema has been a
prominent histological finding that presumably results from increased endoneurial
fluid pressure (Powell et al. 1989). Wallerian degeneration has been shown to evoke
endoneurial plasma extravasation (Powell et al, 1979). It has been suggested that
increased endoneurial fluid pressure may be reflected back to the dorsal root ganglia,
providing a mechanical stimulus for evoking activity in sensory neurones (Howe et al,
1977; Myers et al, 1988).
Overview
These studies suggest that peri-axonai inflammation, endoneurial fluid
pressure and restriction of the perineural blood supply may contribute to the
development of the behavioural changes associated with the Bennett & Xie model.
Comparable behavioural changes have been obtained using the Seltzer and Kim &
Chung models which both use silk to ligate the nerve. This argues against the
importance of the chemicals in chromic gut and a marked inflammatory response as
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silk causes only a small inflammatory response. Thus, the factors involved in the
development of the behavioural changes of the Seltzer and Kim & Chung model also
requires investigation. It has been suggested that fibre loss produced by the Bennett
& Xie model may result in the behavioural changes associated with this model. This
will be discussed in more detail.
2.3.2. ALTERATIONS IN NERVE FIBRES AFTER PERIPHERAL NERVE
INJURY
In the model of Bennett & Xie alteration of the fibre spectrum in the nerve
distal to the constriction injury has been found to be variable with most observers
reporting animal-to-animal variability (Gautron et al, 1990; Basbaum et al, 1991;
Carlton et al, 1991; Munger et al, 1992; Nuytten et al, 1992; Coggeshall et al, 1993;
Guilbaud et al, 1993). The variability in fibre damage may arise due to several
factors. Variability in the tightness of the constriction may be important as chromic
gut is not a malleable material and is thus difficult to knot (Nuytten et al, 1992; Ro &
Jacobs 1993). Alternatively, the alteration in fibre loss may vary for different strains
of rat (Nuytten et al, 1992). Another possibility is that differences in the type of
suture material may account for the variability as Maves and co-workers suggested
that the chemicals released from chromic gut may be important (Maves et al, 1992;
1993).
2.3.2.(a) Large diameter myelinated fibres
The primary morphological effect of this model to the nerve distal to the
ligature is a major disruption in the population of large to medium sized myelinated
axons. The proximal nerve has been found to have a relatively normal complement of
myelinated fibres (Basbaum et al, 1991; Munger et al, 1992; Coggeshall et al, 1993)
although some studies have reported a small loss of large myelinated fibres (Carlton et
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al, 1991; Guilbaud et al, 1993). At light magnification level, distal to the injury each
nerve had fewer myelinated fibres, much degenerating myelin and Schwann cell
process proliferation although many activated Schwann cells appeared normal
(Carlton et al, 1991). An acute axonopathy which greatly affected myelinated fibres
has been found distal to the ligature (Bennett & Xie, 1988; Gautron et al, 1990;
Carlton et al, 1991; Munger et al 1992; Guilbaud et al, 1993). The decrease in large
myelinated fibres has been described as almost total although considerable variability
in this decrease has been reported (Basbaum et al, 1991; Munger et al, 1992; Nuytten
et al, 1992). The loss of myelinated fibres has been reported to range from a
minimum of 84% to a maximum decrease of 99% (Carlton et al, 1991). Most studies
focused on one time point however Coggeshall and co-workers assessed the fibre size
and number over 56 days. Large fibre loss was found by day 3 postoperatively
(Coggeshall et al, 1993) since there is evidence that it takes at least 2 days after a
peripheral axon is separated from its cell body for morphologic signs of death to
become apparent (Maynard et al, 1977). From 3 days until 2 weeks a steady and
extensive decline in the numbers of all sizes of fibres occurred with the larger the axon
diameter the greater the loss. The decrease in large myelinated fibres was found to be
maximal at 2 weeks with recovery reported to begin from between 14 and 28 days
which was confirmed by Guilbaud et al, (1993). By 56 days postoperatively the
number of large fibres had increased to almost normal values (Coggeshall et al, 1993).
However, Guilbaud and co-workers found that a total recovery of large fibres was not
complete until week 15 (Guilbaud et al, 1993).
2.3.2.(b) Small diameter myelinated fibres
The loss of small myelinated fibres is not as great as that reported for large
myelinated fibres. Decreases (Basbaum et al, 1991; Munger et al, 1992; Nuytten et al,
1992), increases (Coggeshall et al, 1993; Guilbaud et al, 1993) and no change in the
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number of small myelinated fibres have been reported (Gautron et al, 1990). The
increases are likely the result of regeneration and remyelination (Coggeshall et al,
1993; Guilbaud et ah 1993). In support of remyelination, abnormal but intact thin
myelinated sheaths have been found with very short internodal lengths (Basbaum et al,
1991; Coggeshall et al, 1993).
Significant variation in the severity of the loss of the smallest diameter
myelinated fibres has been reported (Basbaum et al, 1991). In some fascicles there
were no surviving myelinated axons distal to the ligature whereas in others there
appeared to be a normal complement of small myelinated fibres. In contrast, a
consistent group of small myelinated nerve fibres with a thin myelin sheath has been
observed and these were surrounded by endoneurial capillaries in the centre of each
nerve fascicle (Nuytten et al, 1992).
2.3.2.(c) Unmyelinated axons
The decrease in the unmyelinated axon population is less extensive but more
variable than that obtained for myelinated axons after peripheral nerve injury
(Basbaum et al, 1991; Carlton et al, 1991; Munger et al, 1992; Coggeshall et al,
1993). Although the unmyelinated fibres have been found to decrease by
approximately 70% by 3 studies other studies have found greater variability (Basbaum
et al, 1991; Coggeshall et al, 1993; Carlton et al, 1991). This variability in the results
is evident in the percentage decreases obtained in a study involving just 2 animals
which reported a decrease in unmyelinated afferents of 34% and 71 % (Basbaum et al,
1991). A maximum decrease of 84% was obtained in a study reporting decreases of
62-84% (Carlton et al, 1991).
The typical tightly packed clusters of unmyelinated axons as seen in the
proximal segment of the ligatured nerve and in normal nerve have not been found
distally (Nuytten et al, 1992; Basbaum et al, 1991). In addition, the morphology of
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these axons has been found to change. They were not round and smooth as in the
proximal nerve but instead had a crelated appearance. Variability in the size of the
unmyelinated axons has been reported (Nuytten et al, 1992). Although a minority of
unmyelinated fibres had diameters within the normal range, the majority had
pathologically small diameters (Nuytten et al, 1992).
Abnormal unmyelinated fibre bundles have been found by day 5 with
maximal changes occurring at day 14 and a return to control conditions by day 28
(Coggeshall et al, 1993). Empty Schwann cell bands and an increase in the number of
Schwann cell processes have provided indirect evidence of degeneration of
unmyelinated fibres (Dyck & Hopskins, 1972; Ochoa, 1978). Regenerating axons are
likely to include unmyelinated axons as well as regenerating myelinated axons before
the onset of myelination.
2.3.2.(d) Relationship between fibre loss and pain behaviours
It has been suggested that the development of mechanical hyperalgesia and
allodynia is a result of the fibre losses produced by nerve ligatures. For example there
may be a release of inhibition of nociceptive primary afferent input into the spinal cord
dorsal horn as a result of the elimination of large myelinated axons (Gautron et al,
1990; Garrison et al, 1991; Laird & Bennett, 1992; Guilbaud et al, 1993). The
initiation of pain-related behaviours has not been closely correlated with the
development of large myelinated fibres degeneration as most studies have focused on
the changes when the behavioural changes are near maximal (Gautron et al, 1990;
Mungeretal, 1992; Carlton et al, 1991). Coggeshall and co-workers found that the
initiation of pain coincided with the initial degeneration and demeylination reported
from day 3 onwards. Twenty eight days postoperatively, most of the large myelinated
fibres had been lost and the signs of hyperalgesia had almost resolved. Therefore no
relation between the disappearance of the pain related behaviour and the large fibre
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population was established (Coggeshall et al, 1993). Two additional studies have also
found that the behavioural symptoms disappeared although the large myelinated
population was depleted (Gautron et al, 1990; Guilbaud et al, 1993).
In addition, it has been suggested that the small myelinated and
unmyelinated axons which are spared injury may be responsible for the pain related
behaviour (Gautron et al, 1990; Basbaum et al, 1991). The pathological state of those
which remain may contribute to the behavioural changes as the properties of these
nociceptive afferents may change (Basbaum et al, 1991; Munger et al, 1992). Carlton
and co-workers hypothesised that the input from surviving axons in the distal
segments results in increased activity in the neuroma which in turn sends signals
centrally that are interpreted as nociceptive by the animal.
The simultaneous presence of both degenerating and regenerating fibres of
relatively thin diameter has been suggested to be the major cause of the pain related
behaviours (Guilbaud et al, 1993). It has been suggested that the unequal rates of
successful regeneration and or remyelination may underlie the difference between
painless diabetic neuropathy in which the success of regeneration and remyelination is
minimal and sensation is decreased, and painful neuropathies in which there is a
greater incidence of successful reinnervation (Britland et al, 1990).
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2.4. NEUROPEPTIDE CHANGES IN DORSAL ROOT GANGLIA AND
SPINAL CORD AFTER NERVE INJURY
2.4.1. COMPLETE NERVE TRANSECTION
Transection of a peripheral sensory nerve leads to complex metabolic
changes in affected sensory ganglion nerve cell bodies and their terminals in the dorsal
horn of the spinal cord. The expression of neuropeptides in primary sensory neurones
is thus plastic with decreases or dramatic increases (including de novo synthesis)
occurring. Depending on the rate at which the neuropeptide is transported and
released, this will produce alteration in the levels found in cell bodies and their
terminals. Radioimmunoassay, immunohistochemical and in situ hybridisation
experiments have been carried out to determine the neuropeptide changes in the spinal
cord and dorsal root ganglion (reviewed by Hokfelt et al, 1994). Neuropeptide
changes can be grouped into (i) those that decrease: substance P (SP), somatostatin,
calcitonin-gene related peptide (CGRP) and (ii) those that increase: vasoactive
intestinal peptide (VIP), galanin and NPY (McGregor et al, 1984; Shehab &.
Atkinson, 1986; Villar et al, 1989; Wakisakaetal, 1991b; Knyihar-Csillik et al, 1993).
The majority of this work has been carried out in the rat with limited studies in other
species.
The first evidence for plasticity in neuropeptide expression following
peripheral axotomy was presented in 1979 (Jessell et al, 1979). Sciatic nerve section
produced a 75-80% depletion of ir-SP in the ipsilateral dorsal horn but did not change
immunoreactivity levels in the ventral horn. This resulted in an area which was
depleted of ir-SP involving the medial 2/3rds of lamina I-II of lumbar segments L4 &
L5 (Barbut et al, 1981). A decrease in immunoreactivity may indicate increased
release or decreased synthesis of the peptide and hence in situ hybridisation
experiments have been performed to determine the levels of mRNA before and after
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transection since the latter gives information on synthesis. Preprotachykinin (PPT)
mRNA which codes for SP has been found to be reduced in small diameter dorsal
root ganglion cells following sciatic nerve transection (Nielsch et al, 1987; Nielsch &
Keen, 1989; Noguchi et al, 1989). This reduction in mRNA has been shown to be
less marked following peripheral crush when compared with transection. In contrast,
de novo synthesis of PPT mRNA has been demonstrated in medium & large dorsal
root ganglion neurones in response to nerve injury (Noguchi et al, 1994).
Somatostatin has been shown to decrease in the dorsal root ganglia and their
terminals in the spinal cord following peripheral axotomy but was unchanged
following sciatic nerve crush (McGregor et al, 1984; Shehab & Atkinson, 1986). A
reduction in ir-somatostatin has been reported in lamina II of the monkey spinal cord
after transection of the sciatic nerve (Zhang et al, 1993a). Immunoreactive-CGRP
levels have been reported to decrease in L5 dorsal root ganglia after sciatic nerve
transection reaching minimal levels during the second post operative week (Dumoulin
et al, 1991; Doughty et al, 1991). Somatostatin and CGRP mRNA have been found
to be reduced in rat dorsal root ganglia ipsilateral to the sciatic nerve transection
(Noguchi et al, 1993). There are two types of mRNA for CGRP (a & (3) which have
been found to be differentially distributed in sensory neurones. Large dorsal root
ganglion cells have been found to contain the a form of mRNA and small cells contain
both types (Noguchi et al, 1990). The levels of both have been reported to decrease
in dorsal root ganglia, seven days after sciatic nerve transection in the rat (Noguchi et
al, 1990). In contrast, an increase in ir-CGRP in spinal motoneurones occurs at this
time (Noguchi et al, 1990). In the monkey a reduction in the number of ir-CGRP and
ir-SP dorsal root ganglia neurones has been reported as has a decrease in the mRNA
levels of these two peptides (Zhang et al, 1993a).
Immunoreactive-cholecystokinin (CCK) in the ipsilateral lumbar dorsal horn
has been reported to not change or decrease after sciatic nerve transection (McGregor
et al, 1984; Shehab & Atkinson, 1986). The identity of this immunoreactivity is
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uncertain. Evidence has been presented that CCK like immunoreactivity may
represent cross reactivity with CGRP or a CGRP-like peptide or an unknown CCK
like peptide (Ju et al. 1986; Hokfelt et al, 1988). mRNA for CCK has been found to
increase in dorsal root ganglion ipsilateral to the nerve transection which may suggest
increased release since the immunoreactivity levels seem to decrease (Verge et al,
1993; Xu et al, 1993a).
Immunoreactive-VIP has been found to increase in the rat dorsal root
ganglia and spinal cord following peripheral nerve transection (McGregor et al, 1984;
Shehab & Atkinson, 1986; Shehab et al, 1986). In the spinal cord this increase has
been demonstrated by immunocytochemistry to be confined to the substantia
gelatinosa of the ipsilateral cord (McGregor et al, 1984). Similar increases to VIP
have been observed for a related peptide with N-terminal histidine and C-terminal
isoleucine amide (PHI) (McGregor et al, 1984; Hokfelt et al, 1987; Villar et al, 1989).
In the dorsal root ganglia the increase in ir-VIP has been found to occur in mainly
small and also some medium diameter dorsal root ganglion cells (Shehab et al, 1986;
Zhang et al, 1995b). Small neurones containing ir-VIP have also been found to
contain ir-galanin (Kashiba et al, 1992). Four days after transection, half of the dorsal
root ganglia immunoreactive for VIP were also immunoreactive for CGRP (Doughty
et al, 1991). The increase in immunoreactivity in the cell bodies may be due to an
accumulation as a result of decreased axonal transport or alternatively due to an
upregulation of synthesis. To investigate this in situ hybridisation experiments have
been employed. The change in immunoreactivity was subsequently shown to be due
to a dramatic induction of VIP mRNA from an undetectable level of expression in
normal rats (Noguchi et al, 1993).
In the rat the changes in pituitary adenylate cyclase activating peptide
(PACAP) after sciatic nerve transection have been recently investigated (Zhang.Q. et
al, 1995). The N-terminal sequence of this 38 amino acid peptide has been shown to
be 68% homologous to VIP (Miyata et al, 1989). This study by Zhang & co-workers
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found a moderate increase in ir-PACAP levels in the ipsilateral superficial dorsal horn
by 3 days at which time more than 50% of all dorsal root ganglion neurones expressed
ir-PACAP. This increase was found to occur mainly in the medium and large sized
neurones.
Galanin immunoreactivity has been demonstrated in small medium and large
dorsal root ganglion neurones (Villar et al, 1989; Kashiba et al, 1992). An increase in
ir-galanin has been found in the midportion of the superficial dorsal horn ipsilateral to
the transected nerve (Villar et al, 1989). This corresponded to the area where ir-subP
has been shown to decrease and ir-VIP increase. The number of dorsal root ganglion
neurones immunoreactive for galanin was greater than those immunoreactive for VIP
at L5 spinal level (Kashiba et al, 1992). Galanin and VIP have often been found to be
co-localised in neurones with decreased levels of ir-SP and ir-CGRP (Xu et al, 1990;
Doughty etal, 1991; Kashiba et al, 1992). Transection was also found to cause an
increase in ir-galanin in the dorsal root ganglia of the monkey, cat and guinea-pig
(Arvidsson et al, 1991b; Zhang et al, 1993a, Rydh-Rinder et al, 1996). Induction of
galanin mRNA has been demonstrated in rat dorsal root ganglia following transection
(Noguchi et al, 1993).
A subpopulation of dorsal root ganglion neurones have been found to show
NPY immunoreactivity (Wakisaka et al, 1991b, Kashiba et al, 1994).
Immunohistochemical changes occurred mainly in large and some medium sized
dorsal root ganglion neurones (Wakisaka et al, 1992; Zhang et al, 1993b; Kashiba et
al, 1994). Immunoreactive-NPY has been reported to be present in 20-30% of
ipsilateral dorsal root ganglion neurones in lumbar regions L4-5 (Kashiba et al, 1994).
In this study immunohistochemical analysis combined with retrograde tracing detected
ir-NPY in cutaneous and muscular sensory neurones but not in visceral neurones. In
large cells, the newly synthesised NPY has been found to be co-localised with galanin
(Kashiba et al, 1994). In the dorsal horn of the guinea-pig a decrease in ir-NPY in
lamina I & II and an increase in laminae III has been found (Rydh-Rinder et al, 1996).
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In contrast to the rat, changes in NPY have been reported mainly in the small dorsal
root ganglion neurones of the guinea-pig. The alteration of NPY following peripheral
nerve cut using RNA blot and in situ hybridisation has suggested that the NPY
detected is the result of de novo translation of NPY mRNA (Noguchi et al, 1993).
The neurones exhibiting NPY mRNA induction are a subpopulation of the largest
sized labelled neurones with only a few small neurones labelled.
The presence of NPY immunoreactivity has been found to increase in the
spinal cord after peripheral nerve transection (Wakisaka et al, 1991 b; Kashiba et al,
1994; Zhang et al, 1995a & b). This is contrary to an earlier result reported by
Gibson and co-workers which found no change in ir-NPY in the rat lumbar spinal
cord almost 3 weeks following sciatic nerve transection (Gibson et al, 1984). Two
weeks after injury, immunoreactive NPY has been found to increase in laminae III-V
of the spinal cord (Wakisaka et al, 1991b) and III-IV (Zhang et al, 1995b). This
increase occurred in axons and varicosities in the ipsilateral spinal cord only
(Wakisaka et al, 1991b; Zhang et al, 1993). Ohara and co-workers found that
changes in ir-NPY in the dorsal horn were more intense and sustained in response to
transection compared to crushing the nerve with forceps (Ohara et al, 1994). They
also found that lumbar dorsal rhizotomy performed at the same time as sciatic nerve
transection prevented the development of NPY immunoreactivity in laminae III & IV
suggesting that the NPY was contained within large primary afferent fibres.
Neuropeptide changes are not unique to sciatic nerve section. They have
also been found to occur when the mandibular branch of the trigeminal nerve has been
cut (Atkinson & Shehab, 1986). Immunoreactive-VIP has been found to increase
whereas SP, cholecystokinin and somatostatin immunoreactivity decrease in the
trigeminal ganglia. Four weeks after pelvic nerve transection there was a decrease in
ir-VIP and no change in ir-galanin or ir-SP in the dorsal sacral spinal cord of the cat.
Transection of the mandibular nerve resulted in a marked increased galanin, VIP and
NPY mRNA. In contrast, transection of the vagal nerve resulted in a marked increase
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in galanin and VIP in the nodose ganglia with only a moderate increase in NPY
mRNA (Zhang et al, 1996). This change in mRNA has been found in small neurones
of the nodose ganglia whereas the NPY increase has been found in medium and large
sized trigeminal ganglia (Wakisakaet al, 1993; Zhang et al, 1996). In contrast, there
was an increase in ir-VIP and galanin and a decrease in ir-SP in the dorsal sacral cord
after transection of the pudendal nerve (Anand et al, 1991).
2.4.2. PARTIAL NERVE INJURY
Alterations in neuropeptides also occur when a nerve is partially injured
(Wakisakaka et al, 1992, Nahin et al, 1994) such as in the mononeuropathy model of
Bennett and Xie (1988). Immunoreactive-SP (Cameron et al, 1991; Munglani et al,
1995) and ir-CGRP (Cameron et al, 1991) have been reported to decrease in the
dorsal root ganglia and superficial dorsal horn ipsilateral to the peripheral neuropathy.
Similar to transection, an increase in ir-NPY has been found in medium and large
dorsal root ganglion neurones (Wakisaka et al, 1992b). Galanin, VIP and NPY
mRNA all increased from non-detectable levels from day 3 with maximum expression
by day 14 in the dorsal root ganglia ipsilateral to peripheral nerve injury. A maximum
decrease in the messenger RNA levels for SP and CGRP occurred during the second
postoperative week (Nahin et al, 1994).
An increase in ir-NPY in laminae III-V axons and varicosities was found in
the spinal cord at 14 days after partial nerve injury (Wakisaka et al, 1992). An
increase in ir-NPY has also been reported 28 days after partial nerve injury with no
significant changes in laminae I-II and an increase in laminae III-IV (Munglani et al,
1995).
76
2.5. THE ROLE OF THE SYMPATHETIC NERVOUS SYSTEM
Historically, the observation that patients with nerve injury had cold skin led
to the idea of blocking sympathetic activity as it was suggested that the cold skin was
related to sympathetic hyperactivity which excited nociceptive fibres within the
symptomatic area (Leriche, 1939). Although, the role of the sympathetic nervous
system in mediating abnormal behaviours associated with peripheral nerve injuries
remains unclear, sympathectomy has been continued to be used to treat such patients.
Several possibilities to explain the role of the sympathetic system have been suggested
and will be discussed below. The simplest explanation for the beneficial effects of
sympathectomy in neuropathic pain is that some form of link exists between the
autonomic system and primary afferent fibres. A normal physiological coupling may
exist between the sympathetic system and primary afferents whereby chemical changes
in the microenvironment result in the sensitisation of primary afferent terminals.
Alternatively, there may be pathological coupling either at the site of nerve damage or
more peripherally or centrally. Finally some evidence suggests that abnormal central
processing may be involved.
2.5.1. SYMPATHETIC EFFERENTS AND AUTONOMIC EFFECTOR
ORGANS
It has been suggested that sympathetic efferents can influence primary
afferents through autonomic effector organs. The clinical observations of temperature
differences and of sweating in the hands or feet of neuropathic patients (those with
RSD, causalgia or SMP) has lead to the proposal that sympathetic functions are
disturbed in these patients. Disturbance of the vasoconstrictor system may be
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involved leading to changes in the regulation of blood flow in the distal extremities
(Blumberg, 1993).
Only some patients respond well to sympathectomy (DeTakats, 1943;
Bonellietal, 1983; Driessen et al. 1983; Wang et al, 1985; Arner, 1991; Blumberg &
Janig 1993; Blumberg et al, 1994). In clinical case studies of patients who responded
positively to sympatholytic treatment, an increase of hydrostatic pressure by venous
congestion has been found to enhance the pain whilst an occlusion of arterial supply
has relieved the painful symptoms before the ischaemic conduction block of afferent
fibres could have occurred (Gracely et al, 1990; Blumberg, 1992). Interrupting the
circulation of the distal part of the affected extremity has resulted in complete relief of
pain for the duration of the interruption (DeTakats, 1943; Gracely et al, 1990). Thus
it has been suggested that changes of the microcirculation might be involved in the
generation of pain. Blumberg has hypothesised that an indirect sympathetic-sensory
coupling occurs via the vascular system. According to this hypothesis the initial nerve
injury produces a massive input to the spinal cord. Some spinal circuits are sensitised
by nociceptive afferent input which leads to an abnormal discharge pattern in
sympathetic vasoconstrictor neurones. This results in an increase in vasoconstriction
on the postcapillary side compared with the precapillary side, inducing increased
capillary filtration pressure. The related increase in interstitial pressure activates
nociceptive afferent fibres and hence the pain is essentially akin to deep muscle pain.
Supporting this, animal models have demonstrated that peripheral nerve damage can
result in abnormal reflex behaviour of sympathetic vasoconstrictor nerves in skin
(Blumberg & Janig, 1985; Janig & Koltzenburg, 1991). However, direct evidence is
missing as clinical observations and animal experiments have provided no evidence to
support the assumption that the activity of sympathetic neurones (sympathetic tone) is
increased (Blumberg, 1991; Janig & Koltzenburg, 1991; reviewed by Blumberg
1992).
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2.5.2. PHYSIOLOGICAL COUPLING BETWEEN SYMPATHETIC
EFFERENTS AND PRIMARY AFFERENTS
It has been suggested that the sympathetic system might act indirectly on
primary afferents through precipitating a cascade of chemical changes in the
microenvironment surrounding the axon terminals leading to excitation or
sensitisation of afferent endings (Janig & Koltzenburg, 1991; Koltzenburg &
McMahon, 1991; Campbell et al, 1992; Janig & Koitzenburg, 1992; Gracely et al,
1992).
Bradykinin has been found to produce mechanical hyperalgesia in peripheral
tissues (Beck et al, 1974; Chahl & Iggo, 1977). In the experiments of Levine et al
(1986b) bradykinin hyperalgesia was present in normal skin whereas noradrenaline
induced hyperalgesia was only observed in chloroform treated (chemically inflamed)
skin. Repetitive topical application of chloroform induced hyperalgesia which was
enhanced by noradrenaline. Levine and co-workers suggested that noradrenaline
released from sympathetic endings activated other sympathetic endings through an
alpha-2 adrenoceptor mechanism resulting in the liberation of prostaglandins. The
latter would then sensitise nociceptors (Levine et al, 1986a). Both bradykinin- and
noradrenaline-induced hyperalgesia were found to be dependent on the presence of an
intact sympathetic innervation and the production of prostaglandins as they were
blocked both by sympathectomy (Levine et al, 1986b) and by previously administered
non-steriodal anti-inflammatory agents (Lembeck et al, 1976; Levine et al, 1986b).
The latency to onset of hyperalgesia produced by PGE2 has been found to be
significantly shorter than the latency to onset of bradykinin-induced hyperalgesia
suggesting an indirect mechanism for the latter (Taiwo et al, 1987). Taiwo & Levine
(1988) suggested that bradykinin- and noradrenaline-induced hyperalgesia (in
chloroform treated skin) share a common mechanism as they have similar onset
latencies (Taiwo & Levine 1988). The hyperalgesic effects of PGE2 and PGI2 have
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been distinguished by the duration of the hyperalgesia they produced (Taiwo et al,
1987) and were thus used by Taiwo & Levine (1988) to compare the duration of
bradykinin- and noradrenaline-induced hyperalgesia. They found that bradykinin and
PGE2 induced hyperalgesia had a similar duration as did noradrenaline and PGI->
induced hyperalgesia. In addition, the prostaglandin antagonist, SCI9220, selectively
inhibited PGE2 induced hyperalgesia but antagonised the effects of bradykinin
suggesting that bradykinin induced hyperalgesia is mediated by PGE2 and
noradrenaline induced hyperalgesia by PGI2. These proposals of Levine and co¬
workers have been challenged by the experiments of Koltzenburg et al (1992) who
found that the sensitisation of nociceptors by bradykinin does not depend on
sympathetic neurones.
2.5.3. PATHOLOGICAL COUPLING BETWEEN SYMPATHETIC
EFFERENTS AND PRIMARY AFFERENTS
Early ideas favoured ephatic electrical cross talk as a means of
communication between incoming and outgoing fibres. Since the sympathetic system
is tonically active it was suggested that sympathetic efferents and primary afferent
fibres may be involved in cross talk. It was proposed that artificial synapses formed at
the site of the lesion on the peripheral nerve (Doupe et al, 1944). Thus, impulses
leaving the spinal cord in sympathetic fibres were transmitted at the artificial synapse
by ephatic transmission to small somatic afferents fibres resulting in pain. According
to this hypothesis a guanethidine block would have no effect since transmission is
electrical. The introduction of Hannington-Kiffs method (1974) of blocking the
sympathetic nerve endings however has not supported this proposal. Guanethidine
blocks have been found to be as successful in relieving the.pain as are blocks of
sympathetic chain and ganglia (Hannington-Kiff 1974; Schott 1986; Bonica, 1990).
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Clinically, the activation of sympathetic post-ganglionic neurones or
application of noradrenaline to painful skin has been found to exacerbate pain &
hyperalgesia in patients with causalgia (Wallin et al, 1976 ; Wiesenfeld-Hallin & Hallin
1984; Torebjork et al, 1995) while sympathetic interventions can abolish hyperalgesia
and pain (Hannington-Kiff, 1974; Schott, 1986; Bonica, 1990). Therefore it has been
suggested that the neuropathic pain syndrome of certain patients is maintained by the
release of noradrenaline from postganglionic sympathetic fibres activating primary
afferent fibers via alpha adrenoceptors (Campbell et al, 1992). Such an hypothesis
requires the expression of adrenoceptors by primary afferents. Evidence for this has
come from the experimental analysis of the action of catecholamines on damaged
peripheral nerve. It was demonstrated that sprouting fibres trapped in a neuroma
formed by regenerating axons after transection became sensitive to the alpha receptor
mediated action of adrenaline (Wall & Gutnick, 1974 a & b). Exposure to adrenaline
and noradrenaline induced and increased impulse discharge which was stopped by the
non-selective alpha antagonist, phentolamine, and unaffected by isoprenaline (a beta
agonist). Later studies confirmed that fibres in the neuroma (Devor & Janig, 1981;
Korenmann & Devor, 1981; Scadding, 1981; Blumberg & Janig, 1984; Burchiel,
1984b; Habler et al, 1987; Welk et al, 1990) as well as non-axotomised unmyelinated
C fibres with receptive terminals in the territory of the partially lesioned nerve (Habler
et al, 1987; Sato & Perl 1991; Budewiser et al, 1993; Selig et al, 1993) responded to
catecholamines. In addition, it was found that sufficient noradrenaline was released
by stimulation of the postganglionic sympathetic fibres to evoke firing (Devor &
Janig, 1981; Blumberg & Janig, 1984; Habler et al, 1987) by activating alpha
adrenoceptors. Devor & Janig (1981) found that repetitive stimulation of the lumbar
sympathetic trunk resulted in afferent impulses in primary afferents and this was
blocked by the alpha adrenergic antagonist phentolamine whereas the beta adrenergic
antagonist propranolol had no effect.
81
Ectopic activity generated by the cell bodies of damaged afferents may also
be influenced by activity in sympathetic postganglionic fibres (Devoret al, 1991).
After sciatic nerve transection, noradrenergic perivascular axons were found to sprout
into the dorsal root ganglia forming basket-like structures around large diameter
axotomised sensory neurones. Nerve injury thus resulted in a new site of coupling
between the sympathetic and primary afferent system. It has been suggested that this
may be a further origin for abnormal discharge following peripheral nerve damage
(McLachlan et al, 1993).
The observations of Wall & Gutnick first raised the possibility that the
damaged fibres expressed adrenoceptors. A significant elevation of clonidine binding
sites in the neuroma and in the superficial dorsal horn (where many unmyelinated
afferents terminate) has been found by McMahon (1991). In addition, Williams and
co-workers (1991) have suggested that the synthesis of this receptor may be increased
after peripheral nerve injury.
Radioligand binding studies in a variety of mammalian species and tissues
have indicated that alpha 2 adrenoceptors exist in at least 3 pharmacological
distinguishable types 2a, 2b and 2c (Ruffolo et al; 1987). The rat spinal cord contains
alpha 2a and 2c adrenoceptor binding sites whereas alpha 2b adrenoceptors were not
detectable (Uhlen & Wikberg, 1991; Uhlen et al, 1992). Approximately 96% of the
alpha 2 adrenoceptors in the spinal cord have been shown to be of the alpha 2a type
whereas about 4% were of the alpha 2c type (Uhlen et al, 1992). However, the roles
of these receptor subtypes in the modulation of nociceptive information are unclear.
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2.5.4. THE ROLE OF THE SYMPATHETIC NERVOUS SYSTEM IN
PARTIAL NERVE INJURY MODELS
If the animal models of nerve damage are relevant to the human clinical
syndromes then a modification of the pain states by altering sympathetic activity
should occur.
2.5.4.(a) The Bennett & Xie model
With this model there is evidence that the sympathetic nervous system has a
role in the development and maintenance of some abnormal pain-related behaviours.
The development of behavioural sensitisation to mechanical, heat and cold stimuli in
the partially denervated area of the hindpaw in the rat has been investigated. Two
groups have assessed the effects of the sympatholytic agent guanethidine administered
either subcutaneously for 4 consecutive days before surgery or 10 days after surgery
(Neil et al, 1991) or intravenously for seven days starting one week after surgery
(Perrot et al, 1993). The effect of a surgical sympathectomy on pain related
behaviours has been investigated more recently (Desmeules et al, 1995).
Sympathectomy significantly reduced the abnormal response to heat measured by
determining the withdrawal threshold to heat by submersing the limb in a series of
controlled ascending temperature water baths (Neil et al, 1991) or by determining the
struggle latency to paw immersion in a45°C water bath (Desmeules et al, 1995). The
hindpaw was submersed into a water bath at 10°C to determine the latency to
withdrawal or struggle response to a cold stimulus (Neil et al, 1991; Perrot et al,
1993; Desmeules et al, 1995). The abnormal reactions to a cold stimulus in
neuropathic rats was almost completely suppressed (Neil et al, 1991; Perrot et al,
1993). In contrast, the abnormal response to mechanical pressure measured by the
Randali-Selitto analygesymeter was found to be unchanged in 2 of these studies (Neil
et al, 1991; Desmeules et al, 1995). This differs from the study by Perrot and co-
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workers (1993) which found that sympathectomy performed by intraperitoneal
injection of guanethidine resulted in a reduction in the mechanical threshold elicited by
hind-paw pressure.
Wakisaka and co-workers (1991a) compared the temperature differences of
the plantar skin of the hind paws of normal rats and those with a loose ligation on one
side and a sham operation on the opposite side. In normal rats little temperature
difference between the two normal hind paws was obtained. In contrast, the
temperature difference obtained by subtracting the sham-operated plantar hind paw
temperature from the operated hindpaw temperature resulted in abnormally large
temperature differences. The skin on the nerve injured side was warmer than normal
during the first 10 days postoperatively and colder than normal at 3-4 weeks
postoperatively. Sympathetic block delivered at 2 or more weeks post injury was
found to be without effect (Wakisaka et al, 1991). Until recently, the skin temperature
changes after painful neuropathies have been thought to reflect abnormal
vasoconstrictor reflexes with cold skin being associated with inappropriately high
levels of activity in the sympathetic cutaneous vasoconstrictor neurones and a low
level of activity with warm skin. A relationship between skin temperature and activity
in sympathetic neurones has not been proven. This is probably a misconception which
is supported by the findings of this study by Wakisaka's group.
2.5.4.(b) Kim & Chung model
Surgical sympathectomy performed by removing the sympathetic chain
bilaterally from the L2 to L6 level before nerve injury produced similar results to
performing the sympathectomy after surgery in the Kim & Chung model (Kim et al,
1993; Kinnman & Levine, 1995). At 1 week prior to and 1, 3 and 5 weeks after nerve
injury sympathectomy alleviated both mechanical allodynia and heat hyperalgesia
(Kim et al, 1993). Sympathectomy has been found to alleviate the mechanical
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sensitivity within 30 minutes and the heat hyperalgesia within one day. Thus it has
been suggested that the sympathetic nervous system contributes to both the initiation
and the maintenance of nerve injury-induced increased mechanical sensitivity. Sham
sympathectomy had no effect on either mechanical allodynia or thermal hyperalgesia
suggesting that the sham operation per se did not affect the abnormal pain behaviours
(Kim & Chung, 1991). Sympathetic postganglionic neurones at the level of spinal
injury can contribute to neuropathy symptoms independent of input from
preganglionic neurones as a lesion of preganglionic fibres to the L5 level had no
significant effect on sensory abnormalities (Kinnman & Levine, 1995).
2.5.4.(c) Seltzer Model
Sympathetic block using guanethidine administered by intra-peritoneal
injection was first reported to alleviate behavioural changes in an experimental
peripheral neuropathy by Shir & Seltzer (1991). The main observation of this study
was that sympathectomy performed several months after partial sciatic nerve injury
alleviated the sensory disorders bilaterally produced by non-noxious and noxious
stimuli. The presence of sympathetic activity was not essential for the production of
touch allodynia as it did not prevent the postoperative appearance of touch-evoked
allodynia. This suggests that the coupling between sympathetic efferents and low
threshold mechanoreceptive A fibres gradually increases with time. Tracey and co¬
workers found that subcutaneous injection of noradrenaline exacerbated the
mechanical and thermal hyperalgesia in this model while subcutaneous injection of
yohimbine, the alpha 2 adrenergic antagonist, diminished the hyperalgesia. In
contrast, noradrenaline had no effect in control animals. They found that guanethidine
treatment diminished the hyperalgesia associated with this model. From these results
they suggested that behavioural changes are maintained by activation of alpha 2
adrenoceptors located on post-ganglionic sympathetic terminals and that these
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nociceptors are sensitised by increased synthesis of prostaglandins by activation of
these receptors as proposed by Levine (Tracey et al, 1995a).
Experimentally, capsaicin which destroys most C fibres and some A delta
fibers in peripheral nerves had no effect on the touch-evoked allodynia and mechanical
hyperesthesia produced by partial sciatic nerve injury using the Seltzer model (Shir &
Seltzer, 1990). This study thus suggested that these disorders were mediated by
myelinated fibers. However, thermal hyperalgesia failed to develop in these capsaicin-
treated rats suggesting that the thermal hyperalgesia was mediated by heat-nociceptive
C fibers. In agreement, clinical results from differential nerve blocks have suggested
that the noradrenaline-induced ongoing pain and heat hyperalgesia were signalled by
unmyelinated afferents, while touch-evoked pain and cold hyperalgesia were signalled
by myelinated afferents (Torebjork et al, 1995). Nociceptor sensitisation has been
suggested to be at least partly responsible for the reduction of the perceptual
threshold for heat-evoked pain and hyperalgesia present when the skin has been
injured (for review see Meyer et al, 1992).
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2.6. PROPERTIES OF PRIMARY AFFERENTS IN THE BENNETT
AND XIE MODEL
Animal studies have reported that changes in the properties of neurones on
the nerve injured side after peripheral nerve injury may contribute to the abnormal
behavioural changes which occur (Paleck et al, 1992a; b; Sotgiu et al, 1992; Laird &
Bennett, 1993; Sotgiu, 1995 a & b; Koltzenburg et al, 1994). This can be studied
either by investigating the properties of the primary afferents beyond the ligature and
before they enter the spinal cord or by directly investigating the properties of spinal
neurones (see section 2.7.3.). As cited previously there is extensive degeneration of
afferents distal to the ligature and this is probably the reason for the paucity of studies
on the properties of fibres distal to the ligature.
However, Koltzenburg and co-workers found a significant increase in the
mechanical threshold force of mechano-heat-sensitive unmyelinated primary afferents
(C-fibers) in the rat on the injured side compared to normals (Koltzenburg et al,
1994). They found that the mean heat response appeared to be increased after partial
nerve injury with more spikes evoked by a standard heat stimulus at 2 weeks
postoperatively compared to before injury (Koltenburg et al, 1994). The most
outstanding change in the properties of primary afferents proximal to the ligature is
the occurrence of ectopic discharge.
2.6.1. ECTOPIC IMPULSES
An increase in spontaneous activity in primary afferent fibres may be
responsible for the development of continuous pain and may also contribute to the
maintenance of allodynia and hyperalgesia (Xie & Xiao, 1990; Kajander & Bennett,
1992; Devor, 1994; Han et al, 1994). Evidence from both human and animal studies
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supports a correlation between spontaneous firing in primary afferents and pain
(Nystrom & Hagbarth, 1981;Devor, 1994; Seltzer et al, 1991; Gracely et al, 1992).
Spontaneous discharges could be generated in the periphery (from sensory endings) or
from the neuroma at the injury site or in the dorsal root ganglia. Individual axons may
contain more than one locus of afferent impulse generation. Abnormal activity may
also originate from zones of demyelination along the nerve (Kajander & Bennett,
1992; Devor, 1994). Studies on ectopic impulse generation have mostly examined
afferent neurones with myelinated axons probably because recordings from these
fibres are relatively easy to obtain (Burchiel, 1984 a & b; Devor & Bernstein, 1982;
Devor & Janig, 198 1; Meyer et al, 1985; Scadding, 1981; Wall & Gutnick, 1974;
Welk et al, 1990; Devor, 1994; Janig, 1988). Reports on the incidence of
spontaneous discharges after nerve injury have given varying results probably
depending on the site of origin, the time since the injury and the type of nerve injury
as will be described below.
2.6.1.(a) Ectopic impulses and complete nerve transection
(ai) Generation of impulses in dorsal root ganglion cells
After nerve transection, dorsal root ganglion cells increase their tendency to
discharge and to bombard the spinal cord with ectopic sensory signals. Kirk in 1970,
first suggested that the dorsal root ganglia became spontaneously active after
peripheral nerve transection. This was later substantiated by several studies
(Wiesenfeld & Lindblom, 1980; De Santis & Duckworth, 1982; Wall & Devor, 1983;
Burchiel 1984 a, b; Russell & Burchell, 1988). It has been found that a small
percentage of neurones in normal dorsal root ganglia in anaesthetised rats are
spontaneously active but this percentage increases after peripheral transection (Wall &
Devor, 1983). The incidence of spontaneous discharge originating from the dorsal
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root ganglia has been reported as a maximal increase of 6% over normals (Russell &
Burchiel, 1988; Wall & Devor, 1983). Sciatic nerve transection was found to evoke
spontaneous impulse generation from the dorsal root ganglion cell bodies of
myelinated axons (A(3 & A5), but not from the cell bodies of unmyelinated axons
(Wall & Devor, 1983). After peripheral axotomy, activity originating in fibres at the
injury site is typically fast and regular with intermittent bursts whereas that from the
dorsal root ganglia is predominantly a slower, random activity (Wall & Devor, 1983;
Burchiel, 1984a). The dorsal root ganglion has also been found to be the source of
spontaneous discharges recorded from sensory nerve fasicles central to human
amputation neuromas as these discharges persisted after local anaesthetic block of the
neuroma (Nystrom & Hagbarth, 1981).
(aii) Generation of impulses at the neuroma
Transection of a peripheral nerve disconnects the spinal cord from peripheral
sensory end organs. A neuroma is formed by cut fibres being unable to regenerate to
their original target tissue. Wall & Gutnick proposed that outgrowing axon sprouts
are a novel and abnormal source of afferent barrage (Wall & Gutnick 1974 a & b).
They found that dorsal root filaments terminating in the neuroma consistently showed
ongoing activity in the absence of any intentional stimulus. Kirk (1974) suggested
that some of this activity must have originated in intact proprioceptive and thermo-
sensitive fibres as the active roots also contained afferents from nerves which had not
been cut. The ongoing activity in these dorsal root filaments was abolished by
perfusing the neuroma with lidocaine (Wall & Gutnick, 1974b). Wall & Devor
reported that much of the spontaneous firing that occurs after neuroma formation
originates at the site of injury, with the remainder emanating from the dorsal root
ganglia (Wall & Devor, 1983). Fibres within the developing neuroma exhibit
spontaneous, rhythmic, high frequency (up to 100 Hz) bursting discharge activity and
89
mechanosensitivity (Burchiel, 1984a). This activity is observed as early as 2-3 days
after peripheral nerve transection and can be abolished by either local anaesthesia or
removal of the neuroma (Burchiel, 1984a). Pressure and adrenaline applied locally to
the neuroma increased the frequency of activity and local lidocaine abolished it.
Govrin-Lippmann & Devor (1978) made recordings from the peripheral
nerve distal to the dorsal root ganglion but proximal to the cut end of a transected
nerve. This study confirmed that impulses are generated at the site of injury as
resection of the nerve 5-10mm proximal to its cut end or application of lignocaine
abolished all ongoing activity. The ability of the neuroma to generate ongoing activity
after transection may be subject to strain related genetic control. In the study of Hao
& Wiesenfeld-Hallin (1994) ongoing activity was recorded in a much higher
percentage of nerve filaments in Wistar-Kyoto rats compared to Sprague-Dawley rats.
2.6.1.(b) Ectopic impulses and partial nerve injury
(bi) Generation of impulses in dorsal root ganglion cells
There is evidence that much of the spontaneous firing occurring in primary
afferents during the early response to nerve injury originates in the dorsal root ganglia
(Kajander et al, 1992; Xie et al, 1995). Thirty percent of injured A beta & 15% of A
delta axons exhibited spontaneous discharge which originated in the dorsal root
ganglia at one & three days postoperatively (Kajander & Bennett 1992; Kajander et
al, 1992). Kajander et al, (1992) studied the effect of acute transections at various
points along the injured sciatic nerve. Transections just proximal to the nerve injury
and just distal to the dorsal root ganglia failed to prevent the discharge, but
spontaneous discharge disappeared when the transection was made just proximal to
the dorsal root ganglia.
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To determine whether spontaneous action potentials originate from the
dorsal root ganglion cell body, isolated dorsal root ganglion neurones were studied
using the whole cell patch technique (Study & Krai 1996). Spontaneous firing was
found in 20% of neurones from ganglia on the side with nerve injury and only 3% of
neurones from control ganglia. Neurones were characterised by size roughly
corresponding to C (small), A delta (medium) and A beta (large) fibres. The greatest
incidence of spontaneous activity was apparent in medium sized neurones although all
three groups showed activity. Two types of spontaneous activity have been reported
in the dorsal root ganglion cells with some cells showing both types of activity (Study
& Krai, 1996). Random action potentials or short bursts of 2-4 rapid spikes with an
average frequency of 0.5-3Hz have been shown to be more common than long trains
of rapid, regular action potentials at 5-25Hz with occasional random single action
potentials (Study & Krai, 1996). It was suggested that the pattern of activity may be
dependent on the degree of depolarisation rather than being specific for a particular
cell type (Study & Krai, 1996). Spontaneous resting potential fluctuations occurred
in both control and nerve injured neurones and triggered the spontaneous, random
action potentials in neurones in nerve injured rats (Study & Krai, 1996). A
correlation was found between the presence of spontaneous firing after nerve injury
and the action potential threshold which was substantially more negative in
spontaneously active neurones compared with controls (Study & Krai, 1996). These
results suggested that the dorsal root ganglion cell body was the source of this
activity.
In support of this proposal whole cell patch-clamp recordings have revealed
a small proportion of dissociated dorsal root ganglion cells from injured but not
normal nerves that were spontaneously active within 24 hours of culture (Study &
Krai, 1996). This study found that 18% of large diameter neurones 66% of medium
diameter and 42% of small diameter neurones were spontaneously active. Kajander &
Bennett recorded from individual primary afferent axons in microfilaments teased
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from the dorsal roots (Kajander & Bennett, 1992; Kajander et al, 1992). They found
that 35% of A beta, 15% of A delta and 3% of C fibres were spontaneously active.
The rough correlation between cell size and fibre type (Harper & Lawson, 1985)
suggests that fewer large diameter neurones but more medium and small diameter
neurones were found spontaneously active by Study & Krai (1996) compared to the
former study. The differences may be due to differences in the post-injury times, as
Kajander and Bennett studied spontaneous activity at a later time period 1 to 3 days
postoperatively as opposed to within six hours as well as differences in the recording
conditions. At least some ectopic discharge in C fibres may originate in the soma as
the spontaneous activity in these fibres has been reported to remain after the nerve
was transected proximal to the injury site (Xie et al, 1995).
(bii) Generation of impulses at the neuroma
Spontaneous ectopic discharges have been reported to occur at the site of
nerve injury between days 6-44 days postoperatively although this was not measured
quantitatively (Xie & Xiao, 1990). Spontaneous activity has also been found in
unmyelinated primary afferents after loose ligation of the saphenous nerve
(Koltzenburg et al, 1994). In the study of Tal & Eliav (1996) electrophysiological
recording from myelinated primary afferent axons revealed spontaneous impulse
activity which originated at the site of nerve constriction. During the period 2-14
days postoperatively, 10% of the fibres sampled had spontaneous activity. The
spontaneous activity fell into 3 patterns: tonic rhythmic pattern in which the interval
between successive spikes in a train was uniform, ranging from 25-50ms (discharge
rate 20-40Hz), interrupted bursty or "on-off" patterns with variable silent period
between high frequency bursts and irregular ongoing pattern with random inter-spike
intervals 5-15Hz. Axons trapped at the injury site, both those with spontaneous
activity and those without, became hyper-excitable to mechanical stimulation. The
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locus of mechanosensitivity shifted progressively in time from proximal end to the
distal end of the injury site (Tal & Eliav, 1996).
2.6.1.(c) The time course of ectopic impulse generation
(ci) Complete transection
In transected nerves of the rat, ongoing activity originating from the
neuroma begins 2-3 days postoperatively and reaches a maximum at 2 weeks (Wall &
Gutnick, 1974; Govrin-Lippman & Devor, 1978). A peak incidence of spontaneous
activity at the neuroma of approximately 25% occurred 10-14 days after transection
(Devor 1994; Govrin-Lippmann & Devor, 1978). However, a comparable incidence
of spontaneous activity (35% of the A beta and 15% of the A delta fibres) was present
at 1-3 days postinjury with the Bennett & Xie model (Kajander & Bennett, 1992).
Upon reaching a maximum, ectopic impulses from the neuroma rapidly decreased to
approximately 4% of fibres sampled and remained at this level for at least another 190
days (Govrin-Lippman & Devor, 1978).
There is evidence that spontaneous activity develops first in myelinated
fibres and later in unmyelinated fibres (Govrin-Lippmann & Devor, 1978; Janig, 1988;
Devor, 1994). The incidence of evoked discharge in C-fibres begins much more
slowly. Initially these fibres are silent after transection and spontaneous firing does
not peak until about one month after the injury (Devor, 1994; Devor & Govrin-
Lippmann, 1985).
(cii) Partial nerve injury
Increased ongoing activity in dorsal horn neurones has been reported as
early as one hour following loose ligation of the sciatic nerve (Sotgui et al, 1994).
This post injury discharge could be blocked by applying local anaesthetic to the
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constriction site indicating that the source of the peripheral drive was the injury site
(Sotgui et al, 1994). At 1 to 3 days after surgery, the proportion of fibres with
spontaneously firing fibers originating in the dorsal root ganglia has been reported as
20 % (Kajander & Bennett, 1992), with most of the activity occurring in the A beta
and A delta fibres. However, only a small percentage of the A beta and A delta axons
with spontaneous discharges were still able to conduct impulses through the injured
site (Kajander & Bennett, 1992). Abnormal spontaneous activity was found to peak
at 6-9 days postoperatively in the dorsal root ganglia (Tal & Eliav, 1996). During this
peak period an average of 13% of all A fibres fired spontaneously in these rats.
Spontaneous impulses in large diameter afferents continues for at least several weeks
postinjury (Xie & Xiao, 1990; Eliav & Tal, 1994; Xie et al, 1995).
Spontaneous C fibre discharge has been found to be essentially absent from
the dorsal root ganglion cells during the first 3 days after loose ligation of the sciatic
nerve (Kajander & Bennett, 1992). C fibre spontaneous discharge after transection is
also very rare initially (Devor, 1994). As discussed previously, C-fibre discharge has
been demonstrated in the later stages of the constriction-evoked syndrome (Xie &
Xiao, 1990).
2.6.1.(d) Comparison of spontaneous activity after transection and partial nerve
injury of the sciatic nerve
After peripheral nerve transection, the activity originating at the injury site is
primarily fast, regular and continuous or has a bursting pattern whereas that from the
dorsal root ganglia is predominantly a slower, random activity (Wall & Devor, 1983,
Burchiel, 1984a). Spontaneous activity with highly irregular interspike intervals is the
predominant mode of spontaneous activity from the dorsal root ganglia in vivo after
peripheral nerve injury (Xie et al, 1995). An irregular pattern (with random inter¬
spike intervals) was more common at the site of injury after peripheral nerve injury
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than after transection (Tal & Eliav, 1996). This occurred in 41% of fibres at the loose
ligation site as compared to <5% in neuromas at 3-16 days postoperatively (Tal &
Eliav, 1996).
2.6.1.(e) Mechanisms of ectopic impulse generation
It has been suggested that the accumulation of sodium channels could
account for the ectopic discharges found after nerve injury as intense immunolabelling
of sodium channels has been demonstrated at the site of nerve transection in the fish
(Devor et al, 1989). In the rat, sodium channels in membranes of normal peripheral
nerve axons and those following peripheral nerve transection have been investigated
(Devor et al, 1993). Accumulation has been found at the neuroma, especially in
demyelinated axons and end bulbs. From computer simulations of the repetitive firing
process it has been found that the addition of extra Na+ channels with no other
change in active or passive membrane properties is sufficient to render an axon hyper-
excitable and even to shift it from a state of silence to a state of spontaneous firing
(Matzner & Devo, 1992). The action potential threshold has been found to be
substantially more negative in spontaneously active neurones compared with controls
(Study & Krai, 1996). The intrinsic threshold for rhythmic firing has been shown to be
reduced at locations of sodium (Na+) channel accumulation (Matzner & Devor,
1992).
Pharmacological agents that exhibit use-dependent block of Na+ channels
such as carbamazepine and phenytoin have been found to suppress neuroma discharge
(Yaari & Devor, 1985; Burchiel, 1988;Chabal et al, 1989; Devor et al, 1992).
Lidocaine molecules also bind to sites associated with voltage sensitive sodium
channels and prevent channel opening in response to stimuli which depolarise the cell
membrane. Systemic application of lidocaine has been found to suppress spontaneous
activity generated at the neuroma and in the dorsal root ganglion cells in rats with a
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sciatic nerve transection (Devor et al, 1992). The dose effective at blocking ectopic
discharge was lower than that required to block the initiation or propagation of
impulses by electrical stimulation (Devor et al, 1992). The dorsal root ganglia has
been found to be more sensitive than the injury site to systemic lidocaine (Devor et al,
1992). This may be due to a difference in the intrinsic pacemaker encoding properties
of the two ectopic impulse generating sites. As cited previously, there is evidence that
neuroma afferents fire rhythmically at high frequency, while dorsal root ganglion cells
fire slowly and irregularly (Wall & Devor, 1983).
Application of potassium channel blockers to the injured region of the nerve
was without effect which was not unexpected as potassium channel blockers have
been little if any effect on normal myelinated primary afferent axons (Kajander et al,
1992). However, potassium channel blockers such as 4-aminopyridine and gallamine
applied to the dorsal root ganglion cells increased the frequency of spontaneous
discharge or initiated activity from silent fibres (Kajander et al, 1992). Intravenous
gallamine has been shown to increase the frequency of spontaneous activity in 50% of
A beta and 15% of A delta fibres (Kajander & Bennett, 1992). Although no studies
of changes in calcium channels after peripheral nerve injury have been reported,
verapamil, an L-type calcium channel blocker, blocked spontaneous action potential
activity when applied to the injury site (Xie et al, 1993).
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2.7. ALTERED CENTRAL PROCESSING
The previous discussion has dealt with changes in the periphery. There is
however evidence for altered central processing of afferent information particularly in
the spinal cord. Mechanical allodynia present in some neuropathic patients has been
found to be mediated by impulses in large myelinated afferents (A beta low-threshold
mechanoreceptors) that normally convey innocuous tactile sensations (Wallin et al,
1976; Loh & Nathan, 1978; Campbell et al, 1988; Price et al, 1989; Gracely et al,
1990; Ochoa & Yarnitsky, 1993). It has been suggested that touch-evoked pain is the
consequence of an abnormal central processing of A beta fibre input (Price et al,
1989; Gracely et al, 1992; Koltzenburg et al, 1992; Treede et al, 1992) although the
mechanisms involved are uncertain. A number of studies have examined whether
altered central processing contributes to the behavioural syndrome in the rat model
and to neuropathic pain in man.
2.7.1. CLINICAL AND BEHAVIOURAL STUDIES
Cold hyperalgesia which has been reported in some patients may be due to
abnormal central processing of input from normal cold specific afferents impinging on
sensitised central neurones (Fruhstorfer & Lindblom, 1984). Torebjork and co¬
workers however found that block of myelinated fibre conduction did not prevent
heat hyperalgesia and suggested that its aggravation by noradrenaline may reflect
sensitisation of the nociceptors themselves rather than alterations in central neuronal
processes conveying pain (Torehjork et al, 1996)
Supporting these observations in humans are studies in animal models of
partial nerve injury. The associated abnormal behaviours which develop after injury in
these animal models such as thermal hyperalgesia may be due to an over excitation of
dorsal horn cells (Davaretal, 1991; Mao et al, 1992a&b; 1993; Seltzer et al, 1991;
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Tal & Bennett, 1993; Yamamoto & Yaksh 1992). If this is correct then modifying the
hyper-excitability of spinal dorsal horn neurones induced by injury discharge could
reduce the pain associated behaviours characteristic of the neuropathic model. It is
also possible that pre-emptive treatment before surgery which reduced or abolished
the injury discharge might modifying the development of excitability in the dorsal horn
neurones and thus prevent the abnormal behaviours from developing in the Bennett &
Xie model. This has been investigated by a number of pharmacological procedures.
2.7.1.(a) Local anaesthetics
Dougherty et al (1992) found a reduction in both the duration and
magnitude of the heat hyperalgesia in neuropathic animals which had local anaesthetic
applied to the wound for 5 minutes immediately following ligation of the nerve.
Although this study found that injury related discharge is an important factor in the
generation of hyperalgesia in the Bennett & Xie model, the Seltzer model did not
show this sensitivity. Bupivacaine applied to the sciatic nerve before the skin incision
and around the nerve for 10 minutes before ligation delayed the onset of thermal
changes until day 7 postoperatively. When given 15 minutes after the nerve
constriction injury, bupivacaine had no effect on the development of thermal
"hyperesthesia" (Yamamoto et al, 1993). They also showed that systemic bupivacaine
had no effect on the development of thermal hyperesthesia. Sotgiu and co-workers,
pre-treated animals either by applying lidocaine to the nerve for 10 minutes or by
systemic injection of this local anaesthetic for 5 minutes before surgery. They found
that the lidocaine prevented the development of thermal hyperalgesia and postulated
that this was due to blocking the early afferent injury discharge (Sotgiu et al, 1995b).
Lidocaine has also been found to decrease the baseline activity during the
block when given after nerve injury (Sotgiu et al, 1996). In complete nerve
transection studies, systemic lidocaine given postoperatively suppressed the ectopic
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impulses generated both at the site of nerve transection and in axotomised dorsal root
ganglion cells (Devor et al, 1992). The local anaesthetics, lidocaine, tocainide and
mexiletine were found to reduce the spontaneously active fibres originating in the
sciatic neuroma seven days after injury (Chabal et al, 1989). No conduction block
occurred with these intravenous doses.
Clinically, lidocaine has been found to produce a transient effect on
neuropathic and postoperative pain (Cassuto et al, 1985; Kastrup et al, 1987; Bach et
al, 1990). Lumbar epidural blocks of bupivacine and morphine 72 hours before
surgery were shown clinically to prevent phantom limb pain in 3 patients (Bach et al,
1988).
2.7.1.(b) NMDA receptor antagonists
There is evidence that L-glutamate is a major excitatory transmitter released
from the central terminals of primary afferents and that in normal animals the action of
this excitatory amino acid is blocked by the antagonist activity at non-NMDA
receptors (Curtis et al, 1959; Bernardi et al, 1972; Duggan, 1974; Dickenson &
Sullivan 1986; Woolf & King 1987; Ma & Woolf 1995). When inflammation
develops peripherally, glutaminergic transmission within the spinal cord increasingly
involves NMDA receptors (Schaible et al, 1991; Wilcox, 1991; Woolf & Thompson,
1991; Ren et al, 1992). Thus not surprisingly, the role of NMDA receptors has been
investigated in relation to neuropathic pain as the activation of these receptors may
lead to sustained depolarisation of local circuit and second order dorsal horn neurones
(Dubner & Ruda, 1992).
Both pre-emptive studies and post-injury studies using NMDA antagonists
have been performed in the Bennett & Xie model. Beginning 15 minutes prior to
ligation, four daily injections of MK-801, a non competitive NMDA receptor
antagonist, were found to reduce thermal hyperalgesia when administered
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intrathecally (Mao et al, 1992a) or or via i.p. injections (Mao et al, 1992b). This was
also found to occur when HA966, a non-competitive NMDA antagonist acting at the
glycine site was given over the same time course intrathecally (Mao et al, 1992a).
MK-801 injected systemicaliy (i.p.) 30 minutes prior to and seven days following
nerve ligation prevented the development of thermal hyperalgesia over the 10-37 day
postoperative period tested (Davar et al, 1991). Pre-emptive treatment with
subcutaneous MK-801 given 30 minutes prior to and twice daily for 8 days following
loose ligation prevented the development of mechanical hyperalgesia measured 27
days later (Smith et al, 1993). Memantine, another NMDA antagonist, significantly
reduced thermal hyperalgesia induced by partial nerve injury for up to 14 days
following 7 days i.p. administration by osmotic pump before surgery. This study,
found that in a separate group of animals which had not been treated before surgery,
memantine, administered (i.p.) 7 days or 14 days postoperatively reversed the existing
hyperalgesia for 1 hour (Eisenberg et al, 1995).
Thermal hyperalgesia was also found to be reduced for at least 48 hours by a
single injection (i.p. or i.t.) of MK-801 given 3 days after ligation. Intrathecal MK-
801 was without effect upon the response latency of the normal or sham operated
paw but selectively reversed the thermal hyperalgesia when administered intrathecally
7 days after nerve injury (Yamamoto & Yaksh, 1992). Intrathecal administration of
dextrorphan , another non competitive NMDA antagonist, 8-10 days postoperatively
reduced the heat evoked hyperalgesia (Tal & Bennett, 1993).
There is also clinical evidence for the involvement of NMDA receptors in
the spinal generation of neuropathic pain (Backonja et al, 1994; Kristensen et al,
1992; Max et al, 1995). The NMDA antagonist, CPP, was administered intrathecally
to one patient with neurogenic pain (Kristensen et al, 1992). Although the spread of
the pain was reduced, anxiety and nightmares occurred 4 hours after injection. In six
patients with neuropathic pain syndromes studied by Backonja et al (1994) and eight
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patients with chronic pain and widespread allodynia (Max et al, 1995) symptomatic
relief was accompanied by unpleasant side effects.
2.7.1.(c) Alpha two adrenoceptor agonists
Yamamoto & Nozaki-Taguchi (1996) found that intrathecal clonidine, an
alpha 2 adrenoceptor agonist, administered before nerve injury significantly delayed
the onset of thermal hyperesthesia by 3 days. This effect of clonidine was antagonised
by co-administration with idazoxan, an alpha 2 antagonist. Postoperatively, this study
found that clonidine had no effect on the development of hyperalgesia. They
suggested that the delay in the onset of thermal hyperesthesia was due to clonidine
decreasing the sympathetic outflow from the spinal cord.
The development of hyperalgesia between 26 & 29 days following nerve
injury using the Bennett & Xie model was prevented by administering clonidine 30
minutes before and 6 hours after surgery (Smith et al, 1993). In animals pre-treated
with clonidine the paw withdrawal threshold of the ipsilateral paw was not
significantly different from the threshold obtained for the contralateral paw. This
group suggested that clonidine prevented the development of hyperalgesia by
inhibiting the release of primary afferent neuropeptide transmitters such as substance
P and CGRP and depressing the response of dorsal horn neurones (Kuraishi et al,
1985; Go & Yaksh, 1987). An action in the spinal cord was suggested due to the
presence of a high density of alpha 2 adrenoceptor binding sites in Lamina II of the
dorsal horn (Young & Kuhar, 1979; 1980) which is the termination area of
nociceptive C-fibres (La Motte, 1977; Light & Perl, 1979).
Xu et al (1993b) investigated the effect of intrathecal guanfacine (alpha 2a
adrenoceptor selective agonist) & clonidine (non-selective alpha 2 adrenoceptor
agonist) on the flexor reflex in rats with intact & sectioned sciatic nerves. Both
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guanfacine and clonidine dose dependently depressed the flexor reflex in rats with
intact nerves. However. 4 to 18 days after sciatic nerve section there was a dramatic
increase in the sensitivity of this reflex only to the depressive effect of i.t. clonidine.
Xu and co-workers suggested that the analgesic effect of clonidine was not mediated
solely by alpha 2a adrenoceptors since clonidine depressed the flexor reflex with
stronger efficacy than guanfacine. Clonidine has a similar affinity for alpha 2a and
alpha 2c adrenoceptors (Uhlen et al, 1992) which suggests that both adrenoceptors
subtypes were involved in the depressive effect. Yaksh et al (1995) investigated the
effect of alpha 2 agonists in the spinal cord on mechanical allodynia induced by the
Chung model. They found that lumbar injection of alpha-2 but not alpha-1 resulted in
a dose-dependent reversal of the ligation induced allodynia, thus supporting a role for
spinal adrenoceptors in producing the anti-allodynic effects (Yaksh et al, 1995).
2.7.1.(d) morphine
In normal rats and cats, morphine has been found to depress the stimulus-
evoked activity of nociceptive dorsal horn neurones (Duggan et al, 1976; Le Bars et
al, 1975; Lombard & Besson, 1989). Thus, pre-emptive administration of morphine
before nerve injury by the Bennett & Xie method might prevent the spinal dorsal horn
neurones from becoming hyper-excitable. However, Yamamoto & Nazaki-Taguchi
(1996) found that pre-emptive morphine administered i.t. 20 minutes before surgery
had no effect on the development of thermal hyperalgesia which occurs after
peripheral nerve injury.
In contrast, most studies using the Bennett & Xie model found that
morphine reduced hyperalgesia when administered after the surgery producing nerve
injury (Attal et al, 1991; Jazat & Guilbaud, 1991; Yamamoto & Yaksh, 1992;
Yamamoto et al, 1994; Kayseretal, 1995). Morphine given intrathecally 1 week
after nerve injury, resulted in a dose dependent effect by reducing the thermal
102
hyperalgesia associated with this model (Yamamoto & Yaksh, 1992; Yamamoto et al,
1994).
Intravenous morphine administered 2 weeks after injury resulted in a
decrease in the vocalisation threshold for paw pressure which was maximal 15
minutes after injection lasting 20-25 minutes in total (Attal et al, 1991). Two weeks
after nerve injury, intravenous morphine was found by Kayser et al (1995) to increase
the mechanical threshold to paw pressure and by Jazat & Guiibaud (1991) to induce a
prolonged decrease in the pain rating score. In contrast, another study found that i.t.
morphine given 8 days after injury produced significant anti-noiception in sham
operated but not in nerve injured rats with established thermal hyperalgesia (Mao et
al, 1995). Using the Kim & Chung model intrathecal morphine has been found to
have no effect on mechanical allodynia (Bian et al, 1995).
It should be noted that neuropathic pain in man does not always respond
well to morphine. Relatively high doses are needed which are often associated with
significant side effects (Portenoy & Foley, 1986; Arner & Meyerson, 1988; Portenoy
et al, 1990).
2.7.2. CENTRAL STRUCTURAL ALTERATIONS
2.7.2.(a) Transynaptic degeneration
The Bennett and Xie model of loose ligation of the sciatic nerve has been
found to result in the presence of dark neurones in laminae I-IV in both sides of the
lumbar spinal cord (Sugimoto et al, 1989; Sugimoto et al, 1990). These neurones are
pyknotic and hypochromatic and have been described as dark neurones because the
staining densities of their cytoplasm and nucleoplasm has been elevated (Sugimoto et
al, 1984). Many have been shown to be smaller than normal and appear shrivelled
which suggests that they have been damaged. These neurones increased only in the
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lumbar dorsal horn and were reported to be statistically higher in the spinal cord
ipsilateral to the nerve injury (Sugimoto et al, 1989; Sugimoto et al, 1990). They
have been found to be concentrated in the medial two thirds of laminae I-II which
corresponds to the sciatic nerves intraspinal terminal field (Devor & Claman, 1980;
Swett & Woolf, 1985). The remaining area, the lateral one third of laminae I-II not
innervated by the damaged nerve (Devor & Claman, 1980; Swett & Woolf, 1985),
displayed no increase in the number of dark neurones after ligation of the sciatic nerve
(Sugimoto et al, 1989; Sugimoto et al, 1990). The number of dark neurones
produced by the Bennett and Xie model has been found to be enhanced in rats which
received strychnine (Sugimoto et al, 1989). In contrast, dark neurones were found
after transection of the inferior alveolar nerve only in rats that received strychnine.
These changes were most clearly evident 3-4 weeks postoperatively (Sugimoto et al,
1986; Sugimoto et al, 1987a). This perhaps explains why transection of the sciatic
nerve of the rat failed to evoke transynaptic degeneration when investigated eight
days after injury (Sugimoto et al, 1990).
Two mechanisms have been suggested to explain the presence of dark
neurones after chronic constriction injury. Operations where the nerve has been
manipulated but not damaged have found that two days after these bilateral sham
operations of the sciatic nerve, dark neurones were present in laminae I-III bilaterally
(Nachemson & Bennett, 1993). Bilateral nerve surgery with nerve manipulation was
found to produce a greater effect than bilateral surgery without nerve manipulation.
The increase on each side of the cord in the Bennett and Xie model was significantly
less than the increase seen in either bilateral group as the surgery is performed only on
one nerve with this model. It was suggested by this group that nociceptive input
arising from the surgery produces an initial change in neurones which was detectable
for a only a few days after surgery and decreases when the tissue injury has healed.
It is possible that ectopic discharge is the second mechanism involved in the
production of dark neurones in the Bennett and Xie model (Sugimoto et al, 1990,
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Nachemson & Bennett, 1993). Supporting this, it has been proposed that high levels
of ectopic discharge in damaged primary afferents may be critical for the production
of transynaptic degeneration that follows alveolar nerve transection (Sugimoto et al,
1987a, Sugimoto et al, 1987b). It has been hypothesised that dark neurones are the
result of an excitotoxic insult due to excess release of glutamate (Nachemson &
Bennett, 1993; Krogsgaard-Larsen, 1992).
It has also been speculated that at least some dark neurones are inhibitory
interneurones. The strychnine-enhanced presence of dark neurones may be due to
excessive excitation that is exacerbated by strychnine induced disinhibition (Sugimoto
et al, 1989). Supporting this, glycine inhibition by intrathecal strychnine in normal
rats produces allodynia (Yaksh, 1989). The functional impairment or death of these
neurones will result in altered processing of afferent information and may contribute
to a central hyper-excitable state relevant to the behavioural syndrome (Nachemson &
Bennett, 1993).
2.7.2.(b) Sprouting
It has been reported that large sensory axons which normally terminate in
laminae III and below sprout into laminae II after peripheral nerve injury (Lekan et al,
1996). It has been hypothesised that these sprouting fibres make synaptic connections
with post-synaptic cells which normally process nociceptive information. Thus
sprouting may contribute to touch -evoked allodynia which occurs following nerve
injury. Sprouting will be discussed in relation to the immunoreactive NPY changes
that occur after peripheral nerve injury in section 6.3.(g).
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2.7.3. ELECTROPHYSIOLOGICAL PROPERTIES OF SPINAL
NEURONES
2.7.3.(a) Spontaneous activity and afterdischarges
Using extracellular recordings in anaesthetised animals, Laird and Bennett
(1993) sampled dorsal horn neurones of the lumbar enlargement. This study included
low threshold mechanoreceptors which repond to light touch, wide dynamic range
neurones (WDR, responding to innocuous and noxious stimulation) and nocieptive
specific neurones which respond to high intensity stimulation. They found the
majority of neurones (77%) in both the sham-operated and in the nerve-injured rats
had no background activity. In the nerve injured animals 16% of the spontaneously
active neurones had spontaneous firing rates <7Hz and 7% of had firing rates >7Hz as
opposed to 22% of cells in the sham animals having firing rates <7Hz and 1% having
firing rates >7Hz (Laird & Bennett, 1993). They found the mean rate of spontaneous
firing in the 7% of cells in the nerve-injured animals was approximately 26Hz ranging
from 10-60Hz (Laird & Bennett, 1993). Sotgiu and co-workers (1992, 1995) found
that the background activity of WDR neurones on the side ipsilateral to the nerve
injury ranged from 18 to 27Hz which was significantly higher than that of spinal
neurones recorded on the contralateral side (Sotgiu et al, 1992; Sotgiu 1995).
Systemic lidocaine was found to reduce the background activity of these neurones on
the ipsilateral side but had no effect on the normal spontaneous activity of neurones of
the contralateral side (Sotgiu et al, 1992).
Afterdischarges can be defined as the persistence of a response after the
termination of the stimulus. It has been suggested that afterdischarges of spinal
neurones may contribute to the exaggerated behavioural responses (Sotgiu et al,
1995a). In rats with chronic constriction injury of the sciatic nerve, long lasting
afterdischarges have been described in large populations of neurones in the dorsal
horn (Palecek et al, 1992b; Laird & Bennett, 1993; Sotgiu et al, 1993), thalamus and
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cortex (Guilbaud et al, 1990). After discharges have been reported to increase after
nerve injury (Laird & Bennett, 1992; Palecek et al, 1992b; Sotgiu et al, 1995a).
Sotgiu and co-workers have found that the duration and magnitude of the
afterdischarges differed significantly depending on the type of neurone (Sotgiu et al,
1995a). Neurones responding to noxious mechanical stimuli had afterdischarges with
durations of 8-65 seconds compared to nociceptive specific neurones which had
durations of 6-20 seconds (Sotgiu et al, 1995). Laird & Bennett (1993) found that
thirteen percent of dorsal horn neurones displayed abnormal responses such as
prolonged afterdischarges to very brief innocuous mechanical stimuli and high activity
in the absence of any intentional stimulation. These observations suggest enhanced
mechanosensitivity in a fraction of spinal neurones that may be associated with
mechanical allodynia following nerve injury.
A sustained increase in background activity as a result of prior stimulation of
the receptive field or of electrical afferent stimulation was found in 5% of dorsal horn
neurones in sham and with 13% of neurones of nerve injured animals (Laird &
Bennett, 1993). In addition, all of these neurones were activated by tapping the
nerve-injury site (Laird & Bennett, 1993). In contrast, Takaishi and co-workers did
not find prolonged responses or increased spontaneous activity in spinal wide dynamic
neurones using the Seltzer model of ligation in rats (Takaishi et al, 1996). Palecek et
al, (1992a) found increased levels of spontaneous discharge in spinothalamic tract
neurones of primates with an adaptation of the Kim & Chung model whereby the
spinal nerve L7 was ligated.
2.7.3.(b) Responses to mechanical stimulation
Laird & Bennett (1993) studied the receptive field properties of dorsal horn
neurones in the lumbar enlargement of the spinal cord at 9-1 1 days after peripheral
nerve injury using the Bennett & Xie model. Fifty six percent of the neurones excited
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by electrical stimulation proximal to the nerve constriction had no detectable
mechanical receptive field (within the normal innervation territory of the sciatic nerve
or any of the remainder of the body accessible to stimulation) which is indicative of
partial deafferentation. Activity could be evoked by electrical stimulation of the
sciatic nerve at an intensity sufficient to excite C fibres in the majority of neurones
with a low threshold mechanical receptive field. This corresponds with the relatively
greater number of unmyelinated fibres that survive the nerve injury (Basbaum et al,
1991; Carlton et al, 1991; Munger et al, 1992). No statistically significant differences
were found between mean size of the receptive fields between sham-operated and
nerve injured rats in neurones with the same input properties (Laird & Bennett, 1993).
In a study by Takaishi and co-workers (1996) mechanical receptive field areas in the
5-week post-ligation animals were not significantly different from those obtained in
sham animals. In contrast, at 16 weeks after injury the receptive field areas in both
the ipsilateral and contralateral side of the nerve injured rat were significantly greater .
These changes did not occur quickly enough to account for the rapid onset of
behavioural hyperalgesia and allodynia in these animals. Laird & Bennett (1993)
found that the mean mechanical threshold necessary to excite cells (measured with
Von Frey hairs) in the sham operated animals did not differ from the mean threshold
of cells measured after injury. However, the proportion of dorsal horn neurones
excited only by low-intensity stimulation of their receptive field was lower in the
nerve-injured than in sham-operated animals (Laird & Bennett, 1993). This agrees
with the results obtained from recording from primary afferent axons (Kajander &
Bennett, 1992) and anatomical studies which have shown that the large myelinated
fibres which carry information from the low-threshold mechanoreceptors are
preferentially affected (Basbaum et al, 1991; Carlton et al, 1991; Munger et al, 1992).
The difference between the thresholds measured in deep neurones in the sham-
operated and in nerve-injured rats was statistically significant with the nerve injured
rats having a higher threshold (Laird & Bennett, 1993).
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Tapping the neuroma gently evoked a response in 53% of the cells in the
nerve injured animals but tapping the sciatic nerve at a comparable position did not
produce a response in any of the neurones recorded in the sham-operated animals
(Laird & Bennett, 1993). The majority of neurones with a response to tapping the
neuroma had a C-fibre input. In a few dorsal horn cells the effect of extending the leg
which stretched the nerve and moved the neuroma was found to evoke a sustained
discharge (Laird & Bennett, 1993). Similarly, some of the WDR neurones ipsilateral
to the nerve injury responded to mechanical probing around the nerve ligation in the
Seltzer model (Takaishi et al, 1996).
2.7.3.(c) Responses to thermal stimulation
Even though rats display thermal hyperalgesia following a sciatic nerve
partial injury, two studies have reported no alteration in the responses of spinal
neurones to noxious thermal stimuli (Palecek et al, 1992b, Laird & Bennett, 1993). In
contrast enhanced neuronal responses to noxious heat has been reported on the
injured side in monkeys after an L7 spinal nerve tight ligation (Palecek et al, 1992a).
Takaishi et al (1996) hypothesised that in rats exhibiting behaviour of heat
hyperalgesia and allodynia, dorsal horn neurones ipsilateral to the ligation should
show enhanced responsiveness to noxious heat and have enlarged receptive fields,
compared to neurones on the non-ligated side or from sham-operated rats. Contrary
to this hypothesis they found no statistically significant changes in the stimulus-
response functions of dorsal horn neurones evoked by graded noxious heat. Laird and
Bennett reported that 69% of nerve-injured animals responded to a noxious heat
stimulus. A response to innocuous cold stimuli was found in 2/33 neurones tested in
sham-operated animals and in 2 of the 30 neurones tested in the nerve-injured animals.
In addition, these cells all had C-fibre input (Laird & Bennett, 1993). It therefore
remains unclear whether enhanced neuronal thermo-sensitivity underlies heat
hyperalgesia in partial nerve injury models.
109
2.8. PRINCIPLES OF THE ANTIBODY MICROPROBE TECHNIQUE
I shall discuss details of the preparation and use of antibody microprobes in
several sections of this thesis. As an introduction however it is appropriate to outline
the principles of this method and its limitations.
The antibody technique was developed
"as a means of getting better spatial resolution in determining sites of release of
neuropeptides in the central nervous system and to do so with minimal disturbance to
the structures giving release" (Duggan, 1992).
Antibody microprobes were developed by Duggan & Hendry (1988) and is
currently the least damaging technique available for the in vivo detection of peptide
release within the central nervous system. It has been estimated that sites of release of
lOOfim diameter can be detected with this technique (Duggan, 1991). Microprobes
are modified glass micropipettes of similar diameters to those used as microelectrodes
for extracellular recordings in electrophysiological studies. The tip size of each
microprobe is 5- lOjim and thus damage to the preparation is kept to a minimum. This
is in contrast to diameters of 300-500jim when microdialysis and push-pull cannula
techniques are employed (Philippu, 1984; Ungerstedt, 1984).
Microprobes bind molecules from the extracellular space. The detection of
bound ligand (the endogenous peptide) can be done in a number of ways. Ideally a
second antibody which will bind to the bound peptide could be used. Thus an
antibody to the N-terminus or mid-portion of a ligand would be immobilised on
microprobes and a C-terminus antibody, which has been radiolabelled, subsequently
used to locate bound peptide molecules. Two site assays have been unsuccessful
however with substance P (1 1 amino acids) presumably because of steric hindrance.
Therefore more commonly the bound peptide has been detected by the subsequent
failure of binding of radiolabelled peptide molecules.
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Briefly, antibody microprobes are fine glass micropipettes, which have a
siloxane coating bearing free amine groups. Glutaraldehyde, a cross linking molecule,
reacts covalently with the free amine groups of the coating and the amine groups of
protein A. Protein A is bound to the siloxane coating to immobilise the antibodies of
the neuropeptide of interest. Microprobes are inserted into the spinal cord or brain
and left in situ for a defined period of time so that a proportion of the released
endogenous peptide binds to a restricted area of the adjacent microprobe surface.
Following removal from the CNS, the microprobes are incubated with a radiolabeled
form of the peptide. The microprobe is then washed and placed on X-ray film to
obtain an autoradiographic image. Binding of the endogenous peptide is detected as
the failure of regions of the microprobe to bind the radiolabeled form of the peptide
which are analysed quantitatively with a computer assisted image analysis system.
The distribution of the amounts of bound radiolabeled peptide is determined by
changes in the image density (or grey scale value) along the length of the
autoradiographs with any deficits in the tracer binding being represented graphically
as comparatively low grey scale values. A sorting program can select groups of
microprobes according to stimulus /experimental parameters and prepare a mean
image analysis. In addition, pairs of such grouped data can be compared and the
significance of their regional differences evaluated statistically. The release pattern of
an endogenous ligand detected on the antibody microprobes can be related to
histology and hence to the laminae of the spinal cord or to discrete areas of the brain.
The antibody technique has been employed in the spinal cord to study the
release of:
B-endorphin in the cat brain (Williams et al, 1994b) and rat brain (Duggan et al,
1993)
calcitonin gene related peptide in the cat (Morton & Hutchison, 1989, 1990;
Schaible et al, 1994) and the rat (Schaible et al, 1994)
dynorphin in the cat (Hutchison et al, 1990) and in the rat (Riley et al, 1996)
1 11
Figure 2. Principles of the antibody microprobe technique for the in vivo
detetection of neuropeptide release I.
This shows the principles from antibody immobilisation on the outer surface of the
microprobes to the production of autoradiographic images.
1 12
principles of the antibody microprobe technique i
1. Antibodies (y) to a neuropeptide of interest arc immobilised onto the outer surfaces of glass
micropipcttes.
vyyvvvvvvvyyyyy y
2. Locally released neuropeptide (V) binds to adjacent antibodies in vivo.
tyyy¥¥V¥vvvyyyYY y
^AAAAAAAA X
3. Radiolabeled form of the peptide (v) in which microprobcs arc subsequently incubated
in vitro binds to free antibody sites.
4. After washing microprobcs are placed on X-ray film to obtain an autoradiographic image.
5. Autoradiography indicate sites of extracellular neuropeptide presence.
Area of reduced image = area of reduced radioligand binding
= area of endogenous ligand binding
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Figure 3. Principles of the antibody microprobe technique for the in vivo
detection of neuropeptide release II.
Image analysis of the autoradiographic images reveals sites of endogenous peptide
binding.
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PRINCIPLES OF THE ANTIBODY MICROPROBE TECHNIQUE II
1. Using a computer-assisted image analysis system, autoradiographs are converted into plots of
image density (or grey scale values) v.s. length at 30pm intervals. The analysis system allows
data from a group of microprobes to be pooled and a plot of mean image density (+/- s.e.m.) at each
30pm interval to be produced (A). The means are joined to give a continuous line but the s.e.m. at
each analysis point is plotted separately.
in vitro microprobes
2. Mean image analysis for two groups of microprobes can be statistically compared at each 30pm
interval, using multiple Students' t-tests (A). Areas of statistically significant differences (i.e.
where t>2, P<0.05) in level of neuropeptide detection can be referred to depth within spinal cords
(B).
Depth within the spinal cord (mm)
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enkephalins in the cat brain (Williams et al, 1992)
galanin in the spinal cord of the cat (Morton & Hutchison, 1989) and the rat (Hope
et al, 1994)
neurokinin A in the cat spinal cord (Duggan et al, 1990, 1991b, Hope et al, 1990 a;b;
Lang et al, 1991); and in the rat brain (Furmidge et al, 1995)
neuropeptide Y in the cat and rat spinal cord (Mark et al, 1997) and in the cat brain
(Williams et al, 1993)
somatostatin in the cat spinal cord (Morton et al, 1989)
substance P in the spinal cord of the cat (Duggan & Hendry, 1986; Duggan et al,
1987; 1988a; b; 1991a; 1992, 1995, Hutchison & Morton, 1989; Morton et al, 1990;
Schaible et al, 1990; 1992; Zhao et al, 1992; Lang et al, 1994) and rat (Lang & Hope,
1994); and in the brain of the cat (Williams et al, 1994a) and rat (Furmidge et al,
1993).
Thyrotrophin releasing hormone in the rat brain (Waterfall et al, 1993; 1994)
The amount of time the microprobes need to remain in the CNS to detect the
endogenous peptide varies according to local neuropeptide concentrations and the
sensitivity of the particular microprobes, ranging in these previous studies from 5 to
30 minutes. A recent study showed that 150 stimuli delivered at 0.5Hz for a 5 minute
duration, resulted in just detectable release of ir -SP in the spinal cord by microprobes
(Duggan et al, 1995).
Microprobes detect the basal presence of a peptide by comparing the mean
image analysis of a number of microprobes present in the spinal cord in the absence of
any active peripheral stimuli with that of a group of in vitro microprobes not inserted
into the spinal cord but incubated in radiolabeled peptide and processed concurrently
with those used in vivo. To determine the sites at which this basal presence is
significant the differences between these two groups are determined (usually in 30|im
intervals) using the student's t-test. Significance between the two groups is obtained
when the difference between the two groups is large and the variance is small.
Statistical significance indicates the probability that the peptide was detected (see
figure 3).
Release studies commonly depend upon suppression of inactivation
mechanisms to be successful as rapid inactivation of a peptide may make it difficult to
collect released molecules. Collection depends on overflow or that a proportion of
released molecules should escape rapid inactivation. Inactivation of neuropeptides is
believed to be largely enzymatic (uptake has not been demonstrated) but there is a
lack of information on the precise location of enzymes in relation to sites of release
(McKelvey, 1986). Detection of release should not require the use of enzyme
inhibitors if the neuropeptide is not rapidly inactivated following release. The term
"volume transmission" has been used to describe the consequences of slow
inactivation of released compounds (Fuxe et al, 1990). Fuxe & collegues propose
that, at sites of release, low affinity receptors located at the releasing synapse are
activated. If the released substance is not immediately degraded but is able to diffuse
widely, the presence of high affinity receptors outside the releasing synapse effectively
enables physiological effects to occur on neurones located over relatively large areas
remote from sites of release. With such a mechanism, determining extracellular levels
has more meaning in terms of predicting whether stimuli are adequate to produce
receptor activation than the situation where overflow through suppressed inactivation
is needed to detect release.
Microprobe experiments have attempted to define the peripheral stimulus
producing release of the chosen neuropeptide after stimulation. The use of a range of
stimulus types increases the likelihood that peptide release will be detected in
instances where the physiological role of that peptide is not well understood and
hence the relevant stimuli not well known. Antibody microprobes detect the
extracellular presence of a peptide and a working definition of release is when a
stimulus causes an increase in the extracellular levels of the peptide of study. This is
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determined by comparing the mean image analysis of microprobes present in the
spinal cord in the absence of any active peripheral stimuli with those present during
stimulation. The finding of elevated levels of a neuropeptide after a peripheral
stimulus has ceased has been interpreted as persistence and supports the suggestion
that neuropeptides are slowly degraded. An example of this is neurokinin A. This
neuropeptide appears to be relatively resistant to the enzymes believed to be
important in the degradation of substance P (Nyberg et al, 1984; Hooper et al, 1985;
1987; Theodorsan-Norham et al, 1987). Substance P release in the cat spinal cord
following noxious cutaneous stimulation or the development of peripheral
inflammation has been found to be relatively focal in the upper dorsal horn whereas
immunoreactive neurokinin A has been shown to persist and spread after release by
the same stimuli (Duggan et al, 1990; Hope et al, 1990b).
It is usual to average the results from a number of microprobes. Although in
normal cases it is clear that a defined stimulus has produced a localised intense deficit
in the binding of a labelled peptide on single microprobes, this is not always the case.
Particularly when dealing with a slowly degraded compound, relatively diffuse
reductions in the binding of the tracer may not be apparent on single microprobe
images and averaging the images from many microprobes becomes necessary to define
differences between stimulus and non-stimulus groups. The differences between the
mean image analysis of two groups indicates the regions over which a particular
stimulus or treatment has produced release.
Although more of a qualitative technique, Morton and co-workers estimated
the concentration of somatostatin to which the microprobes were exposed in vivo, by
relating images of microprobes exposed to differing concentrations of the
neuropeptide in vitro to those of microprobes that had been inserted into the spinal
cord (Morton et al, 1989).
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2.8.1. LIMITATIONS OF THE MICROPROBE TECHNIQUE
The microprobe technique is a form of radioimmunoassay in which the
antibody has been immobilised. Unlike a conventional radioimmunoassay,
microprobes do not allow the simultaneous competition between ligands for binding
to available sites as uniabelled peptides are allowed first access. Therefore the
antibody must have a sufficiently high affinity such that the radiolabelled peptide does
not significantly displace the peptide within the period of incubation. Microprobes
operate within the constraint of antibody specificity and hence cannot give exact
chemical identity to what is detected. The identity of what is bound can be rendered
only highly probable by other similar results with different antibodies recognising
different sequences of the one polypeptide. C-terminally directed antisera are
commonly used. The use of N-terminally directed antibodies is often limited by the
unavailability of appropriately radiolabelled peptides. Schaible et al (1990) used both
N-terminal and C-terminal directed antibodies and [I125]-Bolton-Hunter SP and [I125-
Tyr8]-SP in studying substance P release in the spinal cord of the cat. Hence it is
possible that as well as detecting the full length peptide, shorter fragments resulting
from enzymatic degradation might also bind to microprobes. Since extracellular
compounds are being sampled it is unlikely that precursor molecules need to be
considered.
Interpretation of results obtained with antibody microprobes also requires
that other causes of reduced binding of the tracer be considered. Apart from the
specific ligand, antibodies can bind non-specifically with other compounds. The
amount of non-specific binding can be determined by in vitro studies and occurs only
at a low level (usually 10-20% of total binding). Degradation of the antibody by
proteases could occur following repeated penetration of the meninges of the brain
during the third or fourth hour of microprobe insertion. This is a form of sterile
inflammation but equally possible with prolonged experiments with the development
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of infection. Protease degradation of antibodies should result in reduced binding of
labelled F(ab)2 fragments directly at the Fc component of the immobilised antibody at
the portion of microprobe which had contact with the subarachnoid space and hence
this control is used. Protease attack can be minimised by limiting the number of
microprobes inserted into the brain and by irrigating the insertion site with autoclaved
Ringers solution.
120




SURGICAL PROCEDURES AND THE NEUROPATHIC MODEL
Male rats were purchased from Charles River Ltd (Margate, Kent, UK.) and
were housed for at least two days prior to their experimental use in order to minimise
any stress-induced alterations in their physiology that might be brought about by
transportation and change of environment. They were housed in groups of 3 to 4 in
standard rat cages on a 12 hour light/12 hour dark cycle, with room temperature of
19-23°C. Food and water were available ad libitum.
3.1.(a) Preparation of the rat neuropathic pain model
For the production of the Bennett & Xie model, adult male Wistar rats (200-
350g) were anaesthetised with sodium pentobarbitone (50mg/kg i.p.). The midthigh
area was shaved and washed with a solution of alcohol and Hibbiscrubb. Using full
aseptic technique, an incision was made midthigh and the sciatic nerve exposed.
Under low magnification, four 4/0 chromic gut loose ligatures were placed round the
sciatic nerve, proximal to its bifurcation, and tensioned so that they were just unable
to move up or down the nerve. This was found to barely arrest circulation. In the
sham group, the right sciatic nerve was exposed and manipulated but not ligated. The
muscle layer was closed and then the skin using subcuticular stitching with Vicryl to
reduce irritation. The wound was then washed with a solution of alcohol and
Hibbiscrub. Animals were allowed to recover under a warm lamp. The rats were
then rehoused in solid floor cages (in small numbers) under controlled conditions of
light and temperature, with free access to food and water, as before. The guidelines
of the IASP were followed and the animals monitored daily to ensure good wound
healing and to check whether autotomy was present.
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3.1.(b) Animal preparation for microprobe experiments
Urethane (Sigma, Chemical UK.) anaesthetised rats were used in all
experiments. Induction of anaesthesia was by intraperitoneal (i.p.) injection of
urethane (25% weight/volume solution (w/v) 1.5g/kg) in sterile Ringers solution. The
depth of anaesthesia was regularly assessed by continuous measurement of mean
arterial blood pressure and ensuring that the corneal blink and hindpaw withdrawal
reflexes remained absent. Further injections of urethane were given i.p. when
necessary to maintain a satisfactory level of anaesthesia. Throughout surgery the rat
was placed on an thermostatically controlled heat blanket linked to a rectal probe to
maintain the animal's core temperature between 36-38°C.
Initial surgery involved the cannulation of an external jugular vein, to allow
subsequent drug administration, and of a carotid artery to permit direct measurement
of arterial blood pressure via a pressure transducer. A trachea cannula (a T-piece)
was inserted to aid unobstructed breathing, with intermittent suction to ensure the
trachea was not obstructed. The use of a stainless steel T-piece enabled the animal to
be attached to a ventilator when artificial ventilation was necessary and permitted
continuous monitoring of end tidal C02 levels (maintained at approximately 4%) by
sampling from the side arm (stem of the T). Blood oxygenation was assisted by
directing a gentle jet of humidified oxygen towards the opening of the tracheal
cannula when the animal was breathing normally and towards the input of the pump
during artificial ventilation.
On the right side of the rat, an incision was made at midthigh level and the
sciatic nerve approached by separating the flexor muscle of the knee and freed lor
over 2cm proximal to its trifurcation. The animal was then placed in ventral
recumbency and the skin over the dorsum was incised rostrocaudally. The connective
tissue overlying the muscles of the transversospinalis muscle group was then cut
longitudinally either side of the dorsal vertebral processes. Transversospinalis and
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longissimus muscles were then retracted laterally from the dorsal surface of the
vertebrae by blunt dissection.
Next the rat was transferred to a stereotaxic frame (Preclinical Veterinary
Sciences, University of Edinburgh) and the thermostatically controlled heat blanket
was replaced by a metal plate with inserted heating elements (Preclinical Veterinary
Sciences, University of Edinburgh) which surrounded but did not touch the animal.
This and the rectal probe were attached to a heat control box to maintain the animal's
core temperature between 36-38°C. The exposed parts of the rat including the head
and tail were covered with a foil blanket to reduce heat loss. The preparation was
held in place by ear bars, jaw vice and spinal swan-necked clamps positioned under
the vertebral transverse processes on each side of the vertebral column. Three pairs
of clamps were used each pair being separated by at least one process. The middle
clamp was positioned at the process corresponding to the 'floating rib' which is
attached to T13 vertebra. An extended laminectomy at vertebral level T12 to L2
exposed the dura mater of the L2-L6 spinal cord segments. The dorsal surface of the
spinal cord was then removed with rongeurs and the exposed spinal cord temporarily
covered with cotton-wool soaked in sterile Ringer's solution.
A pool was formed by pulling up with sutures the edges of skin surrounding
the incision. The cotton-wool covering the exposed spinal cord was removed and
under a dissecting microscope, the edges of the laminectomy were packed with a
sterile haemostatic gauze (Spongel, Houde Laboratories) to prevent subsequent
bleeding. To provide further stability, a thin layer of a sterile solution of agar in
Ringer's solution (4% w/v, Unipath Ltd, UK.) was poured over the entire pool. At
proposed sites of antibody microprobe insertion, a rectangular area of agar was
removed exposing the spinal cord. The dura mater was opened with sterile
watchmakers' forceps, ensuring pressure was relieved at both sides of the cord. This
pool was then continually irrigated with sterile Ringer's solution at 37°C to prevent
drying of the cord surface. This continuous irrigation minimised the collection of
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inflammatory exudates on the surface of the cord as excess fluid was removed by
suction at an edge of the opening.
The right hindpaw was elevated and the skin overlying the midthigh incision
stitched to a pool-maker to expose the sciatic nerve. This nerve was mounted (intact)
on platinum stimulating electrodes and the area flooded with paraffin oil heated at
37°C to create a pool.
3.1.(c) Experiments involving stimulation of high threshold afferents of the
sciatic nerve
In experiments involving stimulation of high threshold afferents animals
were artificially ventilated. To maintain cord stability, neuromuscular paralysis was
necessary as such stimuli produced excessive limb movements. The neuromuscular
blocker, gallamine triethiodide (Flaxedil, 3mg/kg) was administered by injection into
the cannulated vein. Thresholds for nerve stimulation were determined before
neuromuscular blockade and the depth of anaesthesia assessed prior to each injection
of gallamine. In all cases the effects of gallamine were allowed to wear off to allow
verification that the level of urethane anaesthesia was satisfactory.
3.1.(d) Experiments involving spinalisation of the spinal cord
In those experiments where the spinal cord was sectioned, the spinal cord
laminectomy was extended to include more of the lower thoracic cord. At the time of
spinalisation, the use of another micromanipulator allowed access to both sides of the
cord in the region of T9-I0 where 5pl of Xylocaine 1% solution was micropipetted.
The spinal cord was then teased apart using watchmaker forceps with extra care being
taken to leave the dorsal vein intact by just sectioning the cord on either side of this
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vein. This preparation was then left for 1 hour before microprobes were inserted into
the spinal cord.
In the majority of experiments, a microprobe was filled with pontamine sky
blue dye and inserted into the spinal cord to a set depth. Current was passed to eject
dye as an anion from the probe tip. At the end of each experiment the animal, still
anaesthetised was killed by means of intravenous injection of a concentrated solution
of sodium pentobarbitone (1 ml/1.5kg; Euthesate, Willows Francis Veterinary, UK)
which resulted in cardiac arrest within a few seconds. The spinal cord containing the
dye spot was removed, fixed in formaldehyde and subsequently sectioned to provide a
direct measure of the depth of microprobe insertion (see figure 4).
3.1.(e) Experiments involving stimulation of high threshold afferents of the
sciatic nerve after nerve injury
In all experiments involving electrical stimulation the sciatic nerve was
stimulated proximal to the ligature. When the high threshold afferents were
stimulated the animals were artificially ventilated to maintain cord stability. The
neuromuscular blocker vercuronium bromide (Norcuron 1 .Omg/kg) was administered
by injection into the cannulated vein. Flaxedil was not used as it has been found to
increase spontaneous firing in complete nerve injury model as it has been found to
block potassium channels (Michaelis et al, 1996). Thresholds for nerve stimulation
were determined before neuromuscular blockade and the depth of anaesthesia
assessed prior to each injection of vercuronium.
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Figure 4. Histological section of the rat spinal cord.
(A) Transverse 52|um section of the lumbar region of the rat spinal cord from an
antibody microprobe experiment studying the release of ir-NPY. To verify the
placement of microprobes, pontamine sky blue was ejected iontophoretically at
defined depths near some of the sites of prior microprobe insertion, which in this
particular section was 1.1mm below the surface of the cord dorsum. The spinal cord
was removed from the animal, fixed in 10% formal saline and mounted on a
microtome in 0.25% agar. Transverse 52pm frozen sections were cut and stained with
neutral red. (B) is a schematic drawing depicting the lamination of the spinal grey
matter of the fourth lumbar spinal segment of the adult rat (derived from Molander et
al, 1984). This can be seen to bear a resembalance to the spinal cord section
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In all cases the effects of vercuronium were allowed to wear off to allow verification
that the level of urethane anaesthesia was satisfactory. At the end of each experiment
the animal was killed as as previously described. Once dead the sciatic nerve was
removed from the animal. Figure 5 shows four chromic gut ligatures surrounding a
section of the sciatic nerve removed from the animal 14 days after the initial injury.
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Figure 5. Sciatic nerve 14 days after ligature placement.
The ligatured nerve was found to be oedematous, especially distal to the ligatures with
extensive tissue reaction around the 4 chromic gut ligatures. Some of this tissue mass
has been removed so that the ligatures can be seen.
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CHAPTER 4: General Methodology II: Preparation and




PREPARATION OF ANTIBODY MICRQPROBES
4.1.1. ANTIBODY AND PEPTIDE STORAGE
A large number of chemicals are used in the preparation and use of antibody
microprobes. Most of these are inorganic and their handling and storage is
straightforward. The organic compounds such as antibodies are not so robust and
certain precautions were taken in their use.
4.1.1.(a) Antibodies
All antibodies for neuropeptide Y (NPY) were purchased commercially from
Peninsula Laboratories Europe Ltd, and were delivered as freeze dried lyophilates. It
is possible to store these lyophilates for several weeks prior to reconstitution, without
any apparent loss of integrity of the antibody. These lyophilates already contain
buffering salts and bovine serum albumin (BSA) resulting in the addition of a
minimum volume of diluent being required to fully dissolve them. Lyophilates were
reconstituted in distilled and Millipore filtered water and the resulting solution was
immediately divided into 0.5ml aliquots in capped, polythene Eppendorf tubes. These
aliquots were then stored at -20°C until used. As with all organic solutions, the
unused portion of any thawed aliquot of antibody was discarded, as re-freezing
promotes the breakdown of such compounds.
All antisera purchased were polyclonal and thus contained immunoglobulins
of a ranging affinity and specificity. The absolute number of antibody molecules in a
given volume of solution is not determinable when purchasing such commercial
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antisera designed for use in radioimmunoassay studies. However, one batch of
antisera was sufficient for 25 microprobe experiments, and the concentration of
antibody used was constant in all experiments. The suitability of a new batch of
antisera for use in microprobe experiments was tested by a variety of in vitro tests.
4.1.1.(b) Peptides
These were purchased in freeze-dried form and were usually diluted with a
solution of phosphate buffered saline (PBS) containing 0.1 % sodium azide. Peptides
were reconstituted to various concentrations and stored as lOOpl aliquots in capped
Eppendorf tubes at -20°C. The peptide was stored as aliquots of 10'^M, lO'^M, 10"
and lO'^M. All peptides were stored in Eppendorfs treated with Sigmacote
(Sigma Chemical, UK) using pipette tips (also treated with Sigmacote) to prevent the
peptide adsorbing to the plastic and thus reducing the concentration of the peptide in
solution. No peptide aliquots were refrozen after being thawed.
4.1.1.(c) Radiolabelled peptides
Commercially ' 25j_ia5enecj npy was purchased from Amersham being
labelled with Bolton and Hunter's reagent. Each batch was purchased as a freeze
dried lyophilate and was reconstituted immediately on delivery with the recommended
diluent (distilled water) to a total volume of lOOpl and then divided into 2.5 and 5jil
aliquots. These aliquots were stored in a dedicated, lead screened freezer at -20°C
until required. Following thawing, single aliquots were initially diluted in a solution of
PBS/azide containing 0.5% BSA. Better results, however, were achieved with 0.5%
casein instead of BSA when using NPY radioactivity (Grouzmann et al, 1992). The
radioactivity was diluted on the day of use to give a final count of 2000 counts
minute"' |ll"' and was then stored on ice until required. Unused aliquots of
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radioactivity were discarded at approximately 6 weeks after their specific activity date
as ^25j.]a5ei]eci peptides have a half life of 59.6 days.
4.2. PREPARATION OF ANTIBODY MICROPROBES
The technology of antibody microprobe production has been reviewed by
Duggan (1991), but details of the preparation of antibody microprobes have changed
in various subtle ways since then. What is presented here is the method used during
the present experiments. Initially, microprobes are manufactured and coated with
siloxane.
4.2.1. SILOXANE POLYMER COATING OF GLASS MICROPROBES
Gamma-aminopropyltriethoxysilane is a substituted silane and a member of
the organosilicon class of compounds. The organic groups of this molecule can be
used to bind proteins to glass. The initial reaction is shown in Figure 6. The hydroxyl
groups interacting with the substituted silane are shown as part of the glass, but there
is evidence that much of the reaction depends upon chemisorbed water molecules.
4.2.1.(a) Preparation of glass microprobes
Hollow, borosihcate capillary glass (outer diameter 3mm, inner diameter
1.62mm, non-filament GC 300-10, Clark Electrochemical Instruments, UK) was used
to manufacture the antibody microprobes. For the initial cleaning, this glass was
incubated for over 20 hours in a container of xylene followed by 3 x 30 minute
washes each in a different container of absolute alcohol. The glass was then dried in a
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Figure 6. Preparation of antibody microprobes
(A) shows the interaction between 7-aminopropyitriethoxysilane and the glass surface
of a micropippette to produce alkylamine (siloxane coated glass). (B) shows the
stages in the preparation of the antibody microprobes with the sequence of reagents














clean oven at 200°C and stored in a covered beaker until required. Each capillary was
drawn out by heat and tension in a vertical microelectrode puller (Preclinical
Veterinary Science, University of Edinburgh) with the settings adjusted to give an
even taper from tip to shank. The platinum heating coil of the puller extended over
lcm of the glass thus ensuring the melting of a large area of glass to produce a
gradual taper (see figure 7). Both ends of the microprobe were then heat sealed, the
wide, unpulled end in a gas flame and the tip by touching it briefly against a molten
glass bead heated by a micro-coil (Preclinical Veterinary Science, University of
Edinburgh). This latter process was performed using a micromanipulator (D10
Positioner, Research Instruments UK) and a binocular microscope. The resultant
glass microprobes are very flexible and thus resistant to accidental fracture during
subsequent use. Microprobes were then placed in carrying glass buckets in groups of
16-20, for ease of handling. Each carrying bucket has 3 perforations in its base to
permit draining during the many procedures used during microprobe production. The
filled buckets were then immersed in 50% nitric acid for 30 minutes. Immersion into
nitric acid promotes the formation of silanol groups on the glass surface (Weetall
1970). This was followed by 3 x 10 minute washes in Millipore filtered distilled water
to remove the residual acid. The buckets of probes were then dried in a clean oven at
200°C for at least 2 hours, or until further use. This process resulted in clean, dry
microprobes with some degree of surface etching on which subsequent chemical
reactions could proceed.
4.2.1.(b) Preparation of reagents
Clean Pyrex-glass boiling tubes (24/29, Quickfit), each large enough to hold
a carrying bucket, were heated to 200°C for 2 hours in a clean oven and then placed
in a rack and allowed to cool. Whilst still warm they were placed in a fume cupboard
and filled with 30ml of reagent grade toluene (Aldrich, UK) followed by 10ml aliquots
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Figure 7. Manufacture of glass micropipettes for antibody coating
(A) shows a schematic diagram of the microelectrode puller used. The capillary glass
is suspended between two holders (1,2) running through a heated platinum coil at mid
length (3). The lower holder (2) is attached to a solid metal weight (4) by means of a
robust metal cable. As the glass is heated by the coil, it stretches and the lower holder
drops. At a set distance a switch is activated (5) which triggers a strong
electromagnetic field (6) which rapidly pulls the weight down and draws the molten
glass out to a very gradual taper before separating to give two micropipettes. The
heat of the coil, the distance dropped before the magnetic pull is triggered and pull
force are all factors which determine microprobe shape. (B) This shows the typical
dimensions of antibody microprobes used for detection of neuropeptide Y in the










of gamma-aminopropyltriethoxysilane (APTES; Aldrich) taken from a freshly opened
100ml bottle (it was usual to prepare 8-10 such tubes in each session of microprobe
production, with the unused APTES being discarded). Five and a half microlitres of
distilled water was added to each boiling tube which was then closed with a polythene
cap. This was added in an attempt to control the amount of siloxane polymerisation
at the surface of the microprobes. The toluene solution had been previously treated
with molecular sieves (150g of sieves added to 2.5 litres of reagent toluene) for at
least 24 hours, the purpose of the molecular sieves being to remove as much water as
possible from the APTES/toluene mixture, as excessive water in the solution
interferes with the even build up of siloxane polymer on the surface of the
microprobes. The boiling tubes were vortexed to ensure adequate mixing of the
solutions.
The buckets of glass microprobes were carefully removed from the oven
with metal forceps and as quickly as possible, the boiling tubes were then opened, and
the buckets of microprobes lowered into the APTES/toluene mixture. Each tube of
reagent, now containing a bucket of microprobes was then restoppered and removed
from the fume cabinet. Boiling tubes were then placed in a centrifuge (Mistral 2L,
MSE Science Instruments, UK) and spun at 6°C, 2000rpm for 1 hour. This
centrifugation resulted in a more even build up of siloxane polymer on the surface of
the microprobes. This may be due to the centrifugation of free water away from the
tips of the microprobes or to the removal of small particle of debris from the solution
around the tips which may act as foci for the polymerisation reaction. The stoppered
tubes were then removed from the centrifuge and left at room temperature for at least
20 hours. The buckets of microprobes were the removed from the boiling tubes and
the APTES/toluene mixture was discarded. The buckets of microprobes were briefly
washed by dipping in toluene solution and then allowed to dry at room temperature.
One microprobe from each bucket was inspected under a binocular microscope at
x 125 magnification to ensure that the siloxane coating was visible: if too light the
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procedure was repeated. The buckets of microprobes were then placed in an oven at
200°C for at least 24 hours to cure the siloxane polymer. This heating cures the
polymer to a stable water-insoluble form and maximises the number of amine groups
free from steric hindrance (Chiang et al, 1982).
4.2.1(c) Assessment of siloxane coating
Scanning electron micrographs have been taken of the surface of uncoated
and siloxane coated microprobes. These have indicated that the polymer coating not
only provides a chemical base for the subsequent immobilisation of antibodies to the
microprobe but also vastly increases its surface area. (Duggan et al, 1988a).
A good polymer coating on the surface of the microprobe will appear, under
x 40 magnification using incident light, as a milky deposit on the surface of the
microprobes; white prior to heat curing and yellowish afterwards. The microprobes
are subsequently used to detect peptide binding with a resolution of lOOpm and hence
assessment of the eveness of polymer coating in this way is not sufficiently accurate.
Therefore, following curing, individual microprobes were placed in a
micromanipulator mounted under a binocular transmission light microscope and
examined at x 125 magnification to examine the siloxane coating accurately.
This technique produces microprobes with a fine granular siloxane coating.
It was important to identify microprobes with uneven or patchy distribution of
siloxane coating, which were discarded, and also to identify microprobes with small
focal aggregations of polymer. In some cases these 'lumpy' microprobes could be
made usable by wiping the tip vigorously with soft tissue. This tended to remove
irregular lumps of siloxane polymer whilst leaving the underlying layers intact. Only
microprobes with a very even coating of siloxane polymer passed this selection stage
as suitable for in vivo experiments. Microprobes were sorted into three groups of
coating; light, medium and heavy and were stored horizontally in specially prepared
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grooved metal racks inside covered boxes, until required. The covered boxes
protected the probes and ensured they were kept free from dust. Although the
analysis of microprobe images is performed in such a way as to minimise the effects of
coat density on the final result, for each experiment microprobes with similar densities
of siloxane were used to minimise the differences in antibody coating.
141
4.2.2. THE PREPARATION OF ANTIBODY MICROPROBES
FOLLOWING SILOXANE COATING
4.2.2.(a) Antibody coupling to microprobes
The binding of antibodies to siloxane coated microprobes takes a minimum
time of 48 hours therefore the preparation of antibody microprobes must be timed in
relation to proposed experiments to minimise wastage. Siloxane coated microprobes
can be stored for prolonged periods, but once organic molecules have been linked to
the microprobe coating they have a relatively short lifespan. There are three stages in
the coupling of antibodies to the siloxane microprobes, each stage being designed to
maximise both the specifity and affinity of the finished microprobes for the peptide of
interest. Glass capillaries were used as a convient way of incubating the microprobes
in minimal quantities of protein, peptides and radiolabeled peptide since these are all
expensive.
Protein A (Sigma Chemical, UK) a component of the cell wall of
Staphylococcus aureus was bound onto the surface of the polymer to adsorb
selectively the IgG fraction of the antisera. If a monoclonal antibody concentrate
virtually free of unwanted proteins was available, then this antibody could be coupled
directly to the siloxane coating and incubation in protein A would not be necessary.
However, in this study the antisera were raised from rabbit immunisation and
treatment with protein A was necessary to immobilise the desired immunoglobulin as
the antisera were polyclonal and hence contained immunglobulins of a ranging affinity
and specificity. This protein binds to the Fc portion of immunoglobulin of the IgG




The Afunctional reagent glutaraldehyde was used as a cross-linking
molecule to react covalently with the free amine groups of the siloxane polymer and
amine groups of protein A. Siloxane coated probes were selected (and their coatings
given a final check under the microscope) in the desired numbers for the proposed
experiments. Microprobes were placed in groups of 12 in clean carrying buckets (not
those used in siloxane preparation) and immersed in a 2.5% solution of glutaraldehyde
(BDH Laboratory Suppliers, UK) in distilled water for 30 minutes. The buckets of
microprobes were then washed for 3 x 10 minutes in distilled water before proceeding
immediately to step 2.
(aii) Glutaraldehyde / Protein A coupling
Protein A was diluted in phosphate buffered silane (PBS) containing 0.1%
sodium azide, to a final concentration of 0.1 mg ml"'. Five microlitre glass capillaries
(Blaubard, UK) were filled with protein A by capillary action. Under a dissecting
microscope, the tip of each glutaraldehyde treated microprobe was inserted into one
of the protein A filled capillaries with care taken not to touch the capillary internal
wall with the tip as it entered the capillary. If the sealed microprobe tip appeared to
be broken at this stage then the microprobe was discarded. Each microprobe with its
tip inside a capillary was then placed horizontally on a perspex rack. The rack was
placed in a covered plastic tray containing on its base tissue paper soaked in
PBS/azide. This fluid was to prevent loss of the protein A solution from the
capillaries by evaporation during the subsequent incubation. The covered racks were
then placed in a cold room at 6°C for at least 24 hours.
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(aiii) Protein A-Antibody coupling
Following incubation in protein A, microprobes were removed from their
capillaries and placed in glass tanks containing sodium borohydride (Sigma Chemical,
UK.) 2.5%w/v in borate buffer for 5 minutes. During this time, the microprobes were
repeatedly lifted out of solution to disperse the hydrogen bubbles from their surface.
The ensuing reaction, which produces free hydrogen, reduces the Schiff bases which
form by aldehyde coupling to amino groups on the protein A. The microprobes were
then replaced in the handling buckets and given 3x10 minute washes in PBS/azide
solution. Glass capillaries (20jll1, Camlab, UK) were filled with the required antibody
solution and the tip of each microprobe was inserted into a capillary as previously
described. The microprobes were then placed on perspex racks in covered boxes and
incubated at 6°C for at least 24 hours.
4.3. IN VITRO TESTING OF ANTIBODY MICRQPROBES
Before use in vivo, antibody microprobes were subjected too numerous in
vitro tests of their selectivity and affinity for the ligand being studied. This in vitro
testing was carried out in two stages: firstly, by extensive in vitro checking of
antibody microprobes prepared with a newly purchased batch of antibody, prior to
planning any in vivo work with the antibody and secondly, an extensive check of
microprobe function concurrent with in vivo experiments.
When using a new antisera attention was paid to the manufacturers claims
regarding the cross-reactivity of the antisera with other peptides. Thus, for the C-
terminally directed antibody to neuropeptide Y used throughout these studies,
Peninsula Laboratories stated that the antibody cross-reacted with peptide YY a
member of the pancreatic peptide family due to its close sequence homology to
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neuropeptide Y, but had negligible cross reactivity with non members of this family
such as VIP, amylin, insulin, galanin and somatostatin. This antibody was stated as
having 100% cross-reactivity for human, rat and porcine full length sequences of
neuropeptide Y, but only 3% cross-reactivity with pancreatic polypeptide and
negligible cross-reactivity with Prepro NPY 68-97. It was important to verify the
manufacturers claims for antisera specificity using the antibody microprobes prior to
commencing in vivo work.
4.3.(a) Newly purchased antibody
A number of antibody microprobes were prepared as previously described.
These were divided into groups of approximately five and marked with indelible pen
to allow their subsequent identification. The microprobes were placed in carrying
glass buckets and washed for 15 minutes in PBS/azide solution. These microprobes
were then inserted into 5jll1 capillaries filled with various peptide solutions, and
incubated for 30 minutes at 37°C in a humidified box (to prevent evaporation of the
peptide solutions from the capillaries) and to simulate in vivo conditions. The
capillaries were treated with Sigmacote to prevent peptides sticking to the glass wall
and thus required filling under pressure, as the solution would no longer rise by
capillary action. The peptide solutions used might typically be as follows and as
shown in table 3:
Group 1- 0M, no incubation in peptide
Group 2- 10"5MNPY
Group 3- I0~6 M NPY
Group 4- 10-7 M NPY
Following their incubation in peptide the microprobes were washed in the
presence of a magnetic stirrer in a chilled solution of PBS containing 0.1 % Tween 20.
The microprobes were left in the solution, tips down, for 15 minutes with the aim of
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removing unbound peptide from their surfaces. After washing, the tips of the
microprobes were placed in 5pl capillaries filled with a solution of Bolton-Hunter
labelled 125j_npy, diluted in PBS/azide containing 0.5% casein diluted to give 2000
counts minute"' ul "'. Casein was present in the radioactivity solution to block non¬
specific radiolabeled peptide binding to the microprobe surface (Grouzmann et al,
1992). The microprobes were then incubated in the capillaries filled with radioactivity
solution for 24 hours at 6°C.
The probes were again washed for 15 minutes in chilled PBS/Tween 20.
This time, however, the thick ends of the microprobes were mounted in a sealed
perspex block which in turn connected to a vacuum pump. Probes were washed
under suction at this stage to suck the washing solution through the inside of the
microprobes, thus removing any radiolabeled peptide that might have been drawn in
during the preceding incubation.
Next, the terminal 10mm of the microprobes were broken off, between a
thumb and forefinger and were then fixed to narrow strips of cartridge paper with a
small amount of white liquid typing paper applied to the thick end. These strips of
card were numbered according to the number written on the probe shank at the start
of the procedure, to allow subsequent identification. Each strip of card was placed in
a separate gamma-counter tube, and the amount of radioactivity, in counts minute
was determined for each tube using a gamma. Lastly, the strips of card bearing the
microprobe tips were fixed to a sheet of cartridge paper. This sheet of paper was
placed in a standard (non-screen) x-ray film cassette with a sheet of monoemulsion x-
ray film (CEA, Sweden) and left for several days to produce autoradiographic images




With in vitro testing, the terminal lengths of the antibody microprobes are
evenly exposed to radioactivity, so the autoradiographs should show an even
distribution of tracer binding. Study of these autoradiographs allows a very sensitive
assessment of the evenness of the distribution of antibody on the microprobe surface.
The siloxane polymer can itself be visualised under the microscope, but the
examination of autoradiographs is the only way to monitor the even application of the
organic layers to the antibody microprobes. Where in vitro microprobes produced
poor quality images, the procedure was repeated and if this re-occurred then it was
attributed to a degeneration of the radiolabeled peptide solution which was replaced.
On the rare occasions where the autoradiographic images of an in vitro antibody had
lumps, the radioactive count obtained from such probes were discarded and further
microprobes with similar coating were labelled with F(ab)2 fragments of an antibody
raised against the Fc region of IgG of the species in which the original antiserum was
raised. These F(ab)2 treated microprobes were processed in a similar manner as
before to obtain autoradiographs. These almost invariably resulted in even coats,
indicating that the antibody coating was indeed even.
4.3.(c) In vitro testing -measurement of microprobes sensitivity and selectivity
In table 3, microprobes in group 1 are the control microprobes that have not
been incubated in unlabel led peptide and thus represent zero NPY. The amount of
bound radioactivity to these microprobes is dependent on the actual amount of
antibody bound to the probe surface and the binding affinity of the particular antibody
used which may vary from batch to batch. The antibody used was not changed during
a series of experiments. Groups 2, 3 & 4 give an indication of the sensitivity of the
microprobe assay and its suitability for in vivo application. Incubation in peptide for
which the antibody shows affinity, reduces the number of antibody binding sites
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Table 3-The results of an in vitro assay testing the sensitivity of microprobes
bearing antibodies to NPY
Microprobe tips were mounted on card and placed in tubes and assessed for amount
of radioactive emission (in cpm) using a gamma counter. The mean ± SEM were
obtained for microprobes that had been incubated in the same conditions, using cpm
values (or 'counts') that had been corrected for background emissions (cor.cpm).
Group 1: microprobes incubated at OM were not exposed to any concentration of
peptide solution but simply incubated in [125I]-NPY. The mean ±SEM of the cor.cpm
obtained for these 'OM' microprobes represent 100% binding of the radiolabeled
peptide.
Group 2: microprobes incubated at 10~5M NPY resulted in such small counts that
these were not measurable by the gamma counter. Suppression of the mean counts
obtained with OM (i.e. the total counts) was 100%.
Group 3: microprobes incubated at 10"6M NPY resulted in an overall suppression of
the total counts by 83.0%
Group 4: microprobes incubated at 10~7M NPY resulted in an overall suppression of
the total counts by 51.2%
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IN VITRO RESULTS-TABLE 3
Group Concentration Cor.cpm Mean cpm %




1 OM 554.5 614.9 ±30.9 —
1 OM 555.5
1 OM 700.9
2 10"% npy 0
2 10-% npy 0
2 10"% npy 0 0 100%
2 10-% npy 0
2 10'% npy 0
3 10"% npy 154.4
3 10"% npy 90.8
3 10"% npy 86.8 104.5 ± 12.6 83.0
3 10'% npy 97.8
3 10'% npy 92.8
4 10"% npy 319.3
4 10"% npy 127.9 300.2 ± 60.4 51.2
4 10"% npy 408.7
4 10-% npy 344.7
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available for the subsequent radioligand binding. Thus the amount of radioactivity
that binds to the microprobes is reduced compared to the values obtained for control
microprobes. In this assay radiolabeled binding was found to be completely
suppressed by lO'^M of NPY. However, comparing all in vitro tests, the average
suppression by 10'^M of NPY has been found to be 80%. In this assay, the
radiolabeled binding was suppressed by 83% with 10"^M of NPY and by 51.2% with
lO'^M of this peptide.
Previous microprobe studies on tachykinin release in the dorsal horn of the
spinal cord have shown that where radiolabeled tracer binding was suppressed by
50% by prior incubation in a 10'^M solution of unlabeled ligand, microprobes were
found to be effective in detecting release in vivo. In all studies presented here for
NPY, the suppression of tracer binding by 10"^M ligand was in this range, but prior
to actually performing in vivo experiments it was unknown if this would be adequate
to detect endgenous NPY.
The in vitro result shown in table 4 gives an indication of the selectivity of
the NPY antibody when present in the spinal cord. Galanin and VIP have been
chosen, as unlike pancreatic polypeptide, they are present in the spinal cord and are
both found to increase after peripheral nerve injury. Minimal reduction in the
radioactivity counts should occur when microprobes are incubated in a structurally
non-related peptide. The radiolabeled binding was suppressed by only 3% with 10"
of galanin and by 2% with 10"^M of VIP. This result is comparable to the
manufacturers claim that the NPY antisera shows no cross-reactivity for VIP or
galanin. This was the case with all antisera used in these studies.
The in vitro assay result shown in table 5 indicates the ability of this peptide
to recognise PYY, a closely related member of the pancreatic family. The
radiolabelled binding was suppressed by 57.5% with 10'^M of PYY and by 40.9%
with lO'^M and 37.5% with 10"^M. This result agrees with the manufacturers claim
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Table 4-The results of a typical in vitro assay testing the specificity of
microprobes bearing antibodies to NPY.
Group 1-microprobes incubated at OM were not exposed to any concentration of
peptide solution but simply incubated in [125I]-NPY. The mean ±SEM of the cor.cpm
obtained for these OM microprobes represent 100% binding of the radiolabeled
peptide.
Group 2-microprobes incubated at 10~6M of galanin, a peptide unrelated to the
pancreatic polypeptide family, resulted in an overall suppression of the mean counts
obtained with OM (i.e. the total counts) by only 3%.
Group 3-microprobes incubated at I0~6M of VIP, a peptide unrelated to the
pancreatic polypeptide family, resulted in an overall suppression of the mean counts















1 OM 667.7 498.6 ±75.7
1 OM 671.3
1 OM 357.2
2 10'^M galanin 378.9
2 10"^M galanin 590.7 483.5 ±43.2 3.0
2 10'^M galanin 479.4
2 10"^M galanin 485.1
3 10"6M VIP 581.6
3 10"6M VIP 385.9 488.6 ±62.4 2.0
3 10"6M VIP 610.7
3 10~6M VIP 376.2
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that the NPY antisera cross-reacts with PYY. The degree of suppression obtained in
this assay was less than the suppression obtained with NPY in table 4.
4.3.(d) In vitro tests concurrent with in vivo experiments
Periodically, during in vivo experiments, microprobes were chosen with a
coat similar to that used in vivo to carry out small in vitro tests to ensure the assay
was satisfactory. This test was performed to confirm that the microprobe affinities
and sensitivities were still as expected from the earlier in vitro investigations. They
were usually divided into three groups, no incubation in peptide and incubation with
two concentrations of NPY unlabelled peptides to confirm that suppression was
occurring.
4.4. IN VIVO USE OF ANTIBODY MICROPROBES
Prior to the insertion of antibody microprobes into the spinal cord, the
suitability of potential penetration sites was examined. The spinal cord irrigation was
temporarily stopped and the sterile Ringer's solution removed from the cord surface
by gentle suction at an edge of the agar pool. A silver ball electrode was then gently
pressed on to the dorsum of the spinal cord just medial to the line of entry of the
dorsal roots and the threshold stimulus current and voltage needed to evoke a cord
dorsum potential was measured. Cord dorsum potentials elicited by low threshold
electrical stimulation of the sciatic nerve were displayed on a cathode ray
oscilloscope. The ball electrode was positioned at several rostro-caudal locations to
determine the distribution of afferent input from the sciatic nerve and hence to select
sites of insertion for microprobes. The site producing the largest field potential was
chosen for microprobe insertion.
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Table 5-The results of a typical in vitro assay testing the specificity and
sensitivity of microprobes bearing antibodies to NPY
Group 1-microprobes incubated at OM were not exposed to any concentration of
peptide solution but simply incubated in [125I]-NPY. The mean ±SEM of the cor.cpm
obtained for these OM microprobes represent 100% binding of the radiolabelled
peptide.
Group 2-microprobes incubated at 10~5M of peptide YY (PYY) a closely-related
member of the pancreatic polypeptide family, resulted in an overall suppression of the
mean counts obtained with OM (i.e. the total counts) by 59.9%.
Group 3-microprobes incubated at 10~6M of PYY resulted in an overall suppression
of the total counts by 40.9%.
Group 4-microprobes incubated at I0~7M of PYY resulted in an overall suppression
of the total counts by 37.5%.
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TABLE 5
Group Concentration Cor.cpm Mean cpm %




1 OM 668.2 573.4 ±32.6 —
1 OM 597.2
1 OM 467.2
2 10"5m pyy 281.3
2 10"5mpyy 139.3
2 10"5m pyy 335.5 243.6 ± 41.9 57.5
2 10"5m pyy 221.2
2 10-5m pyy 278.2
3 10"6m pyy 403.9
3 10"6m pyy 330.6 338.7 ±24.6 40.9
3 10~6m pyy 284.3
3 10*6m pyy 336.1
4 10"7m pyy 409.6
4 10-7mpyy 310.1
4 10"7m pyy 296.8 358.3 ±22.9 37.5
4 10"7m pyy 389.5
4 10-7m pyy 385.5
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Microprobes, prepared as described earlier, were removed from the 20fil
capillaries containing antisera to neuropeptide Y(NPY) and placed in carrying
buckets. The microprobes were washed in PBS/azide solution at room temperature
for 15 minutes prior to use, to wash away any excess antibody i.e antibody which had
not bound to the microprobe surface. Both sealed ends were removed, the thick end
first using a glass saw to scratch the surface of the glass which was then broken off
between thumb and forefinger. This must be done carefully or the tip of the
microprobe will shatter. Next, the tip was broken back to a diameter of
approximately lOjim by gently bumping it against the surface of a metal coil under a
binocular microscope at x 125 magnification. Again the adequacy of the siloxane
coating was checked and any probe with an uneven coat or tip > 10p.m was discarded.
Microprobes were numbered using a coded system of coloured rings.
One microprobe was then placed in each of two stepping motor
micromanipulators, one oriented vertical and the other 10° from vertical. The
manipulators were then moved down by hand until they were close to the spinal cord
surface. Spinal cord irrigation was temporarily stopped and excess Ringer on the
surface of the cord removed by suction. Under x 15 magnification, the tips of the two
microprobes were moved in the horizontal plane and were positioned as close
together as possible at the proposed site of insertion. The microprobes were then
lowered with the micromanipulators until the tips were just touching the surface of the
spinal cord. The micromanipulators were zeroed and then used to insert the
microprobes into the dorsal spinal cord to a depth of 2.25mm from the dorsal surface.
Once the microprobes were in situ the Ringer irrigation system was turned
on again. All NPY microprobes remained in the spinal cord for 15 minutes. The
peripheral stimuli applied during that time, however, varied according to the
experimental protocol which will be outlined separately in the Methods section for
each study. Following exposure to the spinal cord, microprobes were treated in the
same way as that earlier described for in vitro tests. The microprobes were washed
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for 15 minutes in ice cold PBS/Tween 20 to remove any tissue debris that may have
got trapped inside the probe and then inserted into 5pl capillaries containing
2000cpm/p.l, of the radiolabeled tracer and stored at 6°C for 24 hours. The thick
ends of the microprobes were mounted in a sealed perspex block which in turn
connected to a vacuum pump allowed the microprobes to be washed in PBS/Tween
20 under suction to remove any labelled peptide that may have entered the lumen of
the microprobe during the 24 hour period. This washing procedure also minimised
non-specific binding of the radiolabeled peptide. The terminal 1cm of each
microprobe was removed from the glass shaft (this was possible without shattering
the tip due to the microprobes flexible shape) and was stuck directly onto a sheet of
cartridge paper with white typing correction fluid, lining up in sequence in vivo and in
vitro probes. The previously assigned microprobe number corresponding to each tip
was written on the paper just above it. This sheet was then placed in a cassette with
momoemulsion x-ray film (CEA, Sweden), the emulsion side of the film remaining in
contact with the microprobes. The exposure time required to produce
autoradiographs of microprobes suitable for analysis varied according to the peptide
being studied. The exposure time chosen for NPY microprobes was between 7-12
days and it was usual to obtain two films with different exposure times for each
experiment.
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4.5. ANALYSIS OF ANTIBODY MICROPRQBE AUTORADIOGRAPHS
The principles employed in the analysis of microprobe autoradiographic
images were based on those described by Hendry et al (1988). Microprobe images
were analysed with a computerised image analysis system utilising an Imaging
Technology PC Vision plus frame grabber board operating in a Data Control Systems
286e (AT based) computer.
A satisfactory x-ray image was one with images well above background
silver grain density but below the maximal density for the film. Following
examination of the initial x-ray film, it was usual to expose a second film to the
microprobes for a different time from that used for the first exposure to obtain a back¬
up copy. However, occasionally, single antibody microprobe images would be
blurred due to poor apposition of the microprobe to the film and in this case a minor
repositioning of the affected microprobe was made prior to repeated exposure.
Double images occurred rarely due to movement of the film during storage, thus
exposure to a second film was necessary. The film selected for analysis was then
labelled with indelible marker pen, each image being identified by the assigned number
to that microprobe prior to its use in vivo. The film was cut up into small sections,
each section containing one or two complete microprobe images. Surface dust and
grease were removed from each piece of x-ray film by wiping with lens tissue.
Single microprobe x-ray film images were placed on a mechanical
microscope stage in a light proof box, and illuminated from beneath through a narrow
slit only just wider than the microprobe image itself. The light source (2 X 25W
microscope halogen bulbs) was mounted in a light box fitted with diffusion plates to
give uniform distribution of light. The light source was powered by a stabilised DC
power supply (Farnell) to assist stability of illumination. A video image of the
autoradiograph was obtained by scanning the probe image using a Panasonic camera
(a charge-coupled-device camera) and the field of view restricted to the distal 5mm of
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the microprobe image The automatic gain control function of the camera was
inactivated. This was essential to enable use of the video camera as a densitometer as
it ensures that the digitised video image is linear with respect to the autoradiograph.
This charged coupled digitised video image is linear with respect to the
autoradiograph density. This charged coupled device camera produced a 512 x 512
pixel 'map' of the field of view. A memory map of the 512 x 512 locations was stored
in the image board and as the length of the probe was 5000pm each location
corresponded to approximately 10 x 10pm. The optical density board converted the
optical density of the video image to an arbitrary greyscale value over a range of 0 to
255, where 0 is blackness and 255 is maximum light. Since the background was
bright and the microprobe image was dark, the image processor utilised an "inverse
look-up table". Thus a true value of 255 was converted to 0 and 0 was converted to
255 and intermediate values adjusted proportionately. This has the effect of the
microscope image appearing bright against a dark background. If the light intensity is
increased over 255 no further change in the greyscale reading is obtained and linearity
is lost. Therefore, the light intensity was adjusted to give a value of zero when no
film was present. The video image of each microprobe autoradiograph was displayed
on a colour monitor connected to the output of the image processing board that
allowed a constant monitoring of the illumination of the film. The amount of light
reaching the camera was kept constant from one x-ray film to the next by means of
varying the current passing to the light source.
Two background scans were obtained first by digitising the image from an
unexposed (no microprobe image) part of the film. Once the settings have been set
for any one film, they were left unchanged while all the data on that film was obtained.
Next the image of the microprobe was aligned on the video monitor such that it was
horizontal on the screen and its tip (which is the reference point for averaging
purposes) just contacted the edge of the screen. A background subtraction was then
carried out by the computer whereby the value of each pixel in the microprobe scan
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had subtracted from it the background value at that position. The program then
performed transverse integrations for each vertical column of pixels across the
restricted part of the field which contained the microprobe image. The corrected
image was then displayed on a colour monitor in 16 false colours corresponding to 16
grey scale values. The integrals for each scanned microprobe were stored on hard disk
(512 numbers to represent the 5mm of microprobe image) together with 37 coded
values representing various details corresponding to the experimental parameters
pertaining to that image. For each microprobe scan a plot of darkness of the image,
'greyscale' against distance along the length of the probe tip was displayed.
A small proportion of microprobe x-ray film images were found to be
unsuitable for further analysis despite all the checks of microprobe quality performed
during siloxane polymer coating. Such images most often showed focal intensities of
radioligand binding that could not be attributed to any physiological event and likely
represented dust on the probe. The antibody code of such a microprobe was altered
to 99, as the computer system reads this code first and if the value is 99 the probe is
discarded.
To minimise any differences due to variability in x-ray film exposure time the
values obtained for each microprobe scan were 'normalised'. First the mean image
analysis plot of all microprobes in a complete study is plotted, from this the mean grey
value of a relatively constant 500|im section located outwith the depth of microprobe
insertion into the nervous system was noted (see figure 8). The integral values
obtained for the image scan were then adjusted according to the variability constant
for that microprobe and entered into a new file called the 'normalised' file. If we were
unable to normalise then in vitro microprobes would need to be included in each
experiment for counting. The exposure time of the film would then be adjusted based
on this radioactivity count to give comparable autoradiographic image density
between experiments.
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Figure 8. Determination of standard grey scale value to 'normalise' the values
obtained for microprobe image scans in the NPY study
This is an example of the type of mean image density scan of NPY microprobes used
to decide the standard grey scale of a relatively constant 500(im section of the
grouped microprobes located in a region distal to that inserted into the spinal cord.
The 500pm section region chosen is marked which approximates to a grey scale value
of 3000. This was used to standardise the values obtained for each microprobe image
scan in the neuropathic study. Such a process 'normalises' the values to minimise any
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Subsequently a data sorting program was used to group together
microprobe images fulfilling stated experimental criteria. For mathematical analysis of
microprobe images, the integral mean grey scale values were pooled into groups of 3,
reducing the spatial resolution of the technique from 10pm to 30p.m. Mean image
analyses were produced for each group, by summing the greyscale values
corresponding to each 30pm for all microprobes selected and plotting for each
interval the mean greyscale value and the standard error of the mean. As the depth of
microprobe insertion was known this was converted to a plot of greyscale against the
depth of insertion in the spinal cord (in mm). The average greyscale values for a
particular group of microprobes were plotted as a solid line graph with the values of
the standard error of the mean plotted on one side only. Pairs of mean image
analyses, representing different experimental manipulations, were compared
statistically by subtracting at each 30pm point the values obtained for the control
group from the experimental group to obtain a difference. This enabled a plot of the
Student's t-test derived from the differences between the mean image analyses at 30p
m intervals to be constructed.
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CHAPTER 5: Studies of the Spinal Release of neuropeptide Y in
normal rats
5.0 INTRODUCTION
Histochemical studies first suggested that NPY has a role in the spinal
processing of information conveyed by primary afferents for although there is
negligible NPY in primary afferents of the rat there is a dense plexus of NPY-
containing terminals and fibres in laminae I & II of the dorsal horn (see section
1.2.5.).
There are, however, no reports of the release and the processes controlling
release of NPY in the dorsal horn. When I commenced my studies there was a need
to determine whether NPY is tonically released in both normal and neuropathic rats
and if such a release is increased or decreased by peripheral nerve stimulation. The
aim of this study was to employ microprobes bearing immobilised antibodies to NPY
to determine if there was a basal presence of this peptide in the spinal cord of normal
rats and if so, to determine it's origin. The effects of spinal transection on the spinal
release of ir-NPY was also studied in the rat due to the known presence of NPY in
the spinal termination of fibres of supraspinal origin (Blessing et al, 1987; Holets et al,
1988). Although the near absence of ir-NPY in dorsal root ganglion neurones implies
that this compound cannot be released in significant amounts from the spinal
terminations of primary afferents, peripheral inputs could still evoke intraspinal release
of ir-NPY by activating spinal or supraspinal processes. This was investigated by
stimulating the sciatic nerve at 3 different frequencies.
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5.1 MATERIALS AND METHODS
5.1.1. MICROPROBE PREPARATION
Antibody microprobes were prepared as previously described, using a
polyclonal antiserum (Peninsula Laboratories Europe Ltd) that had been raised in
rabbits against the C terminal end of neuropeptide Y. Data supplied from Peninsula
Laboratories indicated that this antiserum recognised porcine, human and rat full
length sequences equally well as these forms differ by only 1 amino acid located at
position 17. The antiserum recognised peptide YY but not prepro NPY(68-97) or
pancreatic polypeptide.
5.1.2. EXPERIMENTAL PREPARATION
A total of 25 male Wistar rats (weight range 250 to 350g; Charles River
Ltd, UK) were used in this study. Anaesthesia was induced and the animal prepared
as previously described in section 3.1 .(b). All microprobes were inserted into the
spinal cord (2 at a time) with a pair of stepping motor micromanipulators to a depth
of 2.25mm from the dorsal surface and left in situ for 15 minutes. After removal from
the spinal cord, all microprobes were washed and then incubated for approximately 24
hours in NPY radiolabelled with Bolton-Hunters reagent.
In the absence of peripheral stimulation, microprobes were inserted into both
sides of the cord at a level determined by the electrophysiological recordings
corresponding to the site of termination of the sciatic nerve. Only one stimulation
period of 15 minutes (either 1Hz, 20Hz, both 3 x threshold or 2Hz,>100 x threshold)
was used per experiment. In such experiments microprobes were positioned only in
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the spinal cord ipsilateral to the nerve being stimulated. Following electrical
stimulation, it was usual to insert microprobes into this side of the cord for three
periods of no stimulation.
In the spinalisation experiments, 2 pairs of microprobes were inserted into
both sides of the cord prior to cord transection. One hour later, this protocol was
repeated with a further 4 pairs of microprobes thus ensuring that both sides of the
cord were sampled equally. No peripheral stimulation was used in these experiments.
5.2. RESULTS
A total of 273 microprobes coated with antibodies to neuropeptide Y were
inserted into the rat spinal cord form the basis of this analysis. One hundred and
thirteen in vitro microprobes were prepared concurrently with those used in vivo. An
additional 440 microprobes were used for in vitro sensitivity tests.
5.2.(a) In vitro tests
Prior to use and throughout use in vivo, the sensitivity of the prepared
antibody microprobes were tested (as outlined in section 4.3.). In vitro tests indicated
that a 10~^M solution of NPY suppressed such binding on average by 40%, with a
10'^M solution resulting in over 80% suppression. Hence, it can be assumed that the
non-specific binding for these microprobes accounted for less than 20% of the total
binding. Information supplied by Peninsula Laboratories on the specificity of the
antiserum was confirmed on microprobes by demonstrating minimum suppression of
binding of [I125]"NPY by a range of concentrations of the peptides.
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5.2.(b) Preliminary experiments
In preliminary experiments, microprobes were inserted into the spinal cord
for 15 & 30 minute periods in the absence of any active peripheral stimuli. The mean
image analyses obtained from the two groups were compared to determine the
relation between detection of extracellular immunoreactive (ir) neuropeptide Y (NPY)
and the amount of time the microprobes were present in the spinal cord. A
comparison was made of the mean image analysis of 38 microprobes remaining in the
spinal cord for 15 minutes with the mean image analysis of 28 microprobes remaining
in the spinal cord for 30 minutes. The plot of microprobes inserted into the spinal
cord for 30 minutes was displayed above that of the mean image analysis of
microprobes present in the spinal cord for 15 minutes over a restricted range (not
illustrated). However, these differences were found to be significant only at a few 30
pm intervals at approximately 1.0-1.2mm from the dorsal cord surface. As the
differences in the detection of ir-NPY using two time periods were minimal, all further
studies thus used microprobes present in the spinal cord for 15 minutes since more
results could be obtained per experiment.
5.2.(c) Basai presence of ir-NPY in normal rats
The primary aim of this study was to investigate the release of ir-NPY in
animals with a peripheral nerve injury. It was therefore first necessary to investigate
the release of ir-NPY in normal animals to allow comparisons to be made. Thus it
was essential to determine in normal rats:
1/ if there was a basal presence of ir-NPY.
2/ if basal release was present to determine the source of such release.
3/ whether impulses in primary afferents could evoke release.
A basal presence of a neuropeptide at a particular site in the nervous system
is inferred by observing differences in the mean image analysis of microprobes not
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inserted into the nervous system but simply incubated in the radiolabeled peptide (in
vitro) and that of microprobes placed in the chosen area for a comparable time in the
absence of any active stimulus and then incubated in the labelled peptide. With the
latter it was relatively common in the present experiments for the autoradiographs to
show a sharply defined zone of reduced binding [125 I]-NPY. The basal presence was
determined by comparing the first 2-4 microprobes inserted into the spinal cord of 21
rats. In vitro microprobes used per experiment ranged from 1 to 1 1. Figure 9A is a
density scan of such an image with a zone that extends from approximately 0.3mm to
0.9mm and peaks at a depth of approximately 0.6mm from the dorsal surface of the
spinal cord. This zone includes most of the dorsal horn. Figure 9B compares the
mean image analysis of 73 microprobes present in both sides of the spinal cord of the
normal rat for 15 minutes in the absence of any active peripheral stimulus and that of
56 in vitro microprobes that had only been exposed to [125 I]-NPY and processed
concurrently with those used in vivo. The zone of maximal difference between these
two groups includes the zone of reduced binding in figure 9A but encompasses a
broader area as not all autoradiographs produced such a focal zone'. Figure 9C plots
in 30pm intervals the differences between the mean image analyses of the two groups
in relation to a schematic diagram of the lumbar spinal cord. The hatched area
indicates where these differences are significant at the P<0.05 level (t>2) and this is
down to a depth of 2.25mm from the dorsal surface of the spinal cord. Thus in
normal animals, there was a significant basal release of ir-NPY throughout the entire
dorsal horn that peaked at approximately 600pm from the dorsal surface of the spinal
cord but also extended into the dorsal columns. This basal release was also present in
the ventral horn but to a lesser extent.
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Figure 9-The extensive basal presence of ir-NPY in the spinal cord of normal
rats.
(A) is a density scan of a single autoradiographic image with a defined zone indicating
failure of [' ^5 IJ-NPY to bind. This defined zone peaks at a depth of approximately
600|im from the dorsal surface of the spinal cord which corresponds to the peak in
the middle of the dorsal horn in figure C. (B) The mean image analysis of two groups
of microprobes are plotted with respect to depth within the spinal cord: those present
in the spinal cord of drug naive rats for 15 minutes in the absence of any active
peripheral stimulation (no stim, n=73) and those which are not inserted into the spinal
cord but simply incubated in [' ^ I]-NPY (in vitro, n=56). For each mean image
analysis the mean grey scale was determined in 30pm intervals and a line joins these
points. At each analysis point the standard error of the mean (S.E.M.) is also plotted
(+) for no stim and (-) for in vitro. (C) A plot of the 't'-statistics derived from the
standard errors of the differences of the means at each analysis point in the mean
image analyses shown in (B), is related to an outline of a transverse section of the

































Depth within the spinal cord (mm)
- o mm
170
The mean image analysis of microprobes inserted into one side of the spinal
cord in the absence of a peripheral stimulus might reasonably be expected to be
comparable to those inserted into the opposite side. The two plots were found to be
similar and there were no statistical differences between the two groups. Preliminary
studies were also carried out to determine if the surgery necessary to isolate and
mobilise the sciatic nerve preparatory to electrical stimulation changed the basal
presence of extracellular ir-NPY. The mean image analysis plot of 38 microprobes
remaining in the spinal cord in the absence of surgery to the sciatic nerve was similar
to the mean image analysis of 58 microprobes remaining in the spinal cord after the
sciatic nerve had been prepared for stimulation (not illustrated). This suggests that
the additional surgery to isolate the sciatic nerve did not alter the basal presence of ir-
NPY.
5.2.(d) Basal presence of ir-NPY in spinalised rats
The high levels of ir-NPY found in intact animals could represent release
from the spinal terminations of fibres of supraspinal origin. To examine the
contribution of such fibres, 4 rats were spinalised midway through the experiment to
enable comparison of basal levels of ir-NPY before and after spinalisation. The range
of microprobes used per rat prior to spinalisation was 6-13 and 2-8 after spinalisation.
Figure 10A shows that the mean image analysis of 22 microprobes present in either
side of the spinal cord after spinalisation is displayed above that of the mean image
analysis of 35 microprobes present in either side of the spinal cord prior to
spinalisation. This displacement is from 2.25mm to approximately 0.2mm from the
dorsal cord surface, almost the entire length of the inserted microprobe. It suggests
higher levels of extracellular ir-NPY and hence inhibition of release by the brainstem
under normal conditions. These differences however are only significant in the lower
ventral horn (laminae VII/VIII) as illustrated in figure 10B. This result thus
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Figure 10. Spinalisation alters the release of ir-NPY in the ventral horn of the
spinalized cord of normal rats.
The mean image analysis of 22 microprobes present for 15 minutes in both sides of
the spinal cord of normal rats in the absence of any active peripheral stimuli, 1 hour
after spinalisation {post-spinal) is displaced above that of 35 microprobes present in
both sides of the spinal cord for 15 minutes in the absence of any active peripheral
stimuli prior to spinalisation {pre-spinal). (B) The differences between the post-
spinal and pre-spinal groups of microprobes are plotted with respect to an outline of
the spinal cord.
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suggests that the basal release of ir-NPY in the dorsal horn is not under significant
continuous supraspinal control.
5.2.(e) Peripheral nerve stimulation and the spinal release of ir-NPY
Although NPY cannot be significantly released directly from the terminals of
primary afferent fibres in normal rats due to its virtual absence in dorsal root ganglion
neurones, impulses in these fibres could result in intraspinal release (or inhibition of
release) through activating intraspinal or supraspinal pathways. In microprobe
experiments involving electrical nerve stimulation, a large peripheral nerve initially has
been employed. In this study, the sciatic nerve was chosen as this is the nerve that
was to be ligated in studies using the Bennett and Xie model to investigate the effect
of peripheral nerve injury on the spinal release of ir-NPY. Both large and small
diameter fibres of the sciatic nerve were stimulated as a possible means of influencing
the basal release of NPY. Due to uncertainty on the persistence of any possibly
released ir-NPY following peripheral stimulation, only one stimulation period of 15
minutes was used in each experiment during which 2 microprobes were present in the
side of the spinal cord ipsilateral to the nerve that was stimulated. Since there is
evidence that some neuropeptides are not rapidly degraded after in vivo release in the
central nervous system (Duggan et al 1990, Hope et al 1990b) 6 microprobes were
inserted into the ipsilateral side of the cord for a further three periods after electrical
stimulation to determine if persistence following release occurred and to examine the
decline in extracellular levels. Although attempts were made to standardise the time
of insertion of microprobes after stimulation there was some variation due to the need
to alter the sites of insertion. Thus all insertion times are presented as a range during
which the microprobes were inserted into the spinal cord after stimulation. Three
parameters of electrical stimulation were used, all with a pulse width of 0.5ms:
1/ A stimulus intensity of 1 Hz at 3 times the threshold (T) to elicit a cord dorsum
volley was used to stimulate large myelinated fibres.
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2/ A stimulus intensity of 20Hz at 3 times threshold was used to stimulate large
myelinated fibres.
3/ A stimulus intensity of 2Hz greater than 100 times threshold was used to activate
both myelinated and unmyelinated fibres.
The basal presence was determined separately in each set of experiments.
Two microprobes were inserted into each side of the spinal cord before stimulation
since the levels of release of ir-NPY had been shown to be similar for either side.
These 'control' microprobes formed the basis for assessing the possible effects of
nerve stimulation. Thirty six microprobes were inserted into the spinal cord in the
presence of peripheral nerve stimulation at 1Hz, 20Hz and 2Hz as detailed in the
following pages.
5.2.(ei) Stimulation of large myelinated fibres at 1Hz
In 8 rats microprobes were inserted into the spinal cord before, during and
after one 15 minute period of electrical stimulation at 1Hz (3 x T). The mean image
analysis of 16 microprobes inserted into the spinal cord during large fibre stimulation
at 1Hz is displaced below that of 26 microprobes inserted into the spinal cord prior to
stimulation from a depth of approximately 1,9mm to 0.25mm from the dorsal cord
surface as shown in figure 1 l(i)A. The differences between the two groups however,
are not significant as illustrated in figure 1 l(i)B. The mean image analysis of 37
microprobes inserted into the spinal cord from 5-60 minutes following stimulation is
compared to the mean image analysis of those microprobes inserted prior to
stimulation (n=26) in figure 1 l(ii)A. The lower figure (1 l(ii)B) illustrates that the
mean image analyses of the two groups are similar and show no significant
differences. Thus the basal presence of ir-NPY was not altered by this form of
electrical stimulation.
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Figure 11. Failure of large myelinated fibre stimulation of the sciatic nerve at
1Hz to release ir-NPY in the ipsilateral spinal cord of normal rats.
ll(i) microprobes present during stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of normal rats for 15 minutes were plotted with respect to depth within the spinal
cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli {pre-stim, ipsi & contra n=26) and those present in the spinal cord
ipsilateral to the nerve during stimulation at 1Hz (3 x T, 0.05ms). This latter group is
the mean of 16 microprobes (stim IHz, ipsi). A plot of the t-statistics derived from
the standard errors of the differences of means at each 30pm interval is related to an
outline of the lumbar spinal cord. The absence of hatched areas indicates that these
differences are not significant at the P<0.05 level.
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Figure 11. Failure of large myelinated fibre stimulation of the sciatic nerve at
1Hz to release ir-NPY in the ipsilateral spinal cord of normal rats
ll(ii) microprobes inserted after stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of normal rats for 15 minutes in the absence of any active peripheral stimuli are
plotted: those present in both sides of the spinal cord prior to stimulation at 1Hz (pre-
stim, ipsi & contra n=26) and those present in the ipsilateral spinal cord from 5-60
minutes following stimulation (post-stim, ipsi n=37J. (B) The t-statistics show that
the pre-stim and post-stim groups are not different.
178


























pre-stim, ipsi & contra
5.2.(eii). Stimulation of large myelinated fibres at 20Hz
The effects of such stimulation were studied in six rats. The plot of the
mean image analysis of 22 microprobes inserted into the spinal cord prior to
stimulation is very similar to that of 11 microprobes present during stimulation at
20Hz as shown in figure 12(i)A. Thus stimulation of large fibres of the sciatic nerve
at 20Hz failed to release ir-NPY (figure 12(i)B). The mean image analysis of 33
microprobes inserted into the ipsilateral spinal cord from 5-60 minutes following
stimulation is displaced below those inserted prior to stimulation (n=22) in the region
of 0.2-1.3mm from the dorsal cord surface as illustrated in figure 12(ii)A. These
differences, however, are not significant at the P<0.05 level as shown in figure
12(ii)B.
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Figure 12. Failure of large myelinated fibre stimulation of the sciatic nerve at
20Hz to release ir-NPY in the ipsilateral spinal cord of normal rats.
12(i) microprobes present during stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of normal rats for 15 minutes were plotted with respect to depth within the spinal
cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli (pre-stim, ipsi & contra n=22) and 11 microprobes present in the
spinal cord ipsilateral to the nerve during stimulation at 20Hz (3 x T, 0.05ms, stim
20Hz, ipsi). A plot of the t-statistics derived from the standard errors of the
differences of means at each 30pm interval is related to an outline of the lumbar spinal
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Figure 12. Failure of large myelinated fibre stimulation of the sciatic nerve at
20Hz to release ir-NPY in the ipsilateral spinal cord of normal rats following
stimulation.
12(ii) microprobes inserted after stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
for 15 minutes in the absence of any active peripheral stimuli are plotted: those
present in both sides of the spinal cord prior to stimulation at 20Hz (pre-stim, ipsi &
contra n=22) and those present in the ipsilateral spinal cord from 5-60 minutes
following stimulation (post-stim, ipsi n=33J. The pre-stim and post-stim groups are
not statistically different as shown by the t-statistics (B).
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5.2.(eiii) Electrical stimulation of myelinated and unmyelinated fibres at 2Hz
Electrical stimulation of the sciatic nerve at 2Hz was studied in 6 rats. The
plot of the mean image analysis of microprobes present in the spinal cord during nerve
stimulation at 2Hz (n= 12) is displaced above the plot of 24 pre-stimulus microprobes
between approximately 0.5mm and 1.8mm from the dorsal surface of the spinal cord
suggesting release that peaked in the upper ventral horn as shown in figure 13(i)A. At
this zone of displacement, the differences between pre-stimulus and stimulus
microprobes were close to significance at the P<0.05 level (figure 13(i)B). The mean
image analysis of 34 microprobes present in the spinal cord from 5-65 minutes
following stimulation are displaced above the mean plot of microprobes inserted prior
to stimulation from almost 2mm to the dorsal cord surface as illustrated in figure
13(ii)A. Figure 13(ii)B shows that these differences are not significant.
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Figure 13. Failure of myelinated and unmyelinated fibre stimulation of the sciatic
nerve at 2Hz to release ir-NPY in the ipsilateral spinal cord of normal rats.
13(i) microprobes present during nerve stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord for
15 minutes were plotted with respect to depth within the spinal cord: 12 microprobes
present in the spinal cord ipsilateral to the nerve during stimulation at 2Hz (>100 x T,
0.05ms, stim 2Hz, ipsi) are displaced above those present in both sides of the spinal cord
in the absence of any active peripheral stimuli (pre-stim, ipsi & contra n=24). A plot of
the t-statistics at each 30pm interval is related to an outline of the lumbar spinal cord.
The absence of hatched areas indicates that these differences are not significant at the
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Figure 13. Failure of myelinated & unmyelinated fibre stimulation of the sciatic
nerve at 2Hz to release ir-NPY in the ipsilateral spinal cord of normal rats.
13(ii) microprobes inserted after stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
for 15 minutes in the absence of any active peripheral stimuli are plotted: those
present in both sides of the spinal cord prior to stimulation at 2Hz (pre-stim, ipsi &
contra n=24)and those present in the ipsilateral spinal cord from 5-65 minutes
following stimulation (post-stim, ipsi n=34). (B) The t-statistics show that the two
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The significant findings of this study which I shall discuss are:
(a) the presence of ir-NPY in the entire dorsal horn and ventral horn of the lumbar
spinal cord of normal rats in the absence of any active peripheral stimulus.
(b) an alteration in the basal release of ir-NPY only in the deep ventral horn after
spinalisation.
(c) the failure of nerve stimulation to significantly release ir-NPY.
Prior to discussing these results it is first necessary to consider the significance of the
finding of a basal presence of ir-NPY in the absence of peripheral stimuli.
5.3.(a) Basal presence-real or artefact?
Release of ir-NPY from cells and fibres ruptured during the introduction of
microprobes cannot be entirely excluded. Differing patterns of basal release however
have been detected for different neuropeptides both in the spinal cord of the rat (Lang
& Hope 1994; Hope et al, 1994; Riley et al, 1996) and the cat (Duggan et al, 1988a;
Morton et al, 1989; Duggan et al, 1990; Schaible et al, 1994) despite the passage of
microprobes through areas enriched in the relevant compound. Repeatedly placing
microprobes in the same site might be expected to increase the probability of
rupturing neuropeptide -containing structures. In the present study all microprobes
were inserted into the area corresponding to the sciatic distribution in the spinal cord,
but the sites of probe insertion within this area were varied in an attempt to minimise
damage.
The antibodies immobilised to the microprobes of the present experiments
were C-terminus directed and hence, as well as detecting NPY, it is possible that the
shorter fragments resulting from enzymatic degradation might also bind to
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microprobes. NPY appears to be relatively resistant to degradation and although
degraded by some central peptidases little is known about the degradation of NPY
within the spinal cord (Ludwig et al, 1995, see section 1.1.2.).. Although the
immobilised antibodies used in the present experiments did recognise peptide YY,
analysis of chromatographic and radioimmunoassay data led De Quidt and co-workers
to conclude that NPY is the main if not the only, member of the pancreatic
polypeptide family in the central nervous system of the rat, pig and human (De Quidt
et al, 1990). Therefore, it is likely that the antibody microprobes inserted into the
spinal cord of the rat predominantly detected NPY.
5.3.(b) Basal release-The stimulus for release?
A working definition of release is an increase in extracellular levels when a
stimulus is delivered. In microprobe experiments, this is inferred by the difference
between pre and intra stimulus groups. In this study, the basal presence of ir-NPY
was determined by comparing the mean image analysis of in vitro microprobes (not
inserted into the spinal cord but simply incubated in radioactivity) with those present
in the spinal cord in the absence of any active peripheral stimulus. The differences
between these two groups can also be called release as this basal presence is most
likely due to continuous activity in some structure under the conditions of these
experiments. There are several possibilities for such activity. Microprobe studies of
release of neuropeptides in the spinal cord are performed in animals which have been
anaesthetised and subjected to considerable surgery. There is no evidence that
anaesthesia is a stimulus for the release of peptides. Despite general anaesthesia such
animals could have a continued spinal input of impulses in nociceptors of both
superficial and deep origin. This has been proposed as the source of the basal
presence of ir-substance P in the superficial dorsal horn of cats (Duggan et al, 1988b)
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and rats (Lang & Hope 1994) since substance P is readily released in this area by
peripheral noxious stimuli and particularly as inflammation develops (Schaible et al,
1990). In contrast to substance P, NPY is not present in the primary afferents of
normal rats. However, impulses in primary afferent fibres could result in intraspinal
release (or inhibition of release) of NPY by activating intraspinal or supraspinal
pathways.
In this study the sciatic nerve was stimulated in an attempt to release ir-NPY
from the endings of primary afferents and to study the time course of this peptide if it
persisted. However, electrical stimulation of both myelinated and unmyelinated fibres
and large myelinated fibres alone failed to release ir-NPY at the frequencies chosen.
Hence it is unlikely that the large basal presence of ir-NPY can be attributed to
continued activity in peripheral nociceptors as a result of surgery. In the cat, noxious
mechanical and thermal stimulation have failed to release ir-NPY (Mark et al, 1997).
Thus although the present study indicates that ir-NPY is continually released in the
spinal cord of the anaesthetised rat the stimulus for this release is unknown.
5.3.(c) The localisation of ir-NPY in the spinal cord and the possible sources of
the extracellular release
Radioimmunoassay studies of tissue extracts have found higher levels of ir-
NPY in the dorsal horn compared to the ventral horn in all species studied (Allen et
al, 1984; Roddy et al, 1990; Gibson et al, 1984). Immunocytochemical studies have
shown ir-NPY containing cells and terminals mainly in laminae I-III of the
lumbrosacral spinal cord with lower levels around the area of the central canal and the
ventral horn (Hunt et al, 1981 a & b; Sasek & Elde 1985; DeQuidt & Emson 1986;
Krukoff 1987, Leah et al, 1988).
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This is in broad agreement with the results obtained in this study which
found that ir-NPY was present throughout the dorsal horn, dorsal columns and
ventral horn. It should be emphasised however, that microprobes detect the
extracellular presence of ir-NPY and hence release from axon terminals as opposed to
the levels in cell bodies and cell processes as determined by immunocytochemical
means.
NPY immunoreactivity has not been found in primary afferent neurones but
a proportion of intrinsic spinal neurones contain ir-NPY (DeQuidt & Emson 1986;
Sasek & Elde 1985; Rowan et al, 1993; Todd & Spike 1993). A contribution from
descending systems has been suggested due to the similar distribution pattern of
noradrenergic fibres from the brainstem (Westlund et al, 1983). Colocalisation of ir-
NPY in medullary catecholamine containing neurones has been described (Hokfelt et
al 1983; Everitt et al, 1984; Blessing et al, 1987). However, only the CI neurones of
the medulla oblongata (adrenaline containing group of neurones) and the A6 neurones
(noradrenaline containing) of the locus coeruleus have been found to contain spinally
projecting neurones which were immunoreactive for NPY (Holet et al, 1988; Blessing
et al, 1987).
To determine whether continued activity in descending fibres was
contributing to the basal release of ir-NPY in the rat spinal cord, microprobes were
inserted into the lumbar spinal cord one hour after spinalisation of the lower thoracic
cord. The mean image analysis of microprobes inserted after spinalisation was
displaced above those inserted prior to spinalisation. This suggests that the
extracellular levels of ir-NPY were increased after spinalisation and that the
descending fibres inhibit release under normal conditions. These differences were
significant only in the lower ventral horn but not at any of the dorsal horn sites. Thus,
the activity in descending fibres was not found to be a major source of the basal
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presence of ir-NPY. This suggests that intrinsic spinal neurones were predominantly
responsible for the basal presence.
5.3.(d) The wide distribution of this basal release
A surprising finding of the present study was the extent of the basal presence
of extracellular ir-NPY which was present in significant levels throughout the entire
dorsal horn and ventral horn.
Sites of neuropeptide presence can be inferred with great accuracy when dye
is ejected from a single microprobe and its position in the spinal cord subsequently
determined by spinal cord section. The location of sites of release is less precise when
many microprobes are grouped and the average obtained as only one dye spot is
produced per experiment. As microprobes are inserted a fixed distance into the spinal
cord the spinal laminae may vary between individual animals and also with distance
from the midline. These anatomical differences, may contribute to the broadness of
the sites of release obtained from the mean image analyses of many microprobes but
they cannot explain the differences between NPY and other neuropeptides studied in
the rat such as substance P (Lang & Hope 1994, Duggan et al, 1988b), dynorphin
(Riley et al, 1996) and galanin (Morton et al, 1989; Hope et al, 1994).
The ability of a neuropeptide to resist rapid degradation following release is
an important determinant of its ability to access receptors and influence neurones
remote from sites of release (Fuxe et al, 1990; Liu et al, 1994; Beck et al, 1995).
Little is known of the degradation of NPY in the central nervous system but from its
structure of a polyproline like helix lying antiparallel to an amphiphilic alpha-helix
together with an amidated C terminus, NPY has been proposed to be relatively
resistant to endopeptidase and carboxypeptidase attack (Ludwig et al, 1995). Thus
the wide distribution of basal extracellular ir-NPY may represent wide diffusion rather
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than release from a multiplicity of sites. Thus, the finding of a basal presence of ir-
NPY in the dorsal and ventral white matter may also relate to diffusion after release.
High affinity NPY binding sites have been found on cultured dorsal root
ganglion neurones and autoradiographic studies have suggested that NPY receptors
are located on primary afferent terminals concentrated in laminae II of the spinal cord
(Walker et al, 1988; Kar & Quirion 1992). Mantyh and co-workers found binding
sites in laminae I, II, V, X and Onufs nucleus (Mantyh et al, 1994). NPY receptor
mRNA has been described in 20% of dorsal root ganglion neurones of normal rats.
These have been found mainly in small dorsal root ganglion neurones with only a few
medium and large neurones labelled (Jazin et al, 1993b, Zhang et al, 1994a). Zhang
and co-workers have suggested that both Y1 and Y2 receptors are synthesised in
dorsal root ganglion neurones Y2 being transported to nerve terminals and Y1 being
incorporated into somatic plasmalemma. The widespread release of NPY may allow
this neuropeptide to act on the many receptors located throughout the spinal cord.
An unusual finding in the present study was the detection of ir-NPY in the
perfusate just above the dorsal surface of the spinal cord. This may have simply
resulted from the diffusion from the spinal cord but release from the meninges
requires consideration. The spinal pia mater receives a rich innervation of small
sensory axons via the ventral roots. These ventral root afferents are thought to be
involved in the control of the pia blood vessels (Risling et al, 1994). Fibres
immunoreactive to NPY, cGRP and SP have been found in the lumbrosacral pia mater
lining the spinal cord (Risling et al, 1985; Shen et al, 1994). The rupturing of the pia
mater by microprobes may contribute to the presence of ir-NPY which was detected
beyond the surface ot the perfusate.
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5.3.(e) Functional implications of this study
The extensive distribution of extracellular ir-NPY suggests that NPY has an
important role in spinal cord function. As previously described, NPY has been found
to inhibit transmitter release both peripherally and centrally (see sections 1.2.4. &
1.2.6.). How these actions apply to events in the spinal cord in vivo is currently
unknown.
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CHAPTER 6: Studies of the Spinal Release of Neuropeptide Y in
neuropathic rats
6.0 INTRODUCTION
The model of Bennett & Xie results in a partial loss of fibres distal to the site
of injury. This injury differs from transection where the axotomy is complete thus
there is no afferent input from the periphery. It has been suggested that an
interaction between impulses from the periphery and the altered central state is
responsible for the abnormal behavioural changes associated with this model (see
sections 2.6. & 2.7). After peripheral nerve injury, NPY has been shown by in situ
hybridisation studies to be synthesised in medium to large dorsal root ganglion
neurones (Nahin et al, 1994; Kashiba et al, 1994).
The aim of this study was to examine the basal release of ir-NPY and the
effect of peripheral nerve stimulation in rats with a unilateral constriction injury of the
sciatic nerve. Sham experiments were performed in separate animals as controls.
This enabled the basal release in the ipsilateral and contralateral cord with respect to
the ligature to be compared in the neuropathic rat. It was of interest to determine
whether the newly synthesised NPY could be released from the central terminals of
primary afferents and whether release from these afferents was at different sites in the
spinal cord compared to the basal release in normal rats. Using the antibody
microprobe technique, the basal release of ir-NPY has been found to arise mainly
from intrinsic neurones. To determine whether impulses in primary afferents were
necessary to alter the basal presence of this peptide primary afferents in the sciatic
nerve proximal to the ligature were stimulated. To investigate whether persistence
occurred microprobes were inserted into the spinal cord for up to an hour following
stimulation.
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6.1. MATERIALS AND METHODS
6.1.(a) Microprobe preparation
Antibody microprobes were prepared as previously described, using a
polyclonal antiserum (Peninsula Laboratories Europe Ltd) that had been raised in
rabbits against the C terminal end of neuropeptide Y.
6.1.(b) Experimental preparation
A total of 41 male Wistar rats (weight range 190 to 350g when ligated;
Charles River Ltd, UK) were used in this study. Anaesthesia was induced and the
animal prepared as previously described (section 3.1 .(b)). Before, during and after
peripheral stimulation of the sciatic nerve, microprobes were inserted into both sides
of the cord at a level determined by the electrophysiological recordings corresponding
to the site of termination of the sciatic nerve. Only one stimulation period of 15
minutes (either 20Hz, 3 x threshold or 2Hz, > 100 x threshold) was used per
experiment and stimulation was always to the ipsilateral nerve proximal to the ligature
site. Following electrical stimulation, microprobes were inserted into the spinal cord
for three periods of no stimulation.
6.2. RESULTS
A total of 390 microprobes coated with antibodies to neuropeptide Y were
inserted into the rat spinal cord form the basis of this analysis. 205 in vitro
microprobes were prepared concurrently with those used in vivo. An additional 369
microprobes were used for in vitro sensitivity tests.
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6.2.(a) In vitro tests
Prior to use and throughout use in vivo, the sensitivity of the prepared
antibody microprobes were tested (as outlined in section 4.3).
6.2.(b) Behavioural results
Post-operatively, the International Association for the Study of Pain
guidelines for the care of experimental animals were followed (Zimmermann et al,
1983). The animals used displayed the changes associated with this model such as
hopping, licking, everted paw and ventroflexed toes (Bennett & Xie 1988).
Mechanical allodynia was tested by touching the skin with the standard
Semmes-Weinstein set of Von Frey hairs (Stoelting, Wood Dale Illinois). These hairs
are a series of nylon monofilaments (of increasing stiffness) that exert defined levels of
force when pressed to the point where they bend against a hard and level surface.
Increasing stiffness is achieved by increasing the hair's diameter thus the amount of
force per unit area (Newtons) changes as grams of force increases. However, as the
skin has non-trivial elasticity it is impossible to determine the exact contact area and
thus the force was recorded in grams as described by Tal & Bennett (1994).
Animals were placed in cages with a perforated metal sheet that allowed
mechanical stimuli to be applied to the hindpaw from below. The hairs were applied
perpendicular to the mid-plantar glaborous skin of the rats hind paw and depressed
slowly until they bent. Both hind paws were tested prior to surgery and then at
regular intervals during the two weeks following surgery. Von Frey Hairs were tested
in order of increasing force with each applied 5 times to slightly different loci within
the area tested. The first hair to evoke a reflexive withdrawal was designated the
threshold force. The mean paw withdrawal threshold pre-operatively for the left &
right hindpaw were comparable. A significant decrease occurred in the threshold
force of the paw ipsilateral to the nerve injury (the right paw) 3-5 days
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postoperatively, 4.5 ± 0.4g (SEM), which continued to decrease throughout the time
course studied with a mean of 3.4 ± 0.4g at 6-9 days postoperatively. On the
experimental day, the paw withdrawal threshold for the right hindpaw was 3.3 ± 0.6g
which was significantly smaller than the pre-operative mean. The threshold force of
the contralateral paw also decreased (see 6(i) & 14(i)). 3-5 days postoperatively the
mean paw withdrawal threshold for the left paw was 38.6 ± 2.3g which was
significantly smaller from the preoperative value of 45.9 ± 2.8g (P<0.05). In addition,
there was only a slight increase towards the control values over the next two time
periods. The mean paw withdrawal threshold for the left paw was 39.2 ± 2.3g at days
6-9 and 39.7 ± 2.0g at 10-14 days postoperatively (see 6(i)). These means were also
significantly smaller from the preoperative mean paw withdrawal threshold for the left
paw (P<0.05). With sham operated rats there was no statistical difference between
the sham operated paw (right) and normal paw (left) at any time point studied.
Mechano-hyperalgesia was assessed with pinprick. The point of a safety pin
was used to indent but not penetrate the skin . The duration of the normal pin-prick-
evoked hindpaw withdrawal was arbitrarily assigned a duration of 0.5 seconds as it
was too short to time accurately. A measurement cut-off of 30 seconds was applied
to the long-duration withdrawals seen ipsilateral to the nerve injury. The withdrawal
duration of the ipsilateral paw peaked at 3-5 days after injury with a mean paw
withdrawal latency of 20 ± 2s followed by a slight decrease over the next two time
periods (see 6(ii) & 14(ii)). All post-operative means for the right (injured) paw were
significantly greater than the pre-operative mean obtained for both the right and left
paw (PcO.OOl). There was no change in the withdrawal duration of the contralateral
hindpaw (see 6(ii)). With sham operated rats, there was no statistical difference
between the sham operated paw and the normal paw at any time point studied.
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Table 6 (i). Paw withdrawal threshold before and after partial nerve injury.
The mean paw withdrawal threshold (PWT) of the right (ipsilateral) paw, measured in
grams (g), and left paw (contralateral) paw were compared before and following
partial nerve injury. The surgical procedure was always performed on the right paw
and the normal left paw served as a control.
* mean PWT for the right paw was significantly smaller than the mean for the left paw
at P<0.001 level using paired students t-test.
• postoperative mean for the left paw was significantly smaller than the preoperative
mean for this paw at P<0.05 level using unpaired students t-test.
Tble 6(ii). Paw withdrawal latency before and after partial nerve injury.
The mean paw withdrawal latency (PWL) of the right paw, measured in seconds
(sees), and left paw were compared before and following partial nerve injury. The
duration of the normal paw was arbitrarily assigned a duration of 0.5 seconds.
*mean PWL for the right paw is significantly larger than the mean for the left paw at
PcO.OOl level using paired students t-test.
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BEHAVIOURAL RESULTS
6(i)-PAW WITHDRAWAL THRESHOLD BEFORE







0 46.8 ±2.8 45.9 ±2.8 (n= 51)
3-5 4.5 ±0.4 * 38.6 ±2.3 " (n= 31)
6-9 3.4 ±0.4 * 39.2 ±2.3 * (n=29)
10-14 3.3 ±0.6 * 39.7 ±2.0" (n=36)
6(ii)-PAW WITHDRAWAL LATENCY BEFORE







0 0.5 ±0 0.5 ±0 (n= 21)
3-5 20 ± 2 * 0.5 ±0 (n= 29)
6-9 19± 3 * 0.5 ±0 (n= 13)
10-14 18 ± 2 * 0.5 ±0 (n=36)
202
Figure 14(i). Behavioural testing for mechanical allodynia
The mean paw withdrawal threshold (PWT) of the right (injured) paw was compared
with the left control paw. From 3-5 days postoperatively, the mean PWT for the right
paw was reduced. Thus, from this time period until the experimental day the mean
PWL of the right paw was significantly smaller than the mean for the left paw using
student's paired t-test. These results are presented in table 6(i).
Figure 14(ii). Behavioural testing for mechanical hyperalgesia
The mean paw withdrawal latency (PWL) of the right (injured) paw was compared
with the left control paw. From 3-5 days postoperatively, the mean PWL for the right
paw was increased. Thus, from this time period until the experimental day the right
mean PWL was significantly larger than the mean for the left paw using student's
paired t-test. These results are presented in table 6(ii).
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6.2.(c) Histology of injured nerve
Morphological studies of the ligated sciatic nerve have found a near complete
loss of large myelinated fibres and a significant degeneration of small myelinated fibres
distal to the ligature with relative sparing proximal to the lesion at 2 weeks postinjury
(Basbaum et al, 1991; Munger et al, 1992; Coggeshall et al, 1993). The ligatured and
normal sciatic nerves were removed from each animal at the end of the experiment.
Sections of the normal and the ligated nerves were treated with solochrome cyanin
which stains for myelin. This was performed by the histology laboratory of the
department of Preclinical Vet. Science. The two sections shown in figure 15 illustrate
the loss of myelin which occurs in the distal sciatic nerve after nerve injury.
6.2.(c) Spontaneous release of ir-NPY and sham operated rats
A basal presence of ir-NPY in the spinal cord of sham operated rats was
inferred by comparing the mean image analysis of microprobes not inserted into the
nervous system but simply incubated in radiolabeled NPY with microprobes inserted
into the lumbar spinal cord of the sham animals in the absence of any active peripheral
stimuli. The range of in vivo microprobes used was 7-13 per animal and for in vitro
microprobes 4-7 per animal. Figure 16A shows that the mean image analysis of 42
microprobes inserted into either side of the spinal cord of sham animals is displaced
above that of 23 in vitro microprobes derived from 4 sham rats. This displacement is
from the tip to 2.50mm from the tip corresponding to the entire length of the
microprobe within the spinal cord and beyond. Figure 16B illustrates the differences
between the mean image analyses of the two groups in relation to a schematic
diagram of the lumbar spinal cord. The hatched area indicates where the differences
plotted in 30jim intervals are significant at the P<0.05 level (t>2). These differences
are significant throughout laminae I-V of the dorsal horn, the dorsal columns and also
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Figure 15. Histological sections of the sciatic nerve.
The sciatic nerve was removed from the animal, fixed in 10% formal saline and then
wax-embedded. 8|J.m transverse sections were cut with a microtome and the sections
treated with solochrome cyanin to stain for myelin and counterstained with eosin. A
loss of large and small myelinated fibres after nerve injury has been reported by
several studies. In this study a change in the myelin staining was found distal to the
ligature compared to the non-ligatured nerve. (A) shows a section of the non
ligatured sciatic nerve with the abundant myelin stained deep purple. (B) shows a
section of the nerve distal to the ligatures. There is extensive loss of myelinated fibres





Figure 16. The basal presence of ir-NPY in the spinal cord of sham operated
rats.
(A) The mean image analysis of two groups of microprobes are plotted with respect
to depth within the spinal cord: those present in both sides of the spinal cord of sham
operated rats for 15 minutes in the absence of any active peripheral stimulation (no
stim, ipsi & contra n=42) and those which are not inserted into the spinal cord but
simply incubated in [' ^ I]-NPY (in vitro, n=23). For each mean image analysis the
mean grey scale was determined in 30|im intervals and a line joins these points. At
each analysis point the standard error of the mean (S.E.M.) is also plotted (+) for no
stimulus and (-) for in vitro. (B) A plot of the 't'-statistics derived from the standard
errors of the differences of the means at each analysis point in the mean image
analyses shown in (A), is related to an outline of a transverse section of the lumbar




















Depth within the spinal cord (mm)
B 0 mm
209
the superfusate of the spinal cord for 0.3mm. The zone of most significant release of
ir-NPY approximates to laminae I, II and III of the dorsal horn.
It was important to determine whether exposure and manipulation of one
sciatic nerve (the sham operation) produced differences in the basal levels of
extracellular ir-NPY on the two sides of the spinal cord. The mean image analysis of
microprobes inserted into the contralateral side (n=23) and into the ipsilateral side of
the spinal cord of animals subjected to the sham operation (n=19) are compared in
figure 17A. No significant differences were found between the two groups (see figure
17B).
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Figure 17. The basal presence of ir-NPY in both sides of the spinal cord of sham
operated rats is comparable.
The mean image analysis of two groups of microprobes present in the spinal cord for
15 minutes in the absence of any active peripheral stimuli were plotted with respect to
depth within the spinal cord: those present in the spinal cord ipsilateral to the sham
operation (ipsi, n=19) and those present in the contralateral spinal cord of the same
animals for 15 minutes (contra, n=23). These plots are similar thus there are no
statistical differences at the P<0.05 level.
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6.2.(d). Basal presence of ir-NPY in nerve ligated rats
In figure ISA the mean image analyses of microprobes inserted into the
contralateral spinal cord of sham operated rats and that of microprobes inserted into
the contralateral spinal cord of unilaterally nerve ligated rats are compared. In this
figure, the mean image analysis of the nerve ligated rats is displaced above that of the
sham operated rats from approximately 1,5mm to 0.25mm from the dorsal cord
surface. Although this suggests increased basal levels of extracellular ir-NPY in the
nerve ligated rats none of these differences are significant at the P<0.05 level as
shown in figure 18B. When comparisons were made between the ipsilateral side of
the spinal cord in sham operated and nerve ligated animals, significant differences
were found. Figure 19A shows that the plot of the mean image analysis of
microprobes inserted into the spinal cord ipsilateral to the nerve ligation is displaced
above that of microprobes inserted into the sham operated rats. The displacement is
from approximately 2.15mm to 0.3mm from the dorsal surface. Figure 19B illustrates
that these differences are significant from 0.5mm to 1.5mm from the dorsal surface
with a broad peak of greatest difference from 0.7mm to 1. 1mm from the dorsal
surface. The latter zone approximates to laminae IV, V, VI of the dorsal horn and the
total area of significance includes laminae III, IV, V, VI and upper VII. Thus there
was an additional zone of release in nerve ligated animals compared to sham operated
animals and this difference was also apparent when the two sides of the spinal cord
were compared in the nerve ligated rats.
Microprobes were inserted into the spinal cord of 10 rats to determine the
basal presence of each side of the cord. Figure 20A shows the plot of the mean image
analyses of 53 microprobes inserted into the spinal cord ipsilateral to the nerve
ligation is displaced above the mean image analysis of 55 microprobes inserted into
the opposite side of the spinal cord. The number of microprobes used per animal
ranged from 7-14. Figure 20B illustrates that these differences are significant from
0.6 to 1.3mm from the dorsal surface which approxiamtes to laminae III, IV ,V & VI.
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Figure 18. The basal presence of ir-NPY in the contralateral spinal cord of
sham operated and nerve Iigated rats is comparable.
(A) The mean image analysis of 23 microprobes present for 15 minutes in the
contralateral side of the spinal cord of the sham operated animal in the absence of any
active peripheral stimuli (sham operated rats, contra), is displaced below that of 55
microprobes present for the same time period in the contralateral side of the spinal
cord of the nerve ligated rats in the absence of any active peripheral stimuli (nerve
ligated rats, contra). (B) The differences between the two groups of microprobes are
plotted with respect to an outline of the spinal cord. These differences are not
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Figure 19. Additional zone of release of ir-NPY in the ipsilateral spinal cord of
nerve ligated rats when compared to the contralateral cord of sham operated
rats.
(A) The mean image analysis of two groups of microprobes present in the spinal cord
for 15 minutes in the absence of any active peripheral stimuli were plotted with
respect to depth within the spinal cord: those present in the spinal cord ipsilateral to
the nerve ligation (nerve ligated rats, ipsi n=53J and those present in the spinal cord
ipsilateral to the sham operation (sham operated rats, ipsi n=19J. (B) The differences
between the two groups of microprobes are plotted with respect to an outline of the
spinal cord. The hatched area indicates where these differences are significant at the
P<0.05 level.
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Figure 20. Additional zone of release of ir-NPY in the ipsilateral spinal cord of
nerve ligated rats when compared to the opposite side of the spinal cord.
(A) The mean image analysis of two groups of microprobes present in the spinal cord
for 15 minutes in the absence of any active peripheral stimuli were plotted with
respect to depth within the spinal cord: those present in the spinal cord ipsilateral to
the nerve ligation (nerve ligated rats, ipsi n=53) and those present in the opposite side
of the spinal cord (nerve ligated rats, contra n=55). (B) The differences between the
two groups of microprobes are plotted with respect to an outline of the spinal cord.
























6.2.(e) Peripheral nerve stimulation and the spinal release of ir-NPY in nerve
ligated rats
As shown earlier in this dissertation, electrical stimulation of the sciatic
nerve in the normal rat failed to release ir-NPY. It was of interest to investigate
whether electrical stimulation of the sciatic nerve proximal to the ligatures resulted in
the release of ir-NPY in the nerve ligated animal as a de novo synthesis of NPY
occurs in the medium to large sized dorsal root ganglia after nerve injury. Both large
and small diameter fibres were stimulated at frequencies used previously: 20Hz (3 x
T) to stimulate large myelinated fibres and 2Hz(>100 T) to activate both myelinated
and unmyelinated fibres.
In all experiments only the injured nerve was stimulated. Bilateral changes
in the excitatory postsynaptic effects of impulses after electrical stimulation of large
fibres in the sciatic nerve of this model have been reported (Colvin et al, 1996).
Therefore, it was also of interest to investigate whether ipsilateral nerve stimulation
altered the basal presence of ir-NPY in the spinal cord contralateral as well as
ipsilateral to the ligated nerve. Only one 15 minute period of stimulation was used in
these experiments (similar to experiments in normal animals) due to the uncertainty of
whether persistence of release of ir-NPY occurs following peripheral nerve
stimulation. Four microprobes were inserted into the spinal cord prior to stimulation,
two microprobes during electrical stimulation of the sciatic nerve and six after
stimulation in either the cord ipsilateral or contralateral to the nerve injury.
6.2.(ei) Stimulation of large myelinated fibres at 20Hz
In 13 rats microprobes were inserted into the spinal cord before during and
after one 15 minute period of electrical stimulation at 20Hz (3 x T). In figure 21A the
mean image analyses of 14 microprobes present in the spinal cord ipsilateral to the
injured nerve during stimulation of large diameter afferents at 20Hz is displaced above
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Figure 21. Release of ir-NPY in the ipsilateral spinal cord of nerve ligated rats
by large myelinated fibre stimulation of the sciatic nerve at 20Hz.
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of nerve ligated rats for 15 minutes were plotted with respect to depth within the
spinal cord: those present in the spinal cord ipsilateral to the nerve ligation in the
absence of peripheral stimuli (pre-stim, ipsi n=21 J and those present in the same side
of the cord during stimulation of large myelinated fibres at 20Hz (3 x T, 0.05ms, stim
20Hz, ipsi n=14). (B) A plot of the t-statistics is related to an outline of the lumbar























those of 21 microprobes present in the same side before stimulation. This
displacement is the entire length of the probe. Figure 2IB shows that these
injured nerve during stimulation of large diameter afferents at 20Hz is displaced above
differences are significant throughout the dorsal white matter, the entire dorsal horn,
dorsal columns and ventral horn. Microprobes were inserted into the spinal cord for a
further three periods after electrical stimulation to determine whether persistence
occurred following release.
These 3 post-stimulus intervals were grouped to give the mean image
analysis of 32 microprobes inserted into the spinal cord from 5-60 minutes following
stimulation. The mean image analyses of 21 microprobes inserted into the spinal cord
ipsilateral to the nerve ligation in the absence of any active stimuli (before stimulation)
is compared with that of 32 microprobes inserted into the ipsilateral spinal cord within
the period 5-60 minutes after stimulation in figure 22A. This latter group is displaced
above the pre-stimulus from approximately 1.8mm to the dorsal cord surface and
suggests persitence of previously released ir-NPY. These differences, however, are
not significant at the P<0.05 level although the t-values are close to 2 in the upper
ventral horn. The time intervals were also analysed separately. The differences
between the first period (inserted from 5-10 minutes after stimulation, n=9), second
period (from 25-35 minutes, n=16) and the third post-stimulation period (from 45-60
minutes, n=7) mean image analysis groups when compared to the pre-stimulus group
were not significant at the P<0.05 level (not illustrated).
To examine the possibility that stimulation above the nerve ligature was
releasing ir-NPY bilaterally, microprobes were also inserted into the contralateral
spinal cord during and after periods of nerve stimulation. In figure 23(i)A the mean
image analysis of 9 microprobes inserted into the contralateral spinal cord during
stimulation at 20Hz (stim 20Hz, contra) is displaced below the mean image analysis of
17 microprobes inserted into the same side of the cord before stimulation at 20Hz (of
the ipsilateral nerve) which suggests inhibition of tonically released ir-NPY. The
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Figure 22. Detection of ir-NPY in the ipsilateral spinal cord following sciatic
nerve stimulus evoked release in nerve ligated rats.
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of nerve ligated rats for 15 minutes were plotted with respect to depth within the
spinal cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli {pre-stim, ipsi n=21) and 32 microprobes present in the spinal cord
ipsilateral to the nerve ligation from 5-60 minutes after stimulation at 20Hz (3 x T,
0.05ms, post-stim, ipsi). (B) The differences between the two groups of microprobes
are plotted at 30]um intervals with respect to an outline of the lumbar spinal cord.
The absence of hatched areas indicates that these differences are not significant at the





















Figure 23. The effect of myelinated fibre stimulation of the sciatic nerve at 20Hz
on ir-NPY in the contralateral spinal cord of nerve ligated rats
23(i) microprobes present during stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of nerve ligated rats for 15 minutes were plotted with respect to depth within the
spinal cord: 9 microprobes present in the spinal cord contralateral to the nerve during
stimulation at 20Hz (3 x T, 0.05ms, stim 20Hz, contra) are displaced below those
present in both sides of the spinal cord in the absence of any active peripheral stimuli
(pre-stim, contra n= 11). (B) The differences between the two groups of microprobes
are plotted with respect to an outline of the lumbar spinal cord. Since only isolated

























t-statistics illustrate that these differences are mainly not significant with only 4
separate and widely spaced 30|im intervals making significance (figure 23(i)B). The
mean image analysis of microprobes inserted into the contralateral spinal cord after
stimulation (from 5-65 minutes, n=35) is compared with the pre-stimulation plot in
figure 23(ii)A. The differences are not significant at the P<0.05 level.
6.2.(eii) Stimulation of myelinated and unmyelinated fibres at 2Hz
Microprobes were inserted into the spinal cord before during and after one
15 minute period of electrical stimulation at 2Hz (>100 T) in 11 rats. In figure 24A
the mean image analyses of 18 microprobes present in the spinal cord ipsilateral to the
injured nerve before stimulation is compared to those present in the same side during
stimulation at 2Hz (n=9). This latter group is displaced above the before-stimulation
group along the entire length of the probe analysed. Figure 24B shows that these
differences are significant throughout laminae I to IV and peaks at laminae III/IV.
The 3 post-stimulus intervals were grouped to give the mean image analysis
of 27 microprobes inserted into the ipsilateral spinal cord from 5-50 minutes"following
stimulation. This plot is compared to the mean image analyses of 18 microprobes
inserted into the ipsilateral spinal cord before stimulation in figure 25(i)A. The post-
stimulus group is displaced above the pre-stimulus group from 2.25mm to the dorsal
cord surface. The differences are significant in part of laminae III-IV and laminae
V,VI and upper laminae VII.
The 3 post-stimulus time intervals were also analysed separately and are
illustrated in figure 25(ii)A, B, C (all n=9). At all three intervals, the mean image
analysis plot of microprobes inserted into the ipsilateral spinal cord after stimulation at
2Hz is displaced above the mean image analysis of microprobes inserted into the
spinal cord prior to stimulation. These results suggests that the released ir-NPY
persisted after stimulation. The displacement above the no stimulus microprobe plot
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Figure 23. The effect of myelinated fibre stimulation of the sciatic nerve at 20Hz
on ir-NPY in the contralateral spinal cord of nerve ligated rats
23(ii) microprobes present after stimulation.
The mean image analysis of two groups of microprobes present in the spinal cord of
nerve ligated rats for 15 minutes in the absence of any active peripheral stimuli are
plotted: those present in both sides of the spinal cord prior to stimulation at 20Hz
(pre-stim, contra n=17) and those present in the ipsilateral spinal cord from 5-65
minutes following stimulation (post-stim, contra n=35). The two groups are not
significantly different at the P<0.05 level.
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Figure 24. Release of ir-NPY in the ipsilateral spinal cord of nerve ligated rats
during stimulation of large myelinated fibre and unmyelinated fibres of the
sciatic nerve at 2Hz.
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of nerve ligated rats for 15 minutes were plotted with respect to depth within the
spinal cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli (pre-stim, ipsi n=18 ) and 9 microprobes present in the spinal cord
ipsilateral to the nerve ligation during stimulation at 2Hz (>100 x T, 0.05ms, stim
2Hz, ipsi). (B) A plot of the t-statistics at each 30|im interval is related to an outline
of the lumbar spinal cord. The hatched area indicates where these sites are significant
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Figure 25. Persistence of release of ir-NPY in the ipsilateral spinal cord of nerve
ligated rats after stimulation of large myelinated and unmyelinated Fibres of the
sciatic nerve at 2Hz.
(i) microprobes inserted 5-50mins following stimulation
(A) The mean image analysis of two groups of microprobes present in the spinal cord
of nerve ligated rats for 15 minutes were plotted with respect to depth within the
spinal cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli (pre-stim, ipsi n=I8 ) and 27 microprobes present in the spinal cord
ipsilateral to the nerve ligation from 5-50 minutes after stimulation at 2Hz (>100 x T,
0.05ms, post-stim 2Hz, ipsi). (B) The differences between the two groups of
microprobes are plotted with respect to an outline of the spinal cord. Sites of
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Figure 25. Persistence of release of ir-NPY in the ipsilateral spinal cord of nerve
ligated rats after stimulation of large myelinated and unmyelinated Fibres of the
sciatic nerve at 2Hz.
(ii) microprobes inserted 5-10mins, 25-30mins & 40-50 mins following
stimulation
The mean image analysis of microprobes present in the spinal cord for 15 minutes in
both sides of the spinal cord of nerve ligated rats in the absence of any active
peripheral stimuli (pre-stim, ipsi n=21) is compared with (A) 9 microprobes present in
the spinal cord ipsilateral to the nerve ligation 5-10 minutes after stimulation at 2Hz
(first post-stim, ipsi), (B) 9 microprobes present in the spinal cord ipsilateral to the
nerve ligation 25-30 minutes after stimulation (second post-stim, ipsi) and (C) 9
microprobes present in the spinal cord ipsilateral to the nerve ligation 40-50 minutes
after stimulation (third post-stim, ipsi). The first post-stimulation plot differs from the
pre-stimulation plot in the lower dorsal and upper ventral horn. The second post-
stimulation plot differs from the pre-stimulation plot at only a few sites in the dorsal
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decreases with time suggesting a progressive degradation of released ir-NPY. In
figure 25(ii)A the post stimulation plot of microprobes inserted into the spinal cord
from 5-10 minutes after stimulation is significantly different in laminae II-VI when the
differences between this group and the basal group are compared. The second post-
stimulation mean image analysis of microprobes inserted into the spinal cord 25-30
minutes after stimulation is significantly different from the basal plot at only a few
sites in the dorsal horn. In contrast, the differences between the third post-stimulation
plot of microprobes inserted from 40-50 minutes after stimulation are not significant
at the P<0.05 level.
The possibility of bilateral nerve stimulus-evoked release was examined. In
figure 26(i) the mean image analysis of 12 microprobes inserted into the contralateral
spinal cord during stimulation at 2Hz is very similar to the mean image analysis of 19
microprobes inserted into the same side of the cord prior to nerve stimulation at 2Hz
and the mean image analysis of microprobes inserted into the contralateral spinal cord
from 5-55 minutes after stimulation (n=27, figure 26(H)). The differences between
these groups are not significant which suggests that electrical stimulation of the
ipsilateral nerve at 2Hz did not result in bilateral release.
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Figure 26. Failure of stimulation of large myelinated fibres and unmyelinated
fibres of the sciatic nerve at 2Hz to release ir-NPY contralateral to the nerve
ligation.
26 (i) microprobes present during stimulation
The mean image analysis of two groups of microprobes present in the spinal cord of
nerve ligated rats for 15 minutes were plotted with respect to depth within the spinal
cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli (pre-stim, contra n=19) and 12 microprobes present in the spinal
cord ipsilateral to the nerve ligation during stimulation at 2Hz (>100 x T, 0.05ms,
post-stim 2Hz, contra). A plot of the t-statistics derived from the standard errors of
the differences of means at each 30p.m interval is related to an outline of the lumbar
spinal cord. There are no significant differences between the two groups.
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Figure 26. Failure of stimulation of large myelinated fibres and unmyelinated
Fibres of the sciatic nerve at 2Hz to release ir-NPY contralateral to the nerve
ligation
26 (ii) microprobes present after stimulation
The mean image analysis of two groups of microprobes present in the spinal cord of
nerve ligated rats for 15 minutes were plotted with respect to depth within the spinal
cord: those present in both sides of the spinal cord in the absence of any active
peripheral stimuli (pre-stim, contra n=19 ) and 27 microprobes present in the spinal
cord contralateral to the nerve ligation from 5-55 minutes after stimulation at 2Hz
(post-stim, contra). These differences are not significant at the P<0.05 level.
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The significant results of this study which require extended discussion are:
(a) the finding of a comparable basal extracellular presence of ir-NPY in both sides of
the spinal cord in sham operated animals and in the side contralateral to the ligated
nerve.
(b) the deep zone of basal release of ir-NPY in the ipsilateral spinal cord of nerve
ligated rats which was not present in sham operated rats nor the contralateral spinal
cord.
(c) the release of ir-NPY by electrical stimulation of primary afferents in nerve ligated
but not normal rats.
6.3.(a) The basal presence of ir-NPY in the spinal cord of the sham and nerve
ligated rat
Sham experiments were carried out in separate animals to allow both sides
of the spinal cord to be investigated after a unilateral sham operation or a unilateral
sciatic nerve ligation. A basal presence of ir-NPY in sham operated animals was
found throughout the dorsal horn and was similar for both sides of the spinal cord.
This basal presence can also be called basal release as it is most likely due to
continuous activity in some structures under the conditions of these experiments since
it was obtained in the absence of any active peripheral stimuli. Basal release in sham
operated rats was comparable to that of normal rats. The spinal cord contralateral to
the ligatured nerve also had a comparable distribution of extracellular ir-NPY to that
detected in the sham operated animals.
In contrast, significant differences from this distribution were obtained for
the ipsilateral side of nerve ligated rats . In addition to release in the upper and mid-
dorsal horn (which was comparable to normal animals), there was a new zone of
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release of ir-NPY in the mid and deep dorsal horn (approximating to laminae IV, V &
VI). The latter was observed in the absence of any active peripheral stimuli.
Determining the sources of such release requires consideration of other results which
I obtained. The first of these is the effects of nerve stimulation.
6.3.(b) Release by electrical stimulation of the ligated sciatic nerve
Electrical stimulation of large myelinated fibres and of myelinated and
unmyelinated fibres elicited release in the ipsilateral side of the spinal cord in nerve
ligated animals whereas the same nerve stimulation did not elicit release in normal
rats. Electrical stimulation of these fibres did not alter the spatial distribution of
extracellular ir-NPY but simply elevated the levels present prior to electrical
stimulation in the dorsal horn and upper ventral horn. This result implies that
spontaneous activity in large diameter primary afferents of the ligatured nerve could
explain the basal pattern of release seen in the ipsilateral spinal cord.
The distribution of release after stimulation at 20Hz (3 x T) was more
extensive than that obtained at 2Hz (>100 T) which may simply be related to
frequency dependence as large myelinated fibres would have been stimulated by both
frequencies. The low frequency was used with high intensity stimuli in these
experiments to activate C fibres. Alternatively, electrical stimulation at 2 Hz (>100 T)
may result in the activation of an inhibitory process within the spinal cord resulting in
release over a restricted area.
6.3.(c) What is the origin of the deep zone of basal release in nerve ligated
rats?
After axotomy or nerve constriction a cle novo synthesis of NPY has been
reported to occur predominantly in a population of large to medium sized dorsal root
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ganglion neurones (Wakisaka et al, 1992; Zhang et al, 1993a & b; Kashiba et al, 1994,
Nahin et al, 1994). This correlates with the finding that electrical stimulation of the
low threshold (large diameter) fibres proximal to the constriction site was adequate to
elicit release of ir-NPY although it failed to elicit release in normal rats. Zhang and
co-workers found that many synaptic vesicles in laminae III and IV were present in
the presynaptic zone and many vesicles appeared to be involved in exocytosis which
suggests increased transmitter release (Zhang et al, 1995b).
If the phenotypes of large neurones synthesising NPY following peripheral
axon damage includes both proprioceptive and large fibre mechanoreceptors then
impulses in these fibres would result in release of NPY in mid and lower dorsal horn
and the upper ventral horn as found in the present experiments.
Attempts by the nerve to regenerate after peripheral nerve injury may be
similar to the dependence of primary afferent neurones on neurotrophins during
development. Local application of NT-3 directly to the proximal transected nerve has
been found to decrease the number and intensity of staining of ir-NPY on the
ipsilateral side in the dorsal root ganglion neurones and in their central terminals in the
dorsal horn (Ohara et al, 1995). This study suggested that the synthesis of NPY is a
response to the deprivation of retrogradely transported NT-3. Mice deficient in the
gene for synthesis of NT-3 have been found to have movement deficits associated
with abnormal limb positions. These mice have an extensive loss of large diameter
dorsal root ganglion neurones and afferent fibres projecting to the deep dorsal and
upper ventral horn are absent (Farinas et al, 1994; Ernfors et al, 1994; Airakinsen &
Meyer 1996). Both la & lb muscle afferents which project to this area of the cord
and their peripheral sense organs, muscle spindles and Golgi tendon organs have been
found to be absent (Ernfors et al, 1994). In view of the severe gait abnormalities
which these animals have, it has been proposed that the development of
proprioceptive (muscle spindle and tendon organ derived) afferents is NT-3
dependent. Another study found that the Merkel cells of the skin, the end organs of
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slowly adapting mechanoreceptors decreased after birth in NT-3 deficient mice
suggesting that the development of these cells is NT-3 dependent (Airakinsen et al,
1996). These afferents project to laminae III/IV in normal animals (Brown 1981).
The effect of NT-3 on the regulation of NPY is likely to be mediated by
tyrosine kinase C (TrkC) receptors which are predominantly expressed in large-sized
dorsal root cells subserving proprioceptive functions (Ip et al, 1992; Mu et al, 1993;
McMahon & Priesley 1995). Mice with a knockout gene for the TrkC receptor were
found to have movement disorders and a guarded foot. Again a reduction in the large
dorsal root ganglia expressing this receptor was found as well as a reduction in the
number of la afferents (Klein et al, 1994). In contrast to the study by Airakinsen and
co-workers, Klein's group suggested that projections to the dorsal horn of low
threshold mechanoreceptors were grossly normal. This may be due to the earlier time
course studied by Klein and co-workers.
Immunocytochemical studies of ir-NPY distribution in the dorsal horn
following sciatic nerve transection (Wakisaka et al, 1991b; Kashiba et al, 1994; Zhang
etal, 1995b) and partial injury (Wakisaka et al, 1992; Munglani et al, 1995) have
found an increase in lamina III -V of the dorsal horn. Munglani and co-workers found
that pre-emptive treatment with MK-801 reduced the magnitude of the increase in
NPY within structure in laminae III & IV (Munglani et al, 1995). They suggested
that MK-801 may have reduced the effect of the injury discharge within the spinal
cord. Lumbar dorsal rhizotomy performed simultaneously with sciatic nerve
transection prevented the development of NPY immunoreactivity in laminae III & IV
suggesting that the NPY was contained within primary afferent fibres (Ohara et al,
1994). This distribution is consistent with the termination of slowly adapting
mechanoreceptors but not with the presence within muscle spindle derived afferents as
these terminate more deeply in normal rats. Thus, the increased synthesis of NPY
may not be wholly NT-3 dependent. The actions of nerve growth factor (NGF) in
regulating peptide expression have been examined in vivo in adult rat primary sensory
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neurones (Verge et al, 1995). Delayed intrathecal infusion of NGF for 7 days starting
2 weeks after injury reduced the number of neurones expressing VIP. cholecystokinin,
NPY and galanin after injury. NGF appears to regulate peptide expression
differentially and may also be part of the signal that allows reversion to normal of
responses to injury as axons regenerate.
Thus it appears likely that the source of this extracellular release of ir-NPY
arises from the large fibres which synthesise this peptide after injury as: (1) electrical
stimulation of large myelinated fibres results in release in neuropathic rats contrasting
to the failure to evoke release in normal rats and (2) the release of ir-NPY detected by
the microprobes agrees with the distribution of central terminals of these large fibres
and increased immunoreactivity after injury.
6.3.(d) The stimulus for release in neuropathic animals
As mentioned previously NPY release in the ipsilateral spinal cord of rats
with a nerve ligature rats is found in the absence of any active peripheral stimuli. A
possible source of this spontaneous activity is ectopic firing known to occur after
partial and complete nerve injury. Ectopic impulses have been found to originate at
the site of injury and/or in the dorsal root ganglion neurones in this model (Kajander
& Bennett 1992, Study & Krai 1996, Tal & Eliav 1996). This supports the proposal
that the spontaneous release of ir-NPY originated from large afferent fibres as ectopic
impulses have been found to continue for several weeks after partial nerve injury (Xie
& Xiao 1990; Eliav & Tal 1994; Xie et al, 1995). It has been suggested that
peripheral NPY may be involved in ectopic electrical activity in experimental
neuromas (Fried et al, 1989). Ectopic impulses are normally regarded as pathological.
However such impulses may be required after axonal damage to release the newly
synthesised neuroactive compounds during the regenerative phase. Neuropeptide Y
may be one such compound.
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6.3.(e) The wide distribution of release
Where a neuropeptide is found following release however is not necessarily
coincident with sites of release as considerable diffusion can occur following release if
the compound is slowly degraded as has been reported with NKA (Nyberg et al,
1984; Hooper et al, 1985; 1987; Theodorsan-Norheim et al, 1987).
In the present studies the increase in extracellular ir-NPY evoked by nerve
stimulation was suggested after stimulation at 20Hz (although this was not significant)
and found to persist for up to 30 minutes after release following stimulation at 2Hz.
Immunoreactive NPY was significantly elevated compared to basal levels 20-25
minutes after stimulation at 2Hz. By 40-50 minutes after stimulation, the next time
period studied, the levels of ir-NPY had decreased. This suggests a progressive but
slow degradation of released ir-NPY.
Little is known of how NPY is degraded following release in the central
nervous system. With cultured cortical neurones, the degradation of NPY by plasmin
(a serine proteinase) and plasminogen activator has been found to be slow (Ludwig et
al, 1996). The post-stimulus results obtained with the antibody microprobes also
suggest a slow degradation of released NPY. There is evidence with other
neuropeptides that slow degradation results in considerable diffusion away from sites
of release. Neuronal uptake into cells, which would limit the migration within the
spinal cord tissue, has not been found for peptides. The persistence of NKA which is
highly resistant to enzymatic degradation has been found to have a comparable time
course to that of NPY in the present experiments as measured by the antibody
microprobe technique (Hope et al, 1990b) and after superfusion of the cord dorsum
(Beck et al, 1995). NKA has been found to diffuse widely in the spinal cord after
release (Hope et al, 1990 b). Thus it is possible that the new zone of extracellular
presence of ir-NPY is more extensive than the area of releasing neurones. The
presence in the deep dorsal horn could have resulted from release more dorsally.
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Supporting this is the extensive presence in the dorsal columns which almost certainly
resulted from diffusion from the adjacent grey matter. Alternatively, these results
could suggest that release continued after stimulation had ceased perhaps due to the
altered properties of afferents in the nerve ligated animals. However, evidence to
support this in other systems is lacking.
6.3.(f) Volume transmission
It has been suggested that long term changes in the CNS are mediated by
extrasynaptic spread of neuropeptides as a mismatch of receptors and terminals for ir-
NPY have been found in the brain (Agnati et al, 1989; Zoli et al, 1989). Fuxe and co¬
workers proposed the term volume transmission for such a process and much of the
evidence was obtained from NPY's receptor distribution (Fuxe et al, 1990, Fuxe &
Agnati 1991). Low affinity receptors (Y|) were located adjacent to sites of release
where high concentrations of the non-degraded peptide were encountered. In
contrast, the high affinity receptors (Y2) occurred more remotely. This latter receptor
type was activated by both the intact peptide and shorter fragments degraded by
peptidases whereas the low affinity receptor was only activated by the full length
sequence of NPY.
They suggested that the vast majority of synapses operate not only via "hard
wired" transmission (the classical system of chemical communication between cells
which had been characterised on the basis of the minimal distance between release
sites and target cells) but also by volume transmission. When the nerve cell is in low
activity, wire transmission is the main mode in operation, whereas in high activity
states, volume transmission becomes more important.
A marked plasticity in NPY receptor Y1 mRNA expression has been found
14 days after sciatic nerve transection (Zhang et al, 1994b). Before surgery, no large
or medium sized dorsal root ganglion neurones of the lumbar region were found to
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express this receptor compared to 60% after axotomy. Correlation studies by Zhang
and co-workers indicated that NPY receptor mRNA & NPY mRNA were frequently
co-localised after axotomy in large and medium dorsal root ganglion neurones (Zhang
et al, 1994b). In contrast a down-regulation in small dorsal root ganglion neurones
has been reported although a transient increase in the number of neurones expressing
NPY receptor Y1 mRNA at low levels occurred. NPY released in the spinal cord
may act upon receptors in the spinal cord. Y1 receptor RNA-positive neurones have
been found in lamina II of the dorsal horn (Zhang et al, 1994b).
6.3.(g) Is NPY associated with the primary afferent fibres which sprout after
nerve injury?
The growth associated protein GAP-43 has been found to be associated with
axonal growth (Skene & Willard 1981). It has been shown to be increased in small &
large dorsal root ganglion cells after peripheral nerve injury (Hoffman 1989;
Sommervaille et al, 1991). Following nerve injury, ir-GAP-43 has been found in the
damaged peripheral axons (Tetzlaff et al, 1989) and also at the central terminals of
these afferents in the superficial dorsal horn of the spinal cord (Woolf et al, 1990;
Coggeshall et al, 1991; Cameron et al, 1991). The majority of axons that show GAP-
43 immunoreactivity have been found to be unmyelinated (Coggeshall et al, 1991)
although some myelinated axons were also labelled at a later period (Somervaille et al,
1991). Woolf and co-workers (1990) suggested that the increase in GAP-43
production following sciatic nerve transection is due to inhibition of retrograde
transport of a molecular signal from the periphery to neurones of the dorsal root
ganglia. Peripheral axonal growth ensues following nerve injury but Woolf et al
suggested that GAP-43 may permit central regenerative changes to occur. Such
axonal sprouting may occur enabling the terminals of viable neurones to occupy
synaptic sites which become vacant due to death of central terminations of neurones
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as a result of the peripheral axotomy. This form of regeneration has been described as
conditioned collateral sprouting (reviewed by Coggeshall, 1994).
Conditioned because it is elicited by injury to the peripheral process of the sensory
neurone and collateral because the growth of terminals is from an uninjured neurone
into a denervated region. An important question arising from these studies which
need to be answered is whether these sprouting axons contain and release NPY.
Cholera toxin (B-fragments) conjugated to horseradish peroxidase (B-HRP)
has been found to label myelinated sensory axons which have been reported to spread
into lamina II after axotomy and partial nerve injury (Lekan et al, 1996). There is an
increase in B-HRP labelled synapses into lamina II which have been suggested to arise
from these sprouting A fibres (Woolf et al, 1992; Shortland & Woolf 1993; Koerber
et al, 1994). The cells in lamina II normally have a predominantly monosynaptic input
from unmyelinated nociceptors but if the sprouting fibres establish functional contacts
inappropriate responses to innocuous stimuli could occur (Woolf et al, 1992). If
these fibres which sprouted contained ir-NPY then increased staining in laminae I & II
would have been expected after nerve injury. As ir-NPY has been reported to
increase in laminae III & IV only, these fibres may be a subset of large fibres which do
not sprout after peripheral nerve injury.
6.3.(h) Functional implications
Synthesised NPY in dorsal root ganglion cells may be transported both
centrally and peripherally (Hisanaga et al 1993; Rao et al, 1992). Peripherally, NPY
may induce the proliferation of Schwann cells and promote axonal regeneration
(Shigeri & Fugimoto 1993). Centrally, it may induce a trophic effect on glial cells as
does VIP (Brennenman et al, 1987; Hisanaga et al, 1993). The relative ease with
which spontaneous release of ir-NPY was detected in the present experiments
suggests an important role for NPY in the spinal cord response to peripheral nerve
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injury. However, this role remains uncertain. Munglani and co-workers found a
significant correlation between the increase in NPY staining and the degree of
mechanical hyperalgesia and suggested that the increased expression of NPY centrally
may be crucial for the development of hyperalgesia in this model (Munglani et al,
1995). They proposed that NPY may act to effectively silence transmission of
impulses from primary afferents (Munglani et al, 1996b). As cited previously, NPY
has been shown by a variety of techniques to inhibit the release of neurotransmitters
(Walker et al, 1988; Bleakman et al, 1991) including that of substance P in the spinal
cord (Duggan et al, 1991a). Intrathecal NPY has been found to have an
antinociceptive action in the spinal cord which was enhanced after peripheral nerve
transection (Xu et al, 1994). However, the excitatory effect of NPY (as it is usually
biphasic in normal animals), was also increased. A later study by Munglani and co¬
workers reported that the resolution of the hyperalgesia occurs before the central
nerve changes have been resolved (Munglani et al, 1996a). They suggested that long-
term changes in neuropeptides within the central axons of injured nerves (particularly
NPY) may serve to mask a residual hyperalgesia after a peripheral nerve injury. The
injury itself despite apparent peripheral resolution may lead to increased vulnerability
of the nervous system to subsequent injury and the development of chronic pain states
for which there is some clinical evidence (Jensen et al, 1985).
Loss of inhibitory mechanisms may contribute to pathological processing
after nerve injury. It has been suggested that degeneration of neurones is triggered by
intense stimulation associated with ectopic discharges in damaged neurones
(Sugimoto et al, 1989; Nachemson & Bennett 1993). If the affected cells are
inhibitory inter-neurones there may follow significant alterations in the spinal
processing of afferent information. NPY and galanin may be released throughout the
dorsal horn and act in an inhibitory manner to compensate for the loss of inhibitory
mechanisms due to transynaptic degenration. Additonally, it has been suggested that
galanin may be tonically released primarily from glomeruli in lamina II after axotomy
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presynaptically to inhibit C-fibre induced excitability (Randic et al, 1987; Zhang et al,
1995b) and that NPY may have a similar inhibitory action in the lower region of the
dorsal horn (Kashiba et al, 1994; Zhang et al, 1995b). It has been suggested that
NPY may act at autoreceptors to inhibit it's own release after transection of a
peripheral nerve (Kashiba et al, 1994 ; Zhang et al, 1995b). Supporting this there is
evidence that NPY released from the sympathetic nerve terminals to blood vessels
acts as a negative feedback to inhibit it's own release and also that of noradrenaline
(Stjarne & Lundberg 1986; Wahlestedt et al, 1986).
An alternate hypothesis is that NPY is responsible for some of the reported
organisational changes in the dorsal horn following peripheral nerve injury.
Neuropeptides have been shown to induce changes in neuronal cytoarchitecture as
reviewed by Lipton & Kater (1989). Several studies have suggested that
neuropeptides have neurotrophic actions influencing neuronal survival, phenotype and
neurite sprouting (Lipton & Kater 1989; Pincus et al 1990; Mattson 1988). White
and Mansfield (1996) found that the dendritic outgrowth property of dorsal root
ganglion neurones cultured 10 days after axotomy of the sciatic nerve was increased
by NPY. They suggested that NPY as well as other peptides such as VIP may
contribute to the growth of primary afferents after nerve transection.
Although not directly relevant to the role of NPY centrally, it has been
suggested that peripheral NPY contributed to hyperalgesia in the Seltzer & Shir
model (Tracey et al, 1995a). They found that subcutaneous injection of Y| agonist
into the hind paw exacerbated mechanical hyperalgesia but relieved thermal
hyperalgesia, whereas subcutaneous injection of Y2 agonist into the dorsum of the
hindpaw significantly exacerbated mechanical and thermal hyperalgesia. They
concluded that the effect of NPY on mechanical hyperalgesia was mediated by both
Y | and Y2 receptors while the effect of NPY on thermal hyperalgesia was mediated
by the Y2 receptor type. Surgical sympathectomy relieved the hyperalgesia and
eliminated the effects of NPY and its agonist. This suggested that NPY contributes to
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peripheral hyperalgesia by actions at receptors located on postganglionic sympathetic
terminals.
6.4. CONCLUDING REMARKS
Before starting these experiments, it was unknown to me whether NPY
would be easily detected in normal rats. It was surprising therefore to find an
extensive basal presence of extracellular ir-NPY throught the entire dorsal horn and
most of the ventral horn of normal rats. This basal presence was found in the absence
of any active peripheral stimuli and was unaltered by spinalisation in these
experiments. Because of the known coexistence of noradrenaline and NPY in some
brainstem neurones, a greater influence from the descending fibres was expected. It is
posssible that anaesthesia may have dampened the activity of neurones in the
brainstem. Electrical stimulation of primary afferents of the sciatic nerve did not
result in release. This was not unexpecterd since NPY is not present in primary
afferents but it was still possible that an input in primary afferents could evoke
intraspinal release of NPY by activating spinal or supraspinal proceses. These results
suggested that this did not occur and that the extensive basal presence of ir-NPY
originated from intrinsic neurones. This widespread tonic release suggests a role for
NPY in the spinal cord. It would be of interest to know what this role is and whether
it differs in neuropathic animals.
With neuropathic rats, an additional zone of release of lr-NPY was evident
in the ipsilateral spinal cord but not in the cord contralateral to the nerve injury. This
release was obtained in the absence of peripheral stimuli. Before starting these
experiments, I thought it may be necessary to evoke release by nerve stimulation in
these animals as peripheral stimuli are required to demonstrate the behavioural
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abnormalities that develop such as allodynia and hyperalgesia. It is probable that this
spontaneous release was due to ectopic impulses in primary afferents and thus the
release of this neuropeptide might contribute to the abnormal pain state. The former
could be further investigated by using local anaesthetic block both proximal to the
ligature and proximal to the dorsal root ganglion to interrupt these impulses and hence
determine which block abolishes the basal release in the spinal cord.
To investigate the probable role of NPY in the behavioural syndrome
produced by nerve ligation several experiments could be performed. Firstly, it would
be useful to study the release of NPY during the time course of this model to
determine whether the release correlates with the behavioural changes. Additionally,
it would be of interest to use selective antagonists of NPY before during and after the
nerve ligation to investigate the role of NPY in the development of abnormal
behaviours. It would be useful to study this neuropathic model in mice as mice which
lack NPY have been developed to investigate the role of NPY in feeding behaviour
(Erickson et al, 1996). In the absence of good antagonists, the role of NPY could be
investigated by ligaturing the sciatic nerve of mice which lacked this gene to express
NPY. Alternatively, if it is possible to disrupt the NPY gene in rats, it would be of
interest to ligature the sciatic nerve to determine whether the absence of NPY alters
the behavioural changes associated with the neuropathic model.
It would also be of interest to investigate the release of ir-NPY in the other
neuropathic models and investigate the minimal insult that needs to occur to the nerve
to result in NPY release in this new zone in the mid and deep dorsal horn.
Additionally, the release of NPY in rats with complete nerve transection should be
compared to the results obtained with partial nerve injury. Future experiments should
also include the application of neurotophin-3 to the injury site, to determine whether
chronic application would alter the release of ir-NPY in the complete transection and
partial nerve injury models. In determining the role of NPY in neuropathic pain, it
may be more appropriate to consider the co-action of the other neuropeptides with
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which NPY is co-localised such as galanin. More studies investigating the receptor
changes which occur after nerve injury may help to define the proposed inhibitory role
of NPY. Finally, further investigation is required to determine whether NPY's role is
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